%PDF-1.4%âãÏÓ
83 0 obj
<</Metadata 85 0 R/PageLabels 25 0 R/Pages 79 0 R/Type/Catalog>>
endobj
85 0 obj
<</Length 1664/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2009-01-30T16:30:19Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.52</xmp:CreatorTool>
         <xmp:ModifyDate>2014-08-25T20:16:11-07:00</xmp:ModifyDate>
         <xmp:MetadataDate>2014-08-25T20:16:11-07:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.52</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:72dfcc25-1dd2-11b2-0a00-eb09276dce00</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:72dfcc29-1dd2-11b2-0a00-0ef600000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
25 0 obj
<</Nums[0<</S/D/St 251>>]>>
endobj
79 0 obj
<</Count 8/Kids[72 0 R 80 0 R]/Type/Pages>>
endobj
72 0 obj
<</Count 6/Kids[73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R]/Parent 79 0 R/Type/Pages>>
endobj
80 0 obj
<</Count 2/Kids[81 0 R 82 0 R]/Parent 79 0 R/Type/Pages>>
endobj
81 0 obj
<</Annots 86 0 R/Contents 87 0 R/MediaBox[0 0 612 792]/Parent 80 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 88 0 R/GS2 89 0 R>>/Font<</T1_0 33 0 R/T1_1 53 0 R/T1_2 29 0 R/T1_3 69 0 R/T1_4 41 0 R/T1_5 45 0 R/T1_6 37 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
82 0 obj
<</Annots 91 0 R/Contents 92 0 R/MediaBox[0 0 612 792]/Parent 80 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 93 0 R/GS2 94 0 R>>/Font<</T1_0 33 0 R/T1_1 41 0 R/T1_2 37 0 R/T1_3 57 0 R/T1_4 45 0 R/T1_5 69 0 R/T1_6 90 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
91 0 obj
[95 0 R]
endobj
92 0 obj
<</Length 12374>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 162 492 576 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02 Tc 0.02 Tw 8 0 0 8 60 732.5292 Tm
[(22.)-480 (Parazzini F; Progetto Menopausa Italia Study group. T)35 (rends of deter)-25 (mi)-1 (-)]TJ
-0.00101 Tc 0.00101 Tw 1.6875 -1.25 Td
[(nants of hor)-25 (mone therapy use in Italian women attending menopause)]TJ
-0.0251 Tc 0 -1.25 TD
(c)Tj
-0.02499 Tc 0.013 Tw [(linics, 1997\320)-25 (2003. Menopause 2008;15:164)-75 (-70.)]TJ
0 Tc 0.01801 Tw -1.6875 -1.37499 Td
[(23.)-500 (Faber A, Bouvy ML, Loskamp L, van de Ber)20 (g PB, Egberts TCG, de)]TJ
-0.02499 Tc 0.01199 Tw 1.6875 -1.25 Td
[(Jong-van den Ber)20 (g L)90 (TW)90 (. Dramatic change in prescribing of hor)-25 (mone re-)]TJ
0 Tc 0 Tw T*
(placement therapy in the Netherlands after publication of the Million)Tj
-0.02499 Tc 0.013 Tw T*
[(W)80 (omen Study: a follow-up study)65 (. Br J Clin Phar)-25 (macol 2005;60:641)50 (-7.)]TJ
-0.013 Tc -1.6875 -1.375 Td
[(24.)-487 (W)80 (egienka G, Havstad S, Kelsey JL. Menopausal hor)-25 (mone therapy in a)]TJ
-0.02499 Tc 0.019 Tw 1.6875 -1.25 Td
[(health maintenance or)20 (ganization before and after W)80 (omen\325)55 (s Health Initia-)]TJ
0.013 Tw T*
[(tive hor)-25 (mone trials ter)-25 (mination. J W)80 (omens Health 2006;15:369)-25 (-78.)]TJ
-0.015 Tc 0.015 Tw -1.6875 -1.375 Td
[(25.)-485 (Haas JS, Kaplan CP)110 (, Gerstenber)20 (ger EP)110 (, Kerlikowske K. Changes in the)]TJ
-0.02 Tc 0.02 Tw 1.6875 -1.25 Td
[(use of postmenopausal hor)-25 (mone therapy after the publication of clinical)]TJ
-0.02499 Tc 0.013 Tw T*
[(trial results. Ann Inter)-25 (n Med 2004;140:184)-75 (-)-25 (8.)]TJ
-0.01401 Tc 0.01401 Tw -1.6875 -1.375 Td
[(26.)-486 (Grady D. Management of menopausal symptoms. N Engl J Med 2006;)]TJ
-0.02499 Tc 0 Tw 1.6875 -1.25 Td
[(355:2338)-25 (-)-125 (47.)]TJ
0.01601 Tw -1.6875 -1.375 Td
[(27.)-475 (Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the us\e of)]TJ
-0.006 Tc 0.006 Tw 1.6875 -1.25 Td
[(hor)-25 (mone replacement therapy: a population-based study)65 (. J Gen Inter)-25 (n)]TJ
-0.02499 Tc 0.013 Tw T*
[(Med 2006;20:1026)-25 (-)-25 (31.)]TJ
-0.011 Tc 0.011 Tw -1.6875 -1.375 Td
[(28.)-489 (Modelska K, Cummings S. T)35 (ibolone for postmenopausal women: sys-)]TJ
-0.01401 Tc 0.01401 Tw 1.6875 -1.25 Td
(tematic review of randomized trials. J Clin Endocrinol Metab 2002;87:)Tj
-0.02499 Tc 0 Tw T*
[(16)-25 (-)-25 (23.)]TJ
-0.024 Tc 0.024 Tw -1.6875 -1.375 Td
[(29.)-476 (Cummings SR, Ettinger B, Delmas PD, et al., for the LIFT T)35 (rial Investi-)]TJ
-0.02499 Tc 0.008 Tw 1.6875 -1.25 Td
[(gators. The ef)20 (fects of tibolone in older postmenopausal women. N Engl J)]TJ
0.013 Tw T*
(Med 2008;359:697-708. )Tj
ET
0 0 0 1 K
114 473.029 m
240 473.029 l
S
BT
/T1_0 1 Tf
0.01199 Tw 9 0 0 9 60 448.5293 Tm
[(Uso de T)70 (erapia de Reemplazo Hor)-25 (monal, 1998)-90 (\320)-25 (2007: Impacto)]TJ
0 -1.22222 TD
(Sostenido de los Hallazgos de Iniciativa de Salud de las Mujeres)Tj
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 60 423.5293 Tm
[(BG Silver)-25 (man y ES Kokia)]TJ
ET
BT
/T1_1 1 Tf
8 0 0 8 60 407.5293 Tm
(Ann Phar)Tj
0 Tw 3.69799 0 Td
(macother)Tj
ET
BT
/T1_0 1 Tf
8 0 0 8 120.0947 407.5293 Tm
(2009;43:251)Tj
0 Tc 4.7306 0 Td
(-)Tj
-0.02499 Tc [0.3 (8.)]TJ
ET
BT
/T1_0 1 Tf
7.5 0 0 7.5 60 382.0293 Tm
[(EXTRACT)20 (O)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 60 368.5293 Tm
(TRASFONDO:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 100.1778 368.5293 Tm
[(Estudios sobre terapia de reemplazo hor)-25 (monal \(HR)60 (T\) para)]TJ
-4.7268 -1.11764 Td
[(prevenci\227n de enfer)-25 (medad cr\227nica en mujeres postmenop\207usicas)]TJ
0 -1.11764 TD
(sugieren que los riesgos del tratamiento sobrepasan los beneficios. La)Tj
0 -1.11765 TD
(publicaci\227n del estudio Iniciativa de Salud de las Mujeres \(WHI\) en\)Tj
-0.0251 Tc T*
(2002)Tj
-0.02499 Tc 2.13713 0 Td
(provoc\227 un r\207pido descenso en las compras de terapia de)Tj
-2.13713 -1.11764 Td
[(reemplazo hor)-23.9 (monal entre las mujeres norteamericanas.)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 60 308.5293 Tm
(OBJETIV)Tj
-0.02299 Tc 4.19462 0 Td
(OS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 96.7354 308.5293 Tm
(Examinar el impacto de los hallazgos de WHI sobre patrones)Tj
-4.32181 -1.11764 Td
[(de uso de terapia de reemplazo hor)-25 (monal en mujeres israelitas.)]TJ
ET
BT
/T1_2 1 Tf
-0.0231 Tc 0 Tw 6 0 0 6 60 286.5292 Tm
(M\203T)Tj
-0.02299 Tc 2.1828 0.00001 Td
(ODOS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 93.3631 286.5292 Tm
(Comparamos las compras de preparaciones de estr\227geno por)Tj
-3.92507 -1.11764 Td
[(miembros femeninos de or)20 (ganizaciones de mantenimiento de la salud)]TJ
0 -1.11764 TD
[(\(HMO\) de 45 a\226os o m\207s desde 1998)-90 (\320)-25 (2007 con datos sobre membres\222a.)]TJ
0 -1.11765 TD
(Para cada a\226o calculamos el total de compras anuales y la tasa de)Tj
0 -1.11764 TD
[(utilizaci\227n de terapia de reemplazo hor)-25 (monal, caracterizamos las)]TJ
T*
(usuarias nuevas por edad y modalidad terap\216utica, y examinamos los)Tj
0 -1.11765 TD
(cambios entre modalidades terap\216uticas.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 60 217.0293 Tm
[(RESUL)91 (T)75 (ADOS:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 102.0434 217.0293 Tm
[(V)110 (einte por ciento de las mujeres de 45 a\226os o m\207s)]TJ
-4.94628 -1.11764 Td
(compraron estr\227genos en 2001, comparado con 10% en 2007 \(p <)Tj
0 Tw T*
(0.001, )Tj
ET
BT
/T1_3 1 Tf
0 Tc 8.5 0 0 8.5 81.9937 198.0293 Tm
(c)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 86.4462 200.7793 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 88.8212 198.0293 Tm
(\). Los productos vaginales presentaron un aumento en el)Tj
-3.39073 -1.11764 Td
(porcentaje de compras, de 5% en 1999 a 18% en 2007. Un porcentaje)Tj
0 -1.11764 TD
(creciente de usuarias nuevas de 55 a\226os o m\207s comenzaron con un)Tj
0 -1.11765 TD
(producto vaginal \(62% en 1999, 82% en 2007\). Despu\216s de 2002, las)Tj
-0.0251 Tc 30.35294 66.19508 Td
(u)Tj
-0.02499 Tc (suarias nuevas de terapia oral la descontinuaron m\207s r\207pido que)Tj
-0.00001 -1.11765 Td
[(anterior)-25 (mente. Se atribuye a T)35 (ibolona el porcentaje creciente de)]TJ
0 -1.11764 TD
(medicamentos orales comprados \(12% en 2003, 29% en 2007\).)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 700.6874 Tm
(CONCLUSIONES:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 368.0652 700.6874 Tm
(Documentamos el impacto r\207pido y sostenido de los)Tj
-5.89002 -1.11764 Td
[(resultados de WHI en la utilizaci\227n de terapia de reemplazo hor)-25 (monal)]TJ
T*
(en una poblaci\227n grande de mujeres israelitas, incluyendo una ca\222d\a)Tj
0 -1.11765 TD
[(marcada en la tasa de uso, particular)-25 (mente de preparaciones orales,)]TJ
-0.0251 Tc 0 -1.11764 TD
(d)Tj
-0.02499 Tc (uraci\227n reducida de la terapia y aumento en uso de preparaciones)Tj
-0.00001 -1.11765 Td
[(vaginales y T)35 (ibolona como primeras selecciones para tratamiento.)]TJ
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 468.2831 636.6873 Tm
[(T)35 (raducido por Ana E V\216lez)]TJ
ET
BT
/T1_0 1 Tf
0.01199 Tw 9 0 0 9 318 610.6874 Tm
[(L)90 (\325Utilisation d\325Hor)-25 (monoth\216rapie Substitutive, 1998)-90 (\320)-24 (2007: Impact)]TJ
0 -1.22222 TD
(Prolong\216 des R\216sultats de l\325Initiative Pour la Sant\216 des Fem\mes )Tj
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 318 585.6874 Tm
[(BG Silver)-25 (man et ES Kokia)]TJ
ET
BT
/T1_1 1 Tf
8 0 0 8 318 569.6874 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_0 1 Tf
0 Tw 8 0 0 8 378.0947 569.6874 Tm
[(2009;43:251)50 (-)-25 (8.)]TJ
ET
BT
/T1_0 1 Tf
7.5 0 0 7.5 318 544.1874 Tm
(R\203SUM\203)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 530.6874 Tm
(INTRODUCTION:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 368.0593 530.6874 Tm
[(Les \216tudes portant sur l\325hor)-25 (monoth\216rapie substitutive)]TJ
-5.88933 -1.11764 Td
(\(HTS\) dans le but de pr\216venir certaines complications chez les femm\es)Tj
0 -1.11764 TD
(m\216nopaus\216es, sugg\217rent que les risques sont sup\216rieurs aux b\\216n\216fices.)Tj
0 -1.11765 TD
(La publication des r\216sultats de l\325Initiative pour la Sant\216 des \Femmes)Tj
0 -1.11764 TD
(\(ISF\) en 2002 entra\224na un rapide d\216clin des ventes de ces produi\ts aux)Tj
0 Tw 0 -1.11765 TD
(\203tats-Unis. )Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 470.6874 Tm
(OBJECTIFS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 353.8536 470.6874 Tm
(Examiner l\325impact des r\216sultats de l\325ISF sur l\325utilisation)Tj
-4.21807 -1.11765 Td
(d\325HTS par les femmes Isra\216liennes.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 448.6874 Tm
(D)Tj
0.013 Tw [(EVIS EXP\203RIMENT)76 (AL:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 387.6205 448.6874 Tm
(Nous avons analys\216 les achats de pr\216parations)Tj
-8.19065 -1.11764 Td
(d\325estrog\217nes pour la p\216riode de 1998)Tj
0 Tc 14.05162 0 Td
(\320)Tj
-0.02499 Tc [0.1 (2007 par les femmes de 45 ans et)]TJ
-14.05163 -1.11766 Td
[(plus, membres d\325une or)20 (ganisation de gestion des soins de la sant\216, et)]TJ
T*
(reli\216 ces \210 achats \210 l\325ensemble de la population membre de)Tj
0 -1.11764 TD
[(l\325or)20 (ganisation. Pour chaque ann\216e, nous avons calcul\216 le total des ach\ats)]TJ
0 -1.11765 TD
(et le taux d\325utilisation d\325HTS. Nous avons caract\216ris\216 les n\ouvelles)Tj
T*
(utilisatrices selon leur \211ge et le type de traitement et avons examin\\216 les)Tj
0 -1.11764 TD
(changements de th\216rapies. )Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 369.6874 Tm
[(R\203SUL)91 (T)75 (A)76 (TS:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 354.7457 369.6874 Tm
[(V)60 (ingt pourcent des femmes de 45 ans et plus ont achet\216 des)]TJ
-4.32302 -1.11765 Td
(estrog\217nes en 2001, contre 10% en 2007 \(p < 0.001, )Tj
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 8.5 0 0 8.5 487.4508 360.1874 Tm
(c)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 491.9033 362.9374 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 494.2783 360.1874 Tm
[(\). L)90 (\325utilisation de)]TJ
-20.73862 -1.11764 Td
(produits pour administration vaginale a augment\216 de 5% en 1999 \210 1\8%)Tj
0 -1.11765 TD
(en 2007. Une proportion plus grande d\325utilisatrices de 55 ans et plus\ ont)Tj
0 -1.11764 TD
(d\216but\216 la th\216rapie par un produit pour administration vaginale \\(62% en)Tj
T*
(1999, 82% en 2007\). Apr\217s 2002, les nouvelles utilisatrices de th\216\rapie)Tj
0 -1.11765 TD
[(orale ont cess\216 la th\216rapie plus rapidement qu\325avant. Par)-23 (mis les produits)]TJ
T*
(oraux, la tibolone est plus utilis\216e qu\325avant \(12% en 2003, 29% e\n)Tj
0 Tw T*
(2007\). )Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 281.1874 Tm
(CONCLUSIONS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 364.2133 281.1874 Tm
[(Nous avons document\216 un ef)19.8 (fet rapide et prolong\216 des)]TJ
-5.43685 -1.11765 Td
[(r\216sultats de l\325ISF sur l\325utilisation d\325HTS chez une lar)20 (ge population de)]TJ
0 -1.11764 TD
(femmes Isra\216liennes. Les observations incluent une baisse importante \du)Tj
T*
(taux d\325utilisation, en particulier des pr\216parations orales, une r\216\duction de)Tj
0 -1.11765 TD
(la dur\216e de traitement, et une augmentation de l\325utilisation de pr\oduits)Tj
0 -1.11764 TD
(pour administration vaginale et de tibolone comme premier choix de)Tj
0 Tw T*
(traitement.)Tj
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 462.5398 207.6874 Tm
[(T)35 (raduit par Suzanne Laplante )]TJ
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(258)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
33 0 obj
<</BaseFont/CMRXZL+Times-Roman/Encoding 30 0 R/FirstChar 32/FontDescriptor 32 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 833 0 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 564 564 0 0 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 0 667 556 611 722 722 944 722 722 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 611 0 0 0 444 444 444 0 0 0 0 444 444 0 0 278 0 278 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 1000 0 0 0 333]>>
endobj
41 0 obj
<</BaseFont/IUQKRZ+Times-Italic/Encoding 38 0 R/FirstChar 32/FontDescriptor 40 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 0 500 500 500 0 0 0 0 500 0 0 0 0 0 0 0 611 0 0 0 0 611 0 0 0 0 0 0 0 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 667 0 444]>>
endobj
37 0 obj
<</BaseFont/QNCLNF+Times-Bold/Encoding 34 0 R/FirstChar 32/FontDescriptor 36 0 R/LastChar 131/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 332 0 0 499 499 499 499 499 499 499 499 499 499 332 0 0 0 0 0 0 721 666 721 721 666 610 0 0 388 499 0 666 942 721 776 610 0 721 555 666 721 721 0 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 666]>>
endobj
57 0 obj
<</BaseFont/DTWGIJ+Symbol/Encoding 54 0 R/FirstChar 32/FontDescriptor 56 0 R/LastChar 99/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 549]>>
endobj
45 0 obj
<</BaseFont/AGFDFE+ZapfDingbatsITC/Encoding 42 0 R/FirstChar 110/FontDescriptor 44 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
69 0 obj
<</BaseFont/QOFAPH+Times-BoldItalic/Encoding 66 0 R/FirstChar 32/FontDescriptor 68 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 667 667 722 778 389 0 667 0 0 0 0 0 0 667 556 611 0 0 889 0 0 0 0 0 0 0 0 0 500 0 444 500 444 333 500 556 278 0 500 278 778 556 500 500 0 389 389 278 556 444 0 0 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333]>>
endobj
90 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
66 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 66/B 69/E/F/G/H/I 75/K 82/R/S/T 87/W 97/a 99/c/d/e/f/g/h/i 107/k/l/m/n/o/p 114/r/s/t/u/v 121/y 213/quoteright]/Type/Encoding>>
endobj
68 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 67 0 R/FontName/QOFAPH+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
67 0 obj
<</Length 4152/Length1 4152/Subtype/Type1C>>stream
  QOFAPH+Times-BoldItalic   Cø øøøø€û\ûlútú-
 ‹‹
 ‹‹  	    L¯   }“002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku     # ( 4 J M W F S N B O  E & , P L V T U * Q D G I 8  ) ' H 3 5 Z "   †~ë4“öHùqâåpö‚Ê>ÍCÜ	]	ª
6
¯3`ñq'°€œ‹«÷Æ©÷¡«r¤øo÷&è÷äøå®”–”­Ã¨iKû!<sû…ƒm÷Š°p:ûJ:.`y•£’Œš÷}÷œ÷¨Ä¿ãé;¼û/û¤ørÃ‰mˆzƒnûüU}Y{{Z…r÷Á÷NöÖ÷×g²)¬Óy±÷±¤÷Ô¯ ù?ù:ùBnt€~„zl`©4û5kG>*6Rûûû5÷û÷GÒ÷  ¤½§™»÷HÒ‘Á‘¤û²r‰˜–Š‘­‡•‚rp_û?}{y{f_(NÑ÷÷/è÷º÷Så¸Pû¨†-y­ù®‡wğ÷÷÷ø÷Åø@G¿}Ÿ·Í±³ËÜµYû•¦‡ø³÷\ny„uø]l¨‹Aû26!û?÷‰_‹û!FVVC!^áñˆmŒhûs©§—’’¯·hæ÷äÛ÷ŞiÈûíü—vøÃ÷÷÷÷Vù@fmmff©m°°©©°°m©f¨ûr/z…Š#q¹Š—…r†‰„‡{Sûl€b‡v‹|e¦q´ÇÃ¸å¿u™jWqox‹ƒ„’“”Š‹”®‹È÷zª÷ü—v÷³÷µùP3ym‡1‚q¢³jw}\„q'ûÿ}W„j‹zb¤sµÜ¼ÖÇ²ušiUqqy‹‚…’•—’¬šÀûb“vøpwã÷Ş÷BÔè÷~÷^÷Uã÷æ±pªiğnqqlè_¶~‹ijbN6.ˆ÷V…ÃvàW}r‡=€q›ŸŒ{•šr˜0‰!‹‹‰û‰Mûb~Ë÷«÷l¬÷#û#÷÷>çô÷(÷j÷«¾àº”u(AM8v÷<CLegocì^u§ÁœŒ”¢å”÷:Î÷½`¯Oû'û"û<û13ÊLâÙÂ³íÄû™ v÷×÷ vø-÷wøcQ|‰‹û ~p¶Š–†w}V~]>û¡÷½÷2©ëÊö¥‹œ“e‹®®£©·´u¤h\`XûJ†÷—v©vøÔŠwøÚ÷h÷}øaO~~‰ûq·Š•†w„Œ„kû‹ƒkMûq÷÷÷æ÷­––’‚|‚‰~†|‹Gûoiû÷°÷µ÷á÷¹‹™•~b3ûO‹8è_¢v¹Ç´­ìÃu—eQ|z|‹‚„’“°ã÷L‹çºm¨YXL`û?œ¸¡¨ø´q¤b-DûH]ˆû*’vÑ÷ÿµv÷p÷ø9¢Š™xnIHûŒ1rx¢ªÌÜ÷Ş†÷P¯û…yS‰·…s£bûû)ûRû3=µ[ÎÇ·­çÃŒ€b‰ƒ‹}ğd§p³¸½¶ŞÁvšfWxx|‹ƒ†‘•§‘¨§ç-—v©vøbw÷wp÷…øaS~Y„.…p «Œoqj Š†‹ƒlPûh÷÷èâğ½¥˜–‚~i4û[‹:ğb£u¸Ä¼´å¾u˜eP}{zŠƒ„’•¤ã÷i‹Ö½p¢X6N/*J‰ü$û*ÓDÒ÷ıµv÷p÷¢ø9¢šwkbDû /rz£®ÍÛ÷€â÷Š÷«FyW†4…p §˜‚w„‡z…ueût£w”p‹û
û/ûSû1ğB¸UÇÌ¹¯æÀ‚cŠ‚{pd¡u±¼¼µß½u›mZwu{Š…Š†‘“¢º÷:”¬œ‹«÷Æ¬÷Ÿªs£pù:Øùù1ü¯sÏ‚‘‡n‡u…uûüV}X}~Wƒrø¼Ç÷WrKû+Uû!‹_u–¡ŒŒ–‰†›ÅÄ÷e÷©xD~Šˆx§†Ô÷¦qe6gpû‘È÷sø­”˜•®÷½f#¦†œ‹¤øÿ¤vùeøø$÷l÷Y´°—‘³¤ûgrŸ‰¯poMStwûIû6†ŒÇ÷q™¿ŸšÇ¤ûËrÎƒ’ˆk€ˆz„qûüU}X|}Xƒr÷µ¤W}”¨“‹‘‘Ê÷„“‰÷ ûz“zy‹|†T…r÷¬¤hz•€¢û*}©ø5¨ˆ÷÷`÷÷¯øbû'ûû3û;5ÏKç÷%÷÷0÷9èLÉ.ƒn©ŠšvaBSû¬+iy¡·Ö¿÷­ö†û*ƒÑbvø=¤tøp÷±ùOB~o‡ ~p¤²hˆz†zû0üË÷½÷O³§ğû1¤®IÉ¾«¨é¿u–q\{zx‹`s÷H¾ÊÂÏÇ”¼“¤ûbrµ‡”‡|p`aû
0Š-—vø_w«wšøpĞø{øVû
aû&wUgGfFZXn‹}‹ƒ”‹›‹–¡•¬ğé÷ÉEI|B‰p»‡“‡u}†s€f_û+‚k…j‹xV£sÀÂ³¦ØÃ“–‘ª¶‰{\…opc¡w·ÄÅºÜ·v˜fUxx|‹‡‘˜Ğ™“¯š¾û™“vŒ¨ø1«Šw¹ë´ê\÷ßøao{ƒ…†}|nv¡‹^:VZ?T™nÎ=³[›mrlrsjYjºá~qüuû:¥™““‘™|¡¤x‹·äÈÂÙõûÜ‹Ò§Ÿ¢«¸©c<˜\¦ˆü—vø4¶€÷·÷‹øçhZ>^f2dh¾Lûp‚mxF‹n`¥r¸Å»³ëÆu™gStsy‹ƒ„’“š“¯œÈÈ÷oŞ¶Cû™‹£ù ¤køH÷›£S|”§™‹“™À‹’¢÷ø.™¾ º¤û½rÌ„”†r~†q†xûüW}X{|Z„r÷»û*û`¥÷:®øÓ÷Ô÷÷køc*{£û|p¹Š“‡w„nƒjûü>~X}€_Šq÷Œ¥XŒ}’¥§¥Ù•º{«›†¡÷÷"÷J÷<ÙbºIZ\p;R‰ïª£™xlADûˆ*uz› ¬´÷™´Û§º¸²ûb~Ìø¬†÷÷)÷÷Ñ÷!GYov`_n¯ÄÏÄ÷må™”„‚}vz‹pm¤tª²£¦¶Â^®Eûû%û:û//ÉLç×¼­ñÒûÑû`÷ûªøÙµ÷÷‚v÷÷	û÷ª÷€øVÒ¤ì©¾­‹—‘‡ƒ€{‹w²o u¦©  «»d«Qû @8û:_BƒaôÔ|N„m‡wMû­,v~-S€ƒ‘”›“‹¤´§wmoutn\³kÅ÷=½÷fø&Üä”µ-—v©vøbw÷ô÷p÷¹ùO.zn‡6‚q£²h‰}…vû.üË÷¦ì§İ¡¸¸èÊÓ¯‹™‹”…‹{‹a3ûS‹8ğh¦r°á´ÔÉµv›eSrp}‹ƒ„’“å÷‹È¸n¨^GT^û4‰Œ÷ƒvù*¤ÌùÿøÎy÷³øã¤¿œ™´¤ûOr¾‰—„m{ˆrû.ûÙ‰j÷¹ˆ¦ˆ©‹™±“’Á‘¤û rÃ†šwEû(ûÈŠc÷îŠ‘‹‘‹‘®š—¸¤û¨rÊ„…•EÚü×¨÷yø{ŒÇü{ûÑ vùAw÷jà÷ø÷¹ÙåßÃh²Ybnl`LÑ‹afZ[Fl÷‹¤÷Ä·÷£¤sùÉù$¤Vv—§˜Œ—·‹Û÷½´÷)™¿š—¿’¤û¾rÊ„–†r~‡r…u\ûBûƒÁ÷\šÂ¢šÉŒ¤ûÏrÊ„•…p€‡u„sûüU}W}W‚r÷»¤gg…¼™•šÀ½÷H÷‚Kû||TzF†r÷Ñœ‹¤÷Í¬÷«s£~ù3Øù&ù1ü§sÍ‚’‡r|‡s…uûüU~[|}Wr÷»¤T{”¨šŒ™ÀÀ÷]õŠ©x‹GŠˆu§†Õ÷¥o\0s}û‹{Ç÷rø¯•–“·È½~s§¦s”pK¥…û*û_­÷Kv÷4«÷‹ªWâ‹÷÷÷ @÷	ö÷„Øo‚¥~šwt`_qEC^©»·È³›õ÷!øK¨œtcWiûEn|Ÿ±¾¬÷ĞúûCü>+uipSN×`÷ ÷&ëÇæÇg¬ûªVši•y™‹››œ˜š™ƒ‹ õ÷êÚíœŠ’‡ÎÃû¥ik“aû$9*V¦dÀv9]}}emw´|œ‹¤øø«r¤nùğøA÷ëÃ—¦•«¡º¬©Á‹¾‹ì>ºû3‹û¦rÎ‚‘ˆr}‡q…wûüU}W}W‚r÷¼¤Q|“¨™£”«Â÷V§÷ ûß÷^¤U}—wÅğûIø„¯””“ªÃ¬iO:bFPys„j‡bŠd‹¤øõ®i­½øëğùù1üºeû?¤„¹ìÉ´÷‘û'ü¯|UrzI‹r÷ß¤C€‘ª˜¨‘ ğ÷øî†ªh“û¦‰ûbûaÜ:÷ø»w wô÷·÷KËª˜ø0µ–‰ûT²¥û•JjWQIjêqm®‹gntsli¦p°ãäã÷Eõâ÷&¾÷Í½imìnqpkúVÂ‹b]Iûyg‰~Ôw÷wärÙK|vˆJ„xøV˜÷b›š‹÷œ–üv¤
ÚŒ
_÷ù
endstream
endobj
42 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
44 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 43 0 R/FontName/AGFDFE+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
43 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  AGFDFE+ZapfDingbatsITC   6‹û¹Ïƒ
 ˆ?‹‹
 ˆ?‹‹   h   e   k‘   ¬ a73    ‡ %<ø
ú0û¹ÉıÌù7ùÌıYVøçúüçäú!ÑúsúsøÍù
endstream
endobj
54 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 99/chi]/Type/Encoding>>
endobj
56 0 obj
<</Ascent 921/CapHeight 671/Descent -223/Flags 4/FontBBox[-180 -292 1090 1005]/FontFile3 55 0 R/FontName/DTWGIJ+Symbol/ItalicAngle 0/StemH 0/StemV 41/Type/FontDescriptor/XHeight 684>>
endobj
55 0 obj
<</Length 472/Length1 472/Subtype/Type1C>>stream
  DTWGIJ+Symbol   Fø øøøø)ÁûHû¸úÖú
 ‹‹
 ‹‹      ª  ¹ •chigreaterequal002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Simpele is a trademark of Stream Technologies Inc.Simpele   ‡ ˆ wz¦&û|äøÅÛ—øø›YxKypn`Svµ÷b[÷aø	$ûû†e÷:~Ãc³_‹XcQ6†gœÏ›£ª±¶«gMš«ûûmü&ï÷)÷§’]•L‘r–Z•k—u›l¬u©‹Î‹³Ç›÷ü$&‹Ã¨øƒø ÷îÊüƒ÷xMøEûZüEûZNøƒû
ÃüƒSs£ø†÷?˜÷‹ûv¯
´
_÷ù
endstream
endobj
34 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma/hyphen 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F 73/I/J 76/L/M/N/O/P 82/R/S/T/U/V 88/X 131/Eacute]/Type/Encoding>>
endobj
36 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 35 0 R/FontName/QNCLNF+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
35 0 obj
<</Length 3520/Length1 3520/Subtype/Type1C>>stream
  QNCLNF+Times-Bold   @ø øøøøû<ûnúzú:
 ‹‹
 ‹‹   ù   õ  >°  › }‡Œ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku  !               5 3 " 4 ' 0 / %  # + & * 7 . ² 6 - $ 9 1 #   < | ÓC]»&RİCçê7«ôH§BÇ‰Á		‡

t
» ©û+‹¤ù+w÷O÷&øN¤1x›×øÍzûûq Ä™™¤—u\ü:wz(Šrü$šv£v²÷Là÷sµÍ`ºO[jj[[©k·à’’‹“—“‚}fkd>S–tÉ°¢¦©¬± ¾»û+‹÷øM÷÷½÷øq÷hrEo|‚(û*÷3÷.ŞÛ«Ç‹Ö÷@×û*DIûY¦Ä¥¶«¿Ğ¼V@YwSaN^K]Uûûsø3û+}÷(û(½øÏÛ÷­÷&@÷¨øf÷‹ÜbÇ:¯°Ë±©ÇŞM¿(&@Y$U ®Ç°¤À‹Ç²bMIig,mxè÷ `ÇP+EdZT¨Dqí‹7iprlSÇgé÷9÷÷÷&ûÒ v÷@÷·÷†÷²÷@÷û†ûû+ƒÇO÷(÷S÷Ü÷ø	Ø¸øiù8ûÕ+ûí÷
ºƒ»uÎm´VTU^\XøDZã‹BgqrhVÈhå÷4÷	ğ÷ÜfÍH³V«e“û”¡Ü÷©û+~¦÷ş¹÷„¥§øRøn÷p÷AŞû kx‡}e³÷*ÑĞ÷/²¥û¨jû8û/ûwûBæû÷"÷æî÷û-KûnZuy–¡€|¦‚Úåµ¨‘º’Œ “Ì¢Qû6û+ vø¯÷œø^øoù8ü3`ûr¤Ëœ£ Ã÷bûZü¯êû+~ªù§§÷û÷÷9÷û÷
Øøj÷MãbÇûÒÔâ£¼½ÌãAÃû
û 6HûA³UïPè"l]X5&áH÷÷çÚ÷Ôû÷ôa‚gjeR¨CÄÒ¶±±·Â­]?è…ü+Gi_XOeÁàÅ•ª³Æ÷C£kDû+~¥÷„¹÷ı¦¥øRølø&÷>.÷ûû1*ûûÕ9ö°£™¨]û0DDû(kq÷¤÷C÷8÷vû1¦hŠoƒS†s…xMtÅ÷5÷—¨»¡x•›o–62û+~§ù§£øVøn÷ß÷b,÷*ûû,û+ûaûZëû&÷÷ë÷&÷Zû2û û'wN\\wÈ÷'÷y÷&ŸÈººŸNû&û+ v÷#÷øEw÷÷&û$÷$èøm÷#÷MøE;dYk_xrûû4‘#û2ûğ÷Šû#÷&÷#èû$÷ûcğ÷a÷»èü$›‹¤øÿ«¬¦÷U÷6÷T¦ùøoˆ÷]üê‡û]¨¡÷±­÷”ü£B€6„r÷ø¤7}˜Õø£÷€¾oûÒ‹¤øş¬r¤÷÷5÷K÷>øù]¤t‚‚˜û]÷²÷°¶¹ß÷
,ÈûOûÓrÔ‡™{DüNBƒ‚<€r÷å¤@•}šĞ÷V¥÷cûÍYøˆûdjû$Š÷”ø«š•ºŞ±^)Ò‹¤÷@²øZw”ù9ùB£]—W÷ûsø¢nûpü¸e.‚Yr÷_¤Ot—¤š˜±«Ù÷s§QRt~ƒ|ˆ€ˆ‹Y†r÷€ûVè÷‡,x­vù:«®¨w÷÷…÷
ìø”÷SÙaÑG­û'Ö9µw ‹¼È¶²ÊçÑIû­§÷mmoƒ……xgg­1û7<û1¼O÷PÍlç_ r‹THY_?ô$BØ÷onûŒ¨ì¢”•›­±ií÷(ïà÷c‹¤÷Ä¬÷­¬r¤ò÷5÷.¤÷£ŞøÙøo÷]üÉrĞ‡}WüzY}Cƒr÷û¤2u™À÷~õˆ¬i™û	¤÷ærxû	jk&‰÷~ş²—“Ç÷#Æ\û÷x¬ù¬®ùVùy÷ã÷dû'÷(ûbûbû'û(ûdûb÷(û(÷a÷a÷(÷(÷bûEŒûhOûûû	P÷÷h÷_Ë÷÷÷Ìûû_Òv¤ù¤ò¶øB·øùNù¤ûkrÕ„vDûÃ‰ûîø?ûfr£‡™ºSüoT|}Cr÷v¤>•xŸÏø%øøQü²¦øáÄ˜™Ì”Ò‹¤r®øó­r¤ë÷6÷•÷AÜùD÷ë÷eû÷û}ûÃrÌ…œ}\ü^vzN‡r÷Î÷p÷ ÷÷füûA{ûVH)ûa|š¶øŠ°˜•»÷Òûû]ûÒ“vøywİ÷<÷ø¹f±]\ee]\±eº¹°±ºûÑºf±]\ee\]±eº¹°±¹›‹¤r«÷Ê¡÷®©r¤ò÷3÷L÷?®øı÷NåHÊû£÷°²°Øò/Äû;ûÇrÎˆŸzXüyX@‚r÷Õ÷?÷Ó÷şû[÷Ùû lpûˆ÷t®š™±Ñ¬`/§ûİ&cZ8`y¶÷©ô¼Xûû+,¬ù]¤÷"İ÷5øpù¤ûórÜ‰ }UüÀMyr_qv˜£¦”‹«²i®ddmj`DÕSê÷#ÔÔ÷&øHÔ››Ó›‹ªl¤÷Ä¬÷­¬r¤ò÷5÷6¥÷¤·ù÷dpûQBZûKw˜µ÷‡÷
„©n™û¥÷çqzûknûˆ÷}´—’Ï÷#Ä`û ¤÷\üÒÿrĞ…|YüwW~€A‚røÛûš‹¤ù¤÷÷4ø¤Btœ½øxÀ¢ÔŒ¤ûñrÒ‰¡zVüxZuzD‡rÒvù2¤›ù?ùOù¤ûhr«ˆÁŒa{ˆz]ûûÜû÷ĞpÌˆ”‹›§˜‘Ô¤ûãr½‚—¡X÷”üì¦÷vøß£É—–Á•÷¸‹¤ù¤s£óµø¦÷.øú+¤<•–ÒøOÓ™šÔ£ûû[ülû\ølûørÕƒ™WüpO€‚<€r÷~¤7“yÔøf÷üâ¦÷øñüS}@„r› vùMvøX÷ù÷ddûdüÛ¤Õ”˜–¿øw½yšF‘¤øÒû\r÷vR¶û#G„bû}÷«¨œ÷¥ûçq}÷m¨û
’û‡aŸ~Ë÷Ô¼÷Åûù1v~mxû#4T÷÷0›•Ÿ‹¤ŸwsÒx¼ù¤í÷2÷Õ·ùOù¤ûprÛƒyBûÄû*TGû(]É÷÷áÖœ›ÛŒ¤ûårÍ†›yFûá/\¿`a¼Ïvà×Û©¶²¯³ŸÏá÷ÓÆ™›Ë”›‹ªl¤ù¤ó÷6ğù÷xnû*KO\ûDx—¸ølØ™—â¤ûğrÎ‡|XüyğX‚ƒ?røÕÒyºù	­‡w¼÷EûEù`¤ôùA÷m¤;4Ig;‹ûIñ÷a÷kÈö÷çÛEûÇ¤ô÷~pk~}yèoB½‹#ûVû)û0û`ûd÷%û"÷j÷Î®÷îÒ‹¤ù¤›ù<ùL¤[qºt°ûI÷¯÷9÷uœíš¤ûŒrÌ†’„rr‡ûû(*÷+€†–‹•Ÿ—‘Ï¤ûír°ˆ–‚ª^÷Zû¸ûBûqrkt~T€r÷¤P‘u–Œ¤Œ¢£·Íâ²½ñû6™u’x‹v‡E…rc‹¤÷ª®÷Ä­r¤î÷5÷:÷?Üøéø÷0Ëû>ûÓrÎ„š{GüN=z‡I€r÷á¤>”—Ó÷M°öÂ–¦»Å­«ÁËû?ˆûgjû÷ ü¥›•±Ù­]!xøa—÷_›÷p”÷Ÿ“üu¤
¤Œ
_÷ù
endstream
endobj
38 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero 50/two/three/four 57/nine 65/A 70/F 80/P 84/T 86/V 97/a/b/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 119/w 121/y]/Type/Encoding>>
endobj
40 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 39 0 R/FontName/IUQKRZ+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
39 0 obj
<</Length 3543/Length1 3543/Subtype/Type1C>>stream
  IUQKRZ+Times-Italic   Cø øøøø€û=ûmú…ú
 ‹‹
 ‹‹      ü  =¬  ¶ }‰002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z    ' C V  7   X     Y ìLO³E¿|Á>³Ş+Ÿ ­ZÆ	?	¤
4
b
·
ın7- vøÿ®ÆøÑùù"ü§aû.‡¡ºœ¤¥Ÿ¤¬¦‘÷û#ü¥}YszF„{÷¶›9‘‚«•‘¥’¥÷ ø‡ÁÖ¨rKŠ‚‰xœŠû*—v©vøOvø]ğøpô—_Qvwz‹ƒ„’•–‘™“Ä÷e•®‘©‹˜²p§fKFMû#-‰÷
øK…L}w†Bƒz¤ŒœŒ¤‰‹tuj|Pûü‹Ö±÷)›µ²ÆÁÜÍÆ®‹›‹—€‹}‹†Œ‹ƒnWûS}W‚ağpœ{§¾·®Ú»ûb¸ø¢ªá÷yÌø/ø
¸o¢Tûû2û9û&3¾VàÎÕ²ÏÉ—CQk{`‹Se°Á™Ÿ’¥¨÷, ò×‹âJ’7+Gûv·°æÏÔÀ Œš{tü$d v÷v¯ø+vXøûøÈ›Sƒ•Ó,øÌqûµü‰Aû}{bƒ{÷O›\~’¢˜“¥—¢Å÷÷pŸûŒŒ‚‹gx~PŠ{¾÷šûV÷(÷˜û*—v©vøNv™ø`ğønó|˜UFy‹‚…’”’ •±·÷4—·”´‹š°q¤e,4û&H^‰Ë÷e‡ût‘Œ[‚{¾‰˜†x~‚n…v‹ƒl@û§Ö´÷$¢Ã¼ÑÊã±¬¯‹˜‹•‹z‹€…lf`û7{PŠƒ|ğl›{«¹©¤ãËû*€¼[»ø¡œŞğøpï–~~YSy‹„†“•¦–µØ÷Æ…L„€[ŠŒ€®od‹ûû1ûJû-=®bÎÑ²©÷ãˆ{L†q‹wğo˜¨±¬¥ßÍû÷”3,ûz!dr§·åé÷q÷®¢qdü•v´÷‚÷«ù;†Q{ˆ9{¤·Šr„–v>"üv;ˆ}‹zi›yªÁ§¢ñÑ”UCwxu‹†‘•’š“©û™“v¢vøA£Œv÷ Ô¹Ø|øøO}}‚„‡~|nqœ‹cC[aJ-÷?‹@[nkaRl³ìz|üwû4š›’‘–|­ªx‹±ßÉÂÖêûÙ‹Ô¬¢Ÿ­½«g=•|›û*•vøYv¦ß÷¦Şøh÷¹èUÃ2û(û*û0û-/ÂWë÷ ÷*÷<÷8«)Bûmû[k°Âîİ÷p÷¶§fPüûMvøï«÷x¡¯êø:øú±g¦Xaexdjibu\j#0ƒkå3ü9tûlX_‹„‘•””‹™ zšsw}zsi¬q·åĞì÷MµÔ÷Õ÷ ‘« ÷0¦±ÓÂ™•†„Š†€‹|sš{¡¢¡d v÷Å°÷®©ø‰òøğøŠîBÀûûŒz«†±`}‡v`û
ü={R„…P€{÷‰›S’“§š—”­À÷U¶…¤‰±‹÷,óÛ÷	$‘ûOWûxt{Ñ÷‹‘ —“¨‹æ´g;û™ v÷èñŒv¸øğø0øªxŸnX@7(^‚wŠ¼÷[ğˆWW‚W‚{“Œ“ ˜y~…ih:û¹×¶÷ š´®Ğ°ÕµÀ ‹ğ f‹¶¨œ«Ó—v©vø¿\º—ùFxùRô}—ZOxyzŠƒ†•”Œ’£Ä÷g”­‘©‹˜¯s§k24ûHa‰¦ã•±‹œ¯t£iO?Dû8ˆÄ÷[ˆ$vŒŒP€{ÀŠ–‡zƒ‘{M8ûÊÖªğŸßÉãxÑ¼Â»¨˜“‚|ƒŒ|T‹‰;ûº×²÷, Â»ÏºÏÁ»¦‹—‹”‚‹}‹†Œ€^ZûZ}Q‡z~øoš{¦¹º°ØÀûb€¯ø5w©àø<÷ü½a«Hû%û û'û.)¿UëÔÉ®ÔÀ{”cZSk[‹Sh¸Ò÷$ì÷ñ£šƒ{|‚‹ru›|£¦¥ü–vø+¬¯÷˜÷¼øB;§òŒ‹‹ˆ……ŠŠ€‚\Sbib{m€‡ˆ‹‹‚‹”‹‚ÖBû§t5Œ‹‚uŠ y¦¤£–Ÿ¢›˜œ³Ä~‘rlpj{}‹…‘–Œ›ß÷Òßû*ûMv÷Wø¶øåøi÷Éßa¼BL[l=T‰§î‡’û0uz©­ˆ‹p„†s‚jûüN~Y……[†|÷bš\y”¡©¨ğ“®}¦˜ˆ¨÷!÷0÷=÷+1“û(û û5'ltš¡¹»÷(¹Ì¤Ä¼¿³¡mWûbûLvùv÷àéc³Ğø>ø²u£hàv{|wĞZÁ—‹dP,û/p]w÷…¬N÷qy‹vE}VzŸ“Œ”Á¤Yûl¼šG•V~{„|tmxqplww€…‚‹w‹}¨p‹t‹z{‹u‹pŸyª‹°‹¼²Ğà÷	÷#÷÷ƒ‹Úû*‹Öø¥ÔøàøWøíFÔ-*?Q%gŸ„²Íµ§É‹ÒÀWDP`C%ûûeûtz÷÷½÷z’rXv~U‹ûR÷U÷U÷
÷
©º‹Ïû*„§ù§«Ú÷ÈÙø…øH÷*Oæ(û.û,û|û~ûÎ0ê÷1÷&÷j÷y=âû*Tû]J5_jjvhUj½Ü÷½÷UÁîÆ¬·­·¿ª\<û*v÷Š¹ø¥Ğã÷˜Öø€ø[÷Eâûûûûû "É@ä±·›©º‡Mûûûûuy÷œÎ¢Ö¾÷åİ÷$‹÷&@ÅTv3wijwWp^Ke¾á÷ÓõäÌ­\0d v÷Û®÷—¬“ùùù"ü†{Ï…•†n}†p…tûüO{Rƒ„R€{÷›Qy–¨–Œ“©É÷sÅŠÁŠ¹‹Yx‰|…sœ…×÷x‘Z,“ûBˆÌ÷}‘¢•Í‹÷,ª~M}‹‚‰xŸ‰û*¡ø¼øàøn÷ÔÔ[¼D2V:J^Šğø†U‚‹#|{ ‰¸‘nyf‡{ûüŠˆrÕnÉ÷)÷:÷B÷06~#ûûSûh|—¦ìë÷‰÷µ§iWû*€ÀmvøNvªv÷à÷¸øo÷ }”[Nyy|‹„…‘•—Œ˜¼‹ Ù÷¼AaûrT`HP/XUn‹q‹¥“æø ¸ˆQ}zˆ@€} ‰²’lƒ‹Š‚gYûW\†p‹zgx¯Ğ¾¾÷O÷hûƒhwølœy©Ï¯Ğ»®ü$‡÷÷¬³s§invxpz’{š}ƒrurVg•xà¼¶Á‹Ædvù4v×øøùDù›ûN{¿„–…uy|hfKû^ûó‡IøJŠ‘‹‘‹«š”É’›û…{À„‘ƒ™9çüÃøøı›¦™•¥û* v÷EÍKËŒøq°ørù:cü5üCwG÷™ZûGÚğº÷EîšÍ,™÷×,û×ûi÷Å÷Õû*…±øïµ÷ÙÛpâĞøeø½ÑOÁ<FKcLlš†´¼¨œ·‹¾¯fU8,Iû$zŒ{¡àôÅNû3QCDzr–Ÿm¥e„wpz|rf´vÓ÷1÷÷÷#Ør´E­Ğ÷»¬«Òœvø`v¡v÷Õ÷:Ê÷H»üùø¬v jt}|xj¶†‹f]_Iûû&k÷ı‹‡†‹‡‰Šƒ†ûSûÄ‰…çƒæzåü¯„‰ƒü‰ˆ‹Šˆ[z‡V‚}¡Œ‹‹§Œ“…“t•mšû‘#4€ŒŠf™“‘”·¤÷:÷º¨ûĞq…’Œ‘“’¢ÉÖ÷=÷]ïü$€÷¦÷÷·ªr¤mlrrlm¤rª©¤¤©xøA™÷g¢’‹÷¡üs¡
¢
_÷ù
endstream
endobj
30 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P 82/R/S/T/U/V/W/X/Y/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 131/Eacute 135/aacute/agrave/acircumflex 142/eacute/egrave 146/iacute 148/icircumflex 150/ntilde/oacute 208/endash/emdash 213/quoteright]/Type/Encoding>>
endobj
32 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 31 0 R/FontName/CMRXZL+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
31 0 obj
<</Length 9451/Length1 9451/Subtype/Type1C>>stream
  CMRXZL+Times-Roman   @ø øøøøû<ûnú|ú
 ‹‹
 ‹‹   û   ÷  ¨¬  $Ê }ˆ002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  U  S J P  U    F T H O Q M B D N I Z X E G V W  / C  	 ) 3 5 
 L 1 6 4 "        Y o *   8  R + ' [ . 0  $ %  & - K 7 ‰    # ( , ; : 9 Ø È × Ó Ï ² Ò Ô Ë É W   o Ê^¯N¬;z@ÎÍ;³KÃ	 	Š	ë

k
Í
ä"O‹ñkÌtâ\‰X”4kÇMìŒÔBëB]Æ*cà&‘í(K°OÆJ‰÷Œş·vài  œ!!º"pûÑ vø`w wÖßĞ÷âø+¬wŸhblsH]‰ä°†Jqw„Mu{š“Œ•¤•{_ûY‚ƒN{÷ƒ›KvÄ÷sœ˜¤™˜™“”’“‡ƒ”x “‡›¡›¥ü vø^w÷$ğ×ğ8ßğ÷Eù§t¢opttop¡t§§¢¢¦Öı›èK–Ó÷÷†WwZyVy|©Œ‹“¦”{_û{CGˆ{û*‚¦ø4§¨ä÷šäøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûü$ü¿ø«Ğß÷ªÍ~–vrzt‹g|¦Ê÷³ğ«&÷–‰…U<midp„†‰ˆ‹…‹‡Œ‰‹¿ûÂ5©bÉ¸²¤¾¬û*‹×ø¤Ô÷åáøn÷~md†pP‹û„÷=÷Dâæ³Ú‹Úí:Ù&ûHKûlŸ†¯ê²¯Ó‹İÄP6?\*95ûFûP~øû*~¥ù¥£ë÷˜ëøp÷ß÷c÷EÆ¤nd˜[[d~rnFPbûûû³ûÑOr¨²~»»²˜¤¨ÑÇ³÷÷+ûh`!44`õ÷h÷i¶õââ¶!ûiü$›v£vÃ÷  ÷X–¿h²\jrskl¢w¯`™‹”•‡Š‰iogVg•xÎ­¸ÈÄûbĞ÷o«÷¯¤ĞFÒ÷cñôø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½ìû÷-ûcÙš®¯ÇÆ¥m7—û™‚¡vøZw’¢¾È÷:Ñœ÷ğ÷»t«M° Ënœ|¤‹©¯­¨¶Å®d6œ›¬‡÷ƒ†‡‰…†„Œ…œ™cs:QXDOªeáZÅj­xq‹n_koYEi¯òs{\û/˜”’”“•Šˆ–œ´¤‡¥ÙÊÄÓû*ûnÄ÷&Ö@Ôæ¤÷k²§§ĞnŞ÷EÙ¥¨İÀøiø²?u~“w]tm*AE-L¤hĞgCKyvtuš|²{¾ÀFZnfgTØ`ï÷÷ÙæÊ]´@ûTs•‹”˜™˜—˜™“”œ†¨çÏÍä¨‡|°PûSnf_İÀMaÌíÈ¦®»Ä¸B.óûŞR?bûŞÀ3M©µ£•œ²¹¬„›‰¤ˆ»‰À‰ğˆ¡€‹iû* vø)ÂŒwÚÜ:ß÷EßÔøx›]}›¼÷yè^ÄB[p|IDÛ¬„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ì»Ã›”¬»£kJûeN}xZˆ{û*ûVv÷a«øÇŒwÕß÷vàìøi÷ˆ÷Fä*R_sVa‰ÔÜ…TvŠŠ4m{Œ—‹—«‘[ügU„„M„{÷…›AŒ}—É÷0m«©²÷æ÷÷$6fûYAArm—s}—‚—•÷Šì¯“»ªºÕ¼>ûü vìß÷”›MŒ~—Ãøç‡Hwv…Ey{Œ™’‹—°“€YüpV{}N‡{ûb–vŒÄø¤°ã÷6İxøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½¸T‘x·ª§›­§û0ßsˆ€ƒx{yb{sfo­¹Èºµ÷±ûbÓø¨¤×ø0÷(}“`HapQ‹1Kİ÷ğÄÔØ²–‚c—‘w•kš|£‹¦¥ÁEº<û+!û!ûÚ/÷ßÆº÷À÷ vø-¿Œwáß÷Lß÷KŞÜù™›RŒ•»÷c÷dÆ=SXpSUÅxk¤Sbv‚XF†‡ƒ†ƒÖ¼ƒZyŒ‹1py›Œ–¤•x^û’V}}S‰{÷r›Yy™°÷¯••—•Ü£¨«—ª»¡iCûmU~Sˆ{÷s›SŒ|œÈ÷¸«ªœºÁn9ûgS„ƒP„{û* vø+ÁÓß÷Nßøz›X‚—Ğ÷[öaÀ9R_rQ`‰÷Â…\{˜ kzŒ“‘‹°“‚aükF‚U†{÷k›T~œÎ÷…¹µ«±º¦eFûZG€}R‡{û*ûmğøËw™ø`ønøI™û}¯ˆ—„z„”qB<ûqû÷‚‹’‹–œ’’½‘™ûa}¨†—„”w÷ûŠ¦P®J|tpG{rt|z||wuloxzpkªr´Òµ¼÷*Ä÷/ø-–©™˜¡Ó’v¡vødw ù4pùIøG›û{ªˆ˜y~‡u~l0ûr<÷ktÉ„‹˜£™“¶›û^{µŠ™v­%/û\kâH÷C‹†›Š“’Ÿ˜”¬›ûG{¢Š”€ŸX÷ûék˜‘’‘‘”©™÷÷ƒåû°^œ‹Œ’“ŒŒ»÷÷îœµ’û*¿ø§¦á÷wßøµ›ƒ‚Š‹‡f‚—¸øË†Ux|‡=v{Œ˜‘‹¯“‚aû0¬cr•bû.ûûû×2÷Àµ ¶ªNˆÙ§oë­û+Èm^l_9SŞ÷÷¾×ÔÂ»\UûÑ vø7«÷_¨òß7Şğøù«\§UûQAû2Š:kÜûÏB€B‡{÷˜›:–Ö÷Ï÷«èû÷Æ§² ”…oŸk¡”„œ¢¢û*Äø(wÑß÷Fß=Ùèør¯™YŠ–º÷ìû2{ğË‡•‚Yûrˆ€ƒuy^wlcj®µ÷Ûû%{»ˆ˜~[û;ºY×¯±›¦¦è·¶9ˆÙ§”¾™û*’vøewø\øoøG›û{«Šš€v|‚oy]=û[%÷”†˜‡œ‹’œ˜”¬›ûW{ŸŠ•†—¤s÷û¿£N‚˜e”‹’‹’·÷÷Ô¦Î’”©ü$€÷Ñ÷÷I·ªr¤mlrrlm¤rª©¤¤©Ó•v–ù÷ ¸ø1·xùTùŸû~wå„‘k4ûã‰üøuû?w¶Œ–„µ[üM%~y8ƒw÷Ÿ>z£ğø¸øJü¹œø¤ïšŸÚ‘û*«øËÏß÷wäøh÷‡÷?è$SWlXp‰÷Á†a{U{[~{Œ•’‹®”cüœmãiÚ÷ò÷÷!2bû	]L5[\££÷¶µ¬Ä×¿;ûûÑ v÷UË²÷Š÷±÷UËûŠKûÑû1vùêw»à÷Äû6ûáZ÷÷l÷[¶ñ÷î‚›û@û@û‹ûLûµ#ë%²a§t²tÓ‹÷¼·÷±õñ÷ÃñùPŸA~˜ÓøQÓ˜˜ÕŸû¨wÕ‡˜~CûWûÃ÷WÓ˜˜ÕŸû¨wÕ‡˜~CüQC~~A‡w÷¨ŸA~˜Ó÷b÷ÃûbC~~A‡wœ‹÷Á¤÷®¯xññ÷}÷Üù'Ÿdv—p¬ûb÷‘÷¢ÄÀè÷/Êû7û§wÔ†—~DüD4…„=ƒw÷¨Ÿ=’—Ò÷XÃ÷‚ûÉNø"Kcû=Š÷Šì¨—’½÷Å]1d‹øí¶Ÿ¡÷gñ÷|vøãø„÷>üÄ„û>¤÷¡ ›÷Áü’@~8ˆw÷ºŸ8~—Öø’Á÷ {û¡ûÑû1vùêw÷\à÷±÷Š÷aó+ñdµo¢d¢{÷5¼ûûlû[`%û(”{÷@÷Ö÷‹÷Lû* vİßø›`i¡d¼û.÷V¨¦ïè½®Ì‰™û_}“Š‹¢Š”‡Œ~Œƒƒ{|ûû‰ø3†Oxz†>w{Œ˜•‹’¯”ZüuU‰‰B€{÷~›M~”´÷I÷ûLr‡‹…ƒ‚…y{-‹÷¡³÷½±xîò$ñ÷{÷Úø±øw÷$Ñû3ûšwÕƒ“‚DüFCŠp9‰w÷¬Ÿ<Œ|šÕ÷HŠ¤¢ŠÚÅ–¡²È­®ÇÏû‰!S\ûæz‹t÷™§’‘­÷ÍY-Ó}·øúòò÷ü¶ùSùŸû{wÖ‰r(û¢=`slakTtJO\®nn®‚°Û÷ÔÔ––ÚŸû®yÚƒ•BûËû@İ6÷:÷HÙİ÷P÷™ğ› Ù-~¯øø´Ñá÷~ïø~÷<Û\ÄûÕQ­"¼ÜÀµ²ÆåĞLû ¦¤u÷hvs…‚z„|}ŸOw‘q"?D)9­a÷C÷>¬hNGZ\C0MÀ÷Wu©ûh  –—¯«jç÷
ãØóÓ‹÷[´ø4wšùGùVŸ^}˜lÓûøÌwûdüOû!}xY‡w÷ZŸ\Šu™ª••‘›¹÷
÷š´*•t”l‹pzƒWw†÷—û{÷÷§û* v÷iáøš=Œy–ºøí‚ûG0~¥•œ’œ”‹¢•}jüm\y€=Š|û*‰w÷—¶ø§©ç÷€ï+ëôø^ø!÷5/÷
ûû4'û û
Ô:öÀ»±¹øŒˆmû%ûû>qw÷…›÷3÷<‹÷ô+bv‡‚uod}j>\Õ÷÷±ÊÏä¸4û;û*~°øâàÙ÷ùÑøJù?‚‘yuƒ‡w‹ûeûû€Š‰Šˆ‹‰‡‰‘Š÷ƒ÷5Yû.&O?;u„«^¡l}pr}~tb·uİ÷5÷ ò÷.÷@ûÄû)¦µà÷XœŒ’û*}¯øçÆ÷ÑÚgÒĞøC÷lêk¹+·àÏ¹¤°ÅÚKÂ/,MXûdš‡³Ö¸«Ê‹Ì¸^L^r_cnpwvWyÁ¦†zªĞ»p¨XO8QICqv“ h£c‚ys}~ug·vÖ÷1÷ë÷û*™vøèÔŸø@øTùšü|_`%œƒ²Ì¢›Á‹÷mûZüèÌ÷K“v˜ª÷—®š«÷g¤ÏwÈ×÷r¤ÌÖ÷q¥Àù—÷šÑf³Hûû ûû;»WÕóë÷÷ûø2eYYbyDd{’ oŸr{‘oû û	ûB¾QÍõï÷÷™‰–‡ƒ£—‰£·§’ °‰¿ÀûğıºÀø…÷£û:û<du¥·ÏË÷?â²ªf^ü÷¼û:û<cu£¸È°æ¹½£¡¡˜œ‘Š„’•š„¨ƒ‘w‹}û* v÷;ËøQw÷·Ú>Øèøk÷;Ë&øQ_ûÎüQK÷­û;Ø÷;ğ<Ëû„÷‚÷éû* vøWwœøbøs›hy˜n·û÷Xß÷¦§›­Œšû3}¬‡’‡}~uU?~Ÿ…s³xª„š‹“‹›•‘«™ûb}µŠ‡°Sêû%ûû9pd}lŠ{÷%›n€—“—™¡Û÷Üû›s‹Š‹€{€„r‡{û* v÷]¼‹øˆøˆ÷]¼üˆZûÑ‹ù÷ñ÷ÌŸ8~—ÖøOÖ˜—ŞŸûºwŞˆ˜@üO@~8ˆwü›v£v÷ó÷Û÷ û÷h÷Tø)©r¤lmrrml¤r©ª¤¤ª°§ü¿h²\jrskl¢w¯p•”‹”•‡Š‰iogVg•xÎ­¸ÈÄû*~§ù§ÃÖFÕ÷oĞT×ÔøQ÷0Øi»ûæØîÁ®µÎŞCÅ#!;H0J¢iñ4äû<ulG&ØI÷	÷
ØÍòØ1øPuiCVT¯E¿ÔÄ¸³ÊÏ¶_Gä™ü-G__IAUÇİÎ±É¾ªt”„‹èE£rN÷º–vù"ú1ú6ùŸûZwÂ†™‚l|„k‚sûûèû÷épĞ‹Š‹—¤¡•ÂŸûŸwÊ‡‡­:­9 û¯û%øƒ ˆ•‹˜¡—‘ÀŸûˆwÉ‚‡ÒûSÌûC†èû¡š÷.ø;‘y‘|‚‘|¡Uª;±*œ[ª4™Ù÷ƒ–ªÌ÷H¦Ôš³–©šµ›—»‘ûÑÚ÷ ÷oøŞ¿h²\jrskk¢w¯”–‹“”Œ‘†Š‰hohVg•wÎ­¸ÈÅû*ûVv÷aÉø§£à÷|ßø|ûk›]zš´øê†NgUª|_‹û,ûû&ûÍ4ìÀÀ¤»¹ŠûNT|~A„{ä÷ëk„~t~sr…s>W×÷÷	ÁÙÜÍªkFû™’vù&÷CñøùŸû´wÚ‰™}Cüd\€wq|†‘£„²|›qqutp_²nÆ÷ ÈÓ÷øÓ™™Ú-‹÷Èµb´÷“²xîğ÷”¢´¢Ïøµøœˆ÷#ü¦wÕ‡˜~CüQC~~A‡w÷«Ÿ@{šÒ÷p÷&‰ßŠ–š7¢÷|t6|8û&÷q·¨§÷÷~0ûb‹©ø©¦øø6÷yv*|~/‹û÷¢ø*šûïˆûœÕ•™šÈ÷ûü*|ø÷ƒ‹ùö·øœğùïŸFyĞøQÓ™™ÔŸû[ûoüû{øûZwİ†˜~Dü+&|x;„w÷}Ÿ@x¥íø$÷ü·™÷øÎüV9€~<†wÓ}¯øş¯­÷ø?÷ùC÷Ş÷_û÷#ûSûTûû#û_û]÷û#÷T÷S÷÷#÷]ûŒûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRü’vùFw‚÷º÷±ù8IûxıFÎœ}·øOv÷M²§÷ù÷yœ=AOp5‹û+,÷÷K÷Så÷	÷(öÒNû°¡‚÷tvƒu|wŒŒ{x’b™Y“a‹ûZ‹û!û#‹û]‹ûf÷û÷_‹÷‹÷ ¿¾×Ó‹x°øá°xòñø÷œù?÷â÷bû)÷ûû wÕ‡˜~CüQC~~A‡w÷¯÷‚÷&÷÷clû…ûU#)ûa\~”«ø­”‘Á÷Q÷	ûûLü€÷÷÷Ü÷÷Tø)©r¤mlrrml¤rª©¤¤ªûıªr¤mlrrlm¤rª©¤¤©d‹±e÷Èµb´÷“²xîğ÷œ¢¬¢«€øè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥W€wÕ‡˜~CüQC~~A‡wø¯d‹²dùîğ°øè÷Bsû
SizûI0°ønÓ˜˜ÕŸû§wÕ‡˜~CüQpC~~A‡wø­üûXvù7w÷$ğçğ8ßğ÷Uù§t¢pottop¢t§¦¢¢¦èŒıø^†XwXyWy|©Œ‹“¦”{_ü!€jg}‚—€³i†wwwywk²tÂ÷ÆÖ÷"Ó•vù#›ù;àùKùŸû`àxÆ†™‚m}„qmû&üû,÷æmÍ©‹™¤–Êûàw½ˆœ{±6÷‹üºš÷pøÆ¨Õ››º÷ò v÷]¼‹ú|ú|÷]¼ş|Z5—vø w§øø«‚Ïü=÷Vø=÷VÏüû{M5 v÷Í÷Í©ø‹ø©÷ÕÍü‹Iø‹û]Íü‹Iû*}§øº÷‚š­ç÷‘äøh÷m÷Bßû[w„eLª÷1îê÷;«‡šûv‡ûMû;ûûDäû÷÷áê÷2jû cME4Sé÷'²­”™¡˜·´å¾Cûœ‹°f÷È³c²÷—±x÷ñ÷†ğ;÷¦€øå÷DÅo½\§ršy’Z™g è¡²¶Ú÷.Çû<û¬wŞˆ˜AüQA~8ˆw÷â¦€÷%ìÒô§ û÷Ì<Yb)Š› -Š÷y§Ã÷È]0¦€ ûÈ*O]ûO|“¬÷÷VŒĞdûÓ}³÷É÷®³«÷øëùW÷ãû’xÙ‡•@û4iOq?û3'÷
÷O÷Kì÷÷%ôĞUûµ£ƒ÷fuu„{€s…€€¡Ej‘\û[û"û&ûbû|÷A!÷K÷÷Â÷\Å™šÃÓ‹ù÷ñàùeŸXz–ë2û|÷÷Q÷QÇÇ£—ÎŸû˜wÇ‡’ˆtrxs4:tuº¶û@û0÷WàŞ–—Ù‘û¬xÙ…–8ü;8€=…x÷¬=‘€—Ş÷D¥¡õ!Ø>ÀF‹tày‚ˆO‰wd‹±øß±”øŞøç÷Dtûhjq%û–øCøöšü¡xû>¤òŸ°¨÷÷qüHüö|øÆÓ‹ù÷ÏñùRùŸûow¾Œ‚t‡€{û!ûxû)÷t€›…š‹˜¡™‘ÄŸû¬w¯‰™„§iŸt²W¥e÷ûTûM>~€2‰w÷ÆŸ2~–Ø÷U÷'÷wÁß¨¢Â‘Ó‹ù•ùHàùRŸWw˜eÂûS÷¦÷%÷KÅÕ¤šÌŸû€wÅˆ–†r|ƒ}kdûû`ÆCî~¦‹¢£š‘ÈŸûÁwĞ…¢wãû÷û5û0ûU;)~W†w÷}àVs–Œ¡Œœ˜¤°¸÷÷(êû!«\g‹}àuwƒSŠwû*‚¦ø4§¨äÆ÷rxäß÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü#ıèøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûûb–vŒÄø¤°ã¤÷r6İÄ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıtøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½´T‘x·ª§›­§û0ßsˆ€ƒt{yb{sfo­¹Èºµ÷±û* vø)ÂŒwÚÜ:ß<÷İBßŞ÷Şùmf{~r~t‘“{t—v–s‘u‹UhiI}¨ª“š§•˜ˆ„™¡€¯y¢…¢‹Á©©Ö ü1ıÒøx›]}›¼÷yè^ÄB[p|IDÛª„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ê»Ã›”¬»£kJûeN}xZˆ{ü vøbwÌ÷rûUßo ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œû³ıĞ÷›K–Ó÷÷†XyWxXx|©Œ‹“¦”{_û{CGˆ{ûbĞ÷o«÷¯¤ĞFÒÀ÷rGñÃ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıòø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½êû÷-ûcÙš®¯ÇÆ¥m7—d‹±e÷Èµb´÷“²xîğ¬÷r”¢¬¢÷ ÷i ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü[ığªÀøè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥VÀwÕ‡˜~CüQC~~A‡wø¯ûbĞ÷o«÷¯¤ĞFÒv÷r‘ñÃ÷…øû'÷)|š}’|‹z}}zz”}÷.*û•üòø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½êû÷-ûcÙš®¯ÇÆ¥m7—ü vøbw÷|w{÷Êû\ßp0÷Õøû÷:Kûû:¬÷ò÷$û™üÈ÷›K–Ó÷÷†XyWxXx|©Œ‹“¦”{_û{CGˆ{ûb–vŒÄø¤°ãY÷rİÃ÷…øû'÷)|š}’|‹z}}zz”}÷.*û•ütøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½´T‘x·ª§›­§û0ßsˆ€ƒt{yb{sfo­¹Èºµ÷±ûb–vŒÄø¤÷hw°ãX÷Ê*İÊ÷Õøû÷:Kûû:¬÷ò÷$ûóüjøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½ªT‘x·ª§›­§û0ßsˆ€ƒj{yb{sfo­¹Èºµ÷±u¡øW–÷\š’‹÷š”ü}¦
ß
_÷ù
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
93 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
94 0 obj
<</OP false/OPM 0/op false>>
endobj
95 0 obj
<</A 96 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
96 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
86 0 obj
[97 0 R]
endobj
87 0 obj
<</Length 14698>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.019 Tw 10.5 0 0 10.5 60 730.8196 Tm
(for the entire study period, the potential underestimation of)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
[(duration of therapy is not likely to have af)20 (fected our find-)]TJ
-0.006 Tc 0.006 Tw 0 -1.2381 TD
(ing that treatment duration declined dramatically in later)Tj
-0.02499 Tc T*
[(cohorts of new users. Finally)65 (, as noted above, our data may)]TJ
-0.01801 Tc 0.017 Tw 0 -1.23809 TD
(underestimate the rate of tibolone use since, unlike the re-)Tj
-0.017 Tc 0 -1.2381 TD
(mainder of the medications studied, this product is not in-)Tj
-0.02499 Tc 0.013 Tw T*
[(cluded in the standard for)-25 (mulary)65 (. )]TJ
-0.021 Tc 0.021 Tw 1 -1.23809 Td
[(W)80 (e documented a rapid drop in the proportion of wom-)]TJ
-0.02499 Tc 0.01401 Tw -1 -1.2381 Td
[(en aged 45 years and older using HR)60 (T following the publi-)]TJ
-0.022 Tc 0.022 Tw T*
(cation of the WHI findings, as well as marked shifts in the)Tj
0 Tc 0.034 Tw 0 -1.23809 TD
[(type of treatment used and the duration of therapy)65 (. Our)]TJ
-0.011 Tc 0.011 Tw 0 -1.2381 TD
[(analysis of a lar)20 (ge stable population allowed longitudinal)]TJ
-0.002 Tc 0.00101 Tw 0 -1.23809 TD
[(analysis of HR)60 (T use, enabling not only a survey of drug)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
(purchasing trends, but also estimates of utilization rates in)Tj
-0.02499 Tc 0.02499 Tw T*
[(the tar)20 (get population over a period of several years. Longi-)]TJ
-0.009 Tc 0.008 Tw 0 -1.23809 TD
(tudinal data also allowed us to characterize new users by)Tj
0 Tc 0.071 Tw 0 -1.2381 TD
(age and mode of therapy)Tj
-0.00011 Tc 10.10265 0.00001 Td
(,)Tj
0 Tc 0.57073 0 Td
(and to examine switches be-)Tj
-0.02 Tc 0.02 Tw -10.67337 -1.2381 Td
(tween modes before and after 2002. The decrease in over-)Tj
-0.02499 Tc 0.01199 Tw 0 -1.23809 TD
[(all HR)60 (T use in our population can be attributed both to dis-)]TJ
-0.013 Tc 0.013 Tw 0 -1.2381 TD
(continuation by current users and a reduction in the num)Tj
0 Tc 21.95285 0 Td
(-)Tj
-0.02499 Tc 0.024 Tw -21.95285 -1.2381 Td
(ber of new users. This reduction was sustained through the)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(end of December 2007. The finding of increased tibolone)Tj
-0.02299 Tc 0.02299 Tw T*
(use is likely due to patient and provider perceptions of this)Tj
-0.02499 Tc 0.009 Tw 0 -1.2381 TD
[(product as a safer alter)-25 (native to traditional HR)60 (T)75 (. Continued)]TJ
0 Tc 0.058 Tw 0 -1.23809 TD
[(surveillance will be required to deter)-25 (mine whether this)]TJ
-0.013 Tc 0.013 Tw T*
[(trend continues and to assess the long-ter)-25 (m health impact)]TJ
-0.02499 Tc 0 -1.2381 TD
(of tibolone use. )Tj
ET
BT
/T1_1 1 Tf
0.00301 Tc 0.00999 Tw 8.5 0 0 8.5 60 368.8197 Tm
(Barbara G Silverman)Tj
ET
BT
/T1_2 1 Tf
8 0 0 8 147.1593 368.8197 Tm
(MD MPH, Unit Head, Research and Aca-)Tj
0 Tc -0.005 Tw -10.89491 -1.125 Td
(demics, Department of Research and Evaluation, Maccabi Health-)Tj
-0.01401 Tw 0 -1.125 TD
[(care Services, T)111 (el A)17 (viv)74 (, Israel)]TJ
ET
BT
/T1_1 1 Tf
-0.01601 Tc -0.01199 Tw 8.5 0 0 8.5 60 339.8197 Tm
(Ehud S Kokia)Tj
ET
BT
/T1_2 1 Tf
8 0 0 8 114.9503 339.8197 Tm
(MD, Director General, Maccabi Healthcare Services,)Tj
0 Tc -6.86879 -1.125 Td
(T)Tj
-0.00011 Tc 0.5 0 Td
[(el)-264 (A)]TJ
0 Tc 0 Tw 1.69093 0 Td
(viv)Tj
ET
BT
/T1_1 1 Tf
0.01401 Tc 8.5 0 0 8.5 60 319.8197 Tm
(Reprints:)Tj
ET
BT
/T1_2 1 Tf
-0.00101 Tw 8 0 0 8 100.7446 319.8197 Tm
[(Dr)55 (. Silverman, Maccabi Healthcare Services, Rechov)]TJ
0.05 Tc 0.207 Tw -5.09307 -1.125 Td
[(HaMered 27, T)111 (el A)17 (viv 68125, Israel, fax 972-3-514-3795,)]TJ
0 Tc 0 Tw T*
(silver_b@mac.org.il)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 10.5 0 0 10.5 318 730.348 Tm
(References)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.216 Tw 8 0 0 8 322 712.348 Tm
[(1.)-500 (American College of Physicians. Guidelines for counseling post-)]TJ
-0.024 Tc 0.024 Tw 1.1875 -1.25 Td
[(menopausal women about preventive hor)-25 (mone therapy)65 (. Ann Inter)-25 (n Med)]TJ
-0.02499 Tc 0 Tw 0 -1.25 TD
[(1992;1)35 (17:1038)-25 (-)-125 (41.)]TJ
0 Tc 0.00301 Tw -1.1875 -1.375 Td
[(2.)-500 (US Preventive Services T)70 (ask Force. Guide to clinical preventive ser-)]TJ
-0.02499 Tc 0.02 Tw 1.1875 -1.25 Td
[(vices. 2nd ed. W)80 (ashington, DC: Of)20 (fice of Disease Prevention and Health)]TJ
0.013 Tw T*
(Promotion, 1996.)Tj
-0.022 Tc 0.022 Tw -1.20954 -1.375 Td
[(3.)-478 (Manson JE, Martin KA. Postmenopausal hor)-25 (mone-replacement therapy)65 (.)]TJ
-0.02499 Tc 1.20954 -1.25 Td
(N)Tj
0.013 Tw 0.93441 0 Td
[(Engl J Med 2001;345:34)-75 (-)-125 (40.)]TJ
-0.024 Tc 0.024 Tw -2.14577 -1.375 Td
[(4.)-476 (Grodstein F)80 (, Manson JE, Colditz GA, W)40 (illett WC, Spelzer FE, Stampfer)]TJ
0 Tc 0.04201 Tw 1.21136 -1.25 Td
[(MJ. A prospective, observational study of postmenopausal hor)-25 (mone)]TJ
-0.004 Tc 0.004 Tw T*
[(therapy and primary prevention of cardiovascular disease. Ann Inter)-25 (n)]TJ
-0.02499 Tc T*
(M)Tj
0.013 Tw [(ed 2000;133:933)-24.9 (-)-125.1 (41.)]TJ
-0.015 Tc 0.015 Tw -1.20262 -1.375 Td
[(5.)-485 (Grady D, Rubin SM, Pettiti DB, et al. Hor)-25 (mone therapy to prevent dis-)]TJ
-0.022 Tc 0.021 Tw 1.20261 -1.25 Td
[(ease and prolong life in postmenopausal women. Ann Inter)-25 (n Med 1992;)]TJ
-0.02499 Tc 0 Tw T*
[(1)35 (17:1016)-25 (-)-24 (37. )]TJ
-0.01401 Tc 0.01401 Tw -1.20139 -1.375 Td
[(6.)-486 (Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, A)90 (yanian JZ. Use of)]TJ
-0.01801 Tc 0.01801 Tw 1.20139 -1.25 Td
[(hor)-25 (mone replacement therapy by postmenopausal women in the United)]TJ
-0.02499 Tc 0.013 Tw T*
[(States. Ann Inter)-25 (n Med 1999;130:545)-25 (-53.)]TJ
-0.017 Tc 0.017 Tw -1.20433 -1.375 Td
[(7.)-483 (Hersh AL, Stefanick ML, Staf)20 (ford RS. National use of postmenopausal)]TJ
-0.02299 Tc 0.02299 Tw 1.20433 -1.25 Td
[(hor)-25 (mone therapy: annual trends and response to recent evidence. JAMA)]TJ
-0.02499 Tc 0 Tw T*
(2004;291:47-53.)Tj
0 Tc 0.05499 Tw -1.1875 -1.375 Td
[(8.)-500 (W)60 (ysowski DK, Gover)-25 (nale LA. Use of menopausal hor)-25 (mones in the)]TJ
-0.011 Tc 0.011 Tw 1.1875 -1.25 Td
[(United States, 1992 through June, 2003. Phar)-25 (m)1 (a)1 (c)1 (o)1 (e)1 (p)1 (i)1 (d)1 (e)1 (m)1 (i)1 (o)1 (l)1 ( )1 (D)1 (r)1 (u)1 (g)1 ( )1 (S)1 (a)1 (f)]TJ
-0.02499 Tc 0 Tw T*
[(2005;14:171)50 (-)-75 (6.)]TJ
-0.007 Tc 0.007 Tw -1.19476 -1.375 Td
[(9.)-493 (Merom D, Ifrah A, Cohen-Manheim I, Chinich A, Green MS. Factors)]TJ
-0.006 Tc 0.005 Tw 1.19476 -1.25 Td
[(predicting current use of hor)-25 (mone-replacement therapy among meno-)]TJ
-0.024 Tc 0.024 Tw T*
(pausal Jewish women in Israel. The National W)Tj
0 Tw 18.16127 0 Td
(omen\325)Tj
-0.02431 Tc 2.37853 0 Td
(s)Tj
-0.024 Tc 0.024 Tw 0.61461 0 Td
(Health Interview)Tj
-0.02499 Tc 0.013 Tw -21.15441 -1.25001 Td
[(Survey)65 (, 1998. Isr Med Assoc J 2002;4:671)50 (-)-75 (6.)]TJ
0.02499 Tw -1.6875 -1.375 Td
[(10.)-475 (V)60 (inker S, Kaplan B, Y)100 (aphe J, et al. Use of hor)-25 (mone replacement therapy)]TJ
-0.01199 Tc 0.01199 Tw 1.6875 -1.25 Td
(by menopausal women in six family-practice teaching clinics in Israel.)Tj
-0.02499 Tc 0.013 Tw T*
[(Climacteric 2003;6:75)-25 (-)-25 (80.)]TJ
0.004 Tw -1.6875 -1.375 Td
[(1)35 (1.)-475 (W)40 (riting Group for the W)80 (omen\325)55 (s Health Initiative Investigators. Risks and)]TJ
-0.00999 Tc 0.00999 Tw 1.6875 -1.25 Td
(benefits of estrogen plus progestin in healthy postmenopausal women.)Tj
-0.02499 Tc 0.013 Tw T*
(JAMA 2002;288:321)Tj
0 Tw 8.06477 0 Td
[(-)-25 (33.)]TJ
-0.019 Tc -9.75227 -1.375 Td
(12.)Tj
0.019 Tw 1.67486 0 Td
[(US Preventive Services T)68.1 (ask Force. Hor)-25 (mone therapy for prevention of)]TJ
-0.011 Tc 0.00999 Tw 0.01264 -1.25001 Td
(chronic conditions in postmenopausal women: recommendations from)Tj
-0.03999 Tc 0.013 Tw T*
[(the US Preventive Services T)70 (ask Force. Ann Inter)-25 (n Med 2005;142:855)-25 (-)-75 (60.)]TJ
-0.02 Tc 0 Tw -1.6875 -1.375 Td
(13.)Tj
0.02 Tw 1.66912 0 Td
(National Institutes of Health State of the Science Panel. Management of)Tj
-0.02499 Tc 0.013 Tw 0.01838 -1.25001 Td
[(menopause-related symptoms. Ann Inter)-25 (n Med 2005;142:1003)-25 (-13.)]TJ
-0.008 Tc 0 Tw -1.6875 -1.375 Td
(14.)Tj
-0.009 Tc 0.008 Tw 1.71606 0 Td
(Recommendations for estrogen and progestogen use in peri- and post-)Tj
0 Tc 0.11301 Tw -0.02856 -1.25 Td
(menopausal women: October 2004 position statement of the North)Tj
-0.022 Tc 0.022 Tw 5.81267 -1.25 Td
(American Menopause Society)Tj
-0.0217 Tc 11.46642 0.00001 Td
(.)Tj
-0.022 Tc 0.47828 0 Td
[(Menopause 2004;1)35 (1:589)-25 (-)]TJ
-0.02499 Tc 0 Tw -11.94471 -1.25 Td
(600.)Tj
-0.02299 Tc 0.02299 Tw -1.6875 -1.34375 Td
[(15.)-477 (ACOG T)70 (ask Force on Hor)-25 (mone Therapy)65 (. Hor)-25 (mone ther-)]TJ
0 Tc 0.08701 Tw 1.6875 -1.21875 Td
[(apy: executive summary)65 (. Obstet Gynecol 2004;104\(4)]TJ
-0.02499 Tc 0 Tw 0 -1.21875 TD
[(suppl\):1S-)-125 (4S.)]TJ
-0.01801 Tc 0.01801 Tw -1.6875 -1.34375 Td
[(16.)-482 (Hartsfield CL, Connelly MT)75 (, Newton KM, Andrade SE,)]TJ
0 Tc 1.6875 -1.21875 Td
(W)Tj
-0.006 Tc 0.006 Tw 0.85771 0.00001 Td
(ei F)Tj
-0.0061 Tc 1.42934 0.00001 Td
(,)Tj
-0.006 Tc 0.49378 0 Td
[(Buist DS. Health system responses to the W)80 (om-)]TJ
-0.02 Tc 0 Tw -2.78083 -1.21876 Td
[(en\325)55.1 (s)]TJ
0.02 Tw 1.78081 0.00001 Td
(Health Initiative findings on estrogen and progestin:)Tj
0 Tc 0.19 Tw -1.78081 -1.21876 Td
[(or)20 (ganizational response. J Natl Cancer Inst Monogr)]TJ
-0.02499 Tc 0 Tw T*
[(2005;35:1)35.6 (13)-24.9 (-5. )]TJ
-0.002 Tc -1.6875 -1.34375 Td
(17.)Tj
0.002 Tw 1.74316 0.00001 Td
(Grady D, Barrett-Connor E. Postmenopausal hor)Tj
0 Tw 19.47778 0.00001 Td
(mone)Tj
-0.02499 Tc 0.013 Tw -19.53344 -1.21876 Td
[(therapy)65 (. Br Med J 2007;334:860)-75 (-1.)]TJ
-0.01199 Tc 0.01199 Tw -1.6875 -1.34375 Td
[(18.)-488 (Majumdar SR, Almasi EA, Staf)20 (ford RS. Promotion and)]TJ
-0.007 Tc 0.006 Tw 1.6875 -1.21875 Td
[(prescribing of hor)-25 (mone therapy after report of har)-25 (m)-1 ( )-1 (b)-1 (y)]TJ
-0.02499 Tc 0.013 Tw T*
[(the W)80 (omen\325)55 (s Health Initiative. JAMA 2004;292:1983)-25 (-)-25 (8.)]TJ
0 Tw -1.6875 -1.34375 Td
(19.)Tj
0.01601 Tw 1.64999 0.00001 Td
[(Hing E, Brett KM. Changes in US prescribing patter)-23 (ns of)]TJ
0 Tc 0.01401 Tw 0.03751 -1.21875 Td
[(menopausal hor)-25 (mone therapy)65 (, 2001)50 (\320)-25 (2003. Obstet Gy-)]TJ
-0.02499 Tc 0.013 Tw T*
(necol 2006;108:33)Tj
0 Tw 7.08356 0.00001 Td
[(-)-125 (40.)]TJ
-8.77106 -1.34376 Td
(20.)Tj
0.01199 Tw 1.64999 0.00001 Td
(Buist DSM, Newton KM, Miglioretti DL, et al. Hor)Tj
0 Tw 19.64066 0.00001 Td
(mone)Tj
-0.01401 Tc 0.004 Tw -19.60315 -1.21876 Td
[(t)-10 (h)-10 (e)-10 (r)-10 (a)-10 (p)-10 (y)-10 ( )-10 (p)-10 (r)-10 (e)-10 (scribing patter)-25 (ns in the United States. Obstet)]TJ
-0.035 Tc 0.013 Tw T*
(Gynecol 2004;104:1042-50.)Tj
0 Tc 0.131 Tw -1.6875 -1.34375 Td
[(21.)-500 (Menon U, Bur)-25 (nell M, Shar)-25 (ma A, et al.; UKCT)20 (OCS)]TJ
-0.004 Tc 0.004 Tw 1.6875 -1.21875 Td
[(group. Decline in use of hor)-25 (mone therapy among post-)]TJ
-0.02 Tc 0.02 Tw T*
(menopausal women in the United Kingdom. Menopause)Tj
-0.02499 Tc 0 Tw T*
(2007;14:462-7.)Tj
ET
0 0 0 0 k
173 745 379 10 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0.013 Tw 8 0 0 8 251.5303 749.5293 Tm
[(Sustained Impact of the W)75 (omen\325)75 (s Health Initiative Findings on Hor)-25 (mone Replacement Therapy)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_6 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(257)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0.10001 k
59 165.854 275.492 12.644 re
f
59 141.273 275.492 12.645 re
f
59 117.401 275.492 12.644 re
f
59 93.528 275.492 12.644 re
f
59 67.498 275.492 15.279 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
0.011 Tw 9 0 0 9 110.4972 248.7909 Tm
[(T)74 (able 1.)]TJ
ET
BT
/T1_2 1 Tf
9 0 0 9 144.0128 248.7909 Tm
(Switches to Other Hormone Therapy )Tj
ET
0 0 0 1 K
0.5 w 
59.5 232.041 m
334.001 232.041 l
S
BT
/T1_2 1 Tf
9 0 0 9 111.4296 237.7908 Tm
[(Among W)18 (omen Discontinuing Oral Estrogen)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 279.4172 240.5409 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
5.528 Tw 7.5 0 0 7.5 126.63 221.7909 Tm
(Pts.)Tj
7.895 0 Td
(Pts. Pts.)Tj
15.534 0 Td
(Pts.)Tj
-0.01401 Tw -31.42975 -1.06667 Td
[(Y)55 (ear of)-2265 (Discontinuing)-1597 (Switching to )-1446 (Switching to)-1965 (Switching to)]TJ
-0.49976 -1.06666 Td
(Last Oral)Tj
0 Tw 8.417 0.00001 Td
[(Oral )-4864.6 (V)55 (aginal)-2916 (T)55 (ransdermal)-2847 (T)18 (ibolone)]TJ
ET
59.5 193.541 m
334.001 193.541 l
S
BT
/T1_1 1 Tf
7.5 0 0 7.5 62.1961 197.7909 Tm
(Purchase)Tj
-0.01401 Tw 6.84923 0.00001 Td
[(Product \(n\))-2435.9 (Product \(%\))-2042.3 (Product \(%\))]TJ
0 Tw 25.30862 0.00003 Td
(\(%\))Tj
ET
BT
/T1_2 1 Tf
7.5 0 0 7.5 64.752 181.7909 Tm
(1999)Tj
7.748 0 Td
(1,347)Tj
8.631 0 Td
(0.7)Tj
7.703 0 Td
(5.0)Tj
7.864 0 Td
(0.0)Tj
-31.946 -1.6 Td
(2000)Tj
7.74791 0.00001 Td
(2,212)Tj
8.62993 0.00001 Td
(1.1)Tj
7.703 0 Td
(3.8)Tj
7.864 0 Td
(0.0)Tj
-31.94484 -1.60002 Td
(2001)Tj
7.748 0 Td
(2,509)Tj
8.631 0 Td
(1.0)Tj
7.703 0 Td
(5.2)Tj
7.864 0 Td
(0.0)Tj
-31.946 -1.6 Td
(2002)Tj
7.748 0 Td
(4,033)Tj
8.631 0 Td
(1.3)Tj
7.703 0 Td
(9.3)Tj
7.864 0 Td
(0.3)Tj
-31.946 -1.6 Td
(2003)Tj
7.74791 0.00001 Td
(2,181)Tj
8.62993 0.00001 Td
(1.6)Tj
7.703 0 Td
(6.2)Tj
7.864 0 Td
(8.8)Tj
-31.94484 -1.60002 Td
(2004)Tj
7.748 0 Td
(1,350)Tj
8.631 0 Td
(1.5)Tj
7.703 0 Td
(4.4)Tj
7.864 0 Td
(5.8)Tj
-31.946 -1.6 Td
(2005)Tj
7.748 0 Td
(1,225)Tj
8.631 0 Td
(0.9)Tj
7.703 0 Td
(5.5)Tj
7.864 0 Td
(5.3)Tj
-31.946 -1.6 Td
(2006)Tj
7.74791 0.00001 Td
(1,176)Tj
8.62993 0.00001 Td
(1.2)Tj
7.703 0 Td
(4.1)Tj
7.864 0 Td
(4.0)Tj
-31.94484 -1.60002 Td
(2007)Tj
7.748 0 Td
(2,654)Tj
8.631 0 Td
(0.3)Tj
7.703 0 Td
(1.0)Tj
7.864 0 Td
(0.9)Tj
ET
59.5 67.541 m
334.001 67.541 l
S
BT
/T1_2 1 Tf
-0.01401 Tw 7.5 0 0 7.5 64.752 73.7909 Tm
[(All years)-3373 (18,687)]TJ
16.37899 0 Td
(1.1)Tj
7.704 0 Td
(5.3)Tj
7.863 0 Td
(2.2)Tj
ET
BT
/T1_1 1 Tf
0 Tw 5 0 0 5 62.5 56.5409 Tm
(a)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tw 7.5 0 0 7.5 65.2795 53.7909 Tm
(Maccabi Healthcare Services, 1999\3202007.)Tj
ET
59.25 48.25 275.001 210.998 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
53 0 obj
<</BaseFont/DJTMWX+Helvetica-Bold/Encoding 50 0 R/FirstChar 32/FontDescriptor 52 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 889 0 0 333 333 0 0 0 0 278 278 0 556 556 556 556 0 0 0 0 0 333 0 0 0 0 0 0 722 722 722 722 667 611 778 722 278 556 722 611 833 722 778 667 0 722 667 611 722 667 944 0 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 556 278 889 611 611 611 0 389 556 333 611 556 778]>>
endobj
29 0 obj
<</BaseFont/ITNCSN+Helvetica/Encoding 26 0 R/FirstChar 32/FontDescriptor 28 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 889 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 584 0 0 0 1015 667 667 0 722 667 611 778 722 278 0 667 556 833 0 778 667 0 722 667 611 722 667 944 0 0 0 0 0 0 0 556 0 556 556 500 556 556 278 556 556 222 0 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 222]>>
endobj
26 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less 64/at/A/B 68/D/E/F/G/H/I 75/K/L/M 79/O/P 82/R/S/T/U/V/W 95/underscore 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 208/endash 213/quoteright]/Type/Encoding>>
endobj
28 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 27 0 R/FontName/ITNCSN+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
27 0 obj
<</Length 5268/Length1 5268/Subtype/Type1C>>stream
  ITNCSN+Helvetica   @ø øøøøû:ûtú|ú7
 ‹‹
 ‹‹   ó   ï  ~¬  s €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  D  1 # B S C  ( 4 J M W F N O E & I V , P L " U G Q Y  5 T D Z 	 ) 3 
 X H   8  *     [   '     7  R    0 %  - . o 6 @ ! F   D °<uÏÒ<½ßôyØyØGÁû,eÉ3­ÿL…´		R	

l
³
÷(=aÖV¶ëBe”<uuï#w¼×îI_š®eœ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;œ‹Ş÷Ù÷rİÔì÷ØëMëøù÷làg»-±Í­©»Ğö:ÓûûÎıa÷Êô÷%ëá÷øû÷Ë?Ye(ûC÷r÷Cï¼gCô­ûÍ7U\*ûc÷÷R÷Åb;-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³ŸûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙ-{Øcvø`Ù÷GwÅã3ß÷±åzø™÷¨÷24óûMZqTc‰÷˜3ıaŞÌöN¸¯wÎ÷å÷÷D1ƒûW?13TÒ÷÷½×æê¼Iûü÷xŞ`v÷ÁŞ÷Ÿà»ïøeå|ùSøûÎ8÷tˆ@gqfüPcJm8û09ñ÷V÷Eé÷÷'÷ ĞY&«è÷(oûãû7ûbûû,ûûo÷û)÷TöØ®ØÉ|£.œxŞ÷‹Ù`å÷nŞ¼æGè÷êæCèÕøÿ÷YïQÏ#£öûaºQ˜n¬‹½ÖÊºğ÷ÇZ*”æ÷/€3ÕûBû2,7û3¿SñsÙ÷&h÷
o¯p‹N4L_ûûDÆöˆ0ŒD•e©dG¿Ùi÷ ÷KöÛ÷ü@ vøŸw÷íÎã÷/øÿí3)ãüÿøŸ3üŸü@ vùawÎã÷/ùa3ıaû* vøŸw“øwøøŸ+û(ü=‰Šûø>'÷RüŸè-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæ- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖ-|×cvø_Ù÷Hw®å÷±ã4â:Üyø†ùaú4û¡‰Î[d¡Eû7&û5ûEäû÷!Ï»§Å­yDü„÷‰ûTD24UØ÷÷ºËêæ¿>ûœ‹á÷…à÷pàáìøüáüE÷…øàü÷pø<àüıa- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûé-|×cvøŸwÏâ÷‰ã8Şôø|øŸø3û´ TH2Hi²×÷ï4ü%ÉOöÛ´¢Ñ¸ô=œ vùawÖìù)ûÇø@÷¾÷µûûïûğ÷ğ*ıaì÷÷÷÷ûü-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=ûû* vøŸw÷jwÎàø‰ûh÷Û÷\÷Xûûvûqø36ıaà÷ZÔÍ÷7ûœœ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³ü vøUÕ÷awßã÷˜øUÕ3Ì¶›°“”Š‰ÚŒw€Œ‚/_f=1EAÑüUãøU-ûLv÷R×ø#Ú{wÅŞ8ã3ß÷±åéø™÷¨÷24ôûH^qL`‰ùÔ8ılåã÷˜Wµ®yÈ÷#ã÷÷H1…ûX?0ã2UĞ÷÷!¼Õçê¼Jûû* vøŸw˜ørøûL÷ ÷E÷“û ûûMû÷Mû÷Bû“ûKû ÷÷÷Y÷ûYü‹õâó÷Sõ#!d vùà÷•ëøçùàüÙ6÷‡ıëùû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹óû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™û*ûjÚù&w–øqø|øŸ+û!ü?‰ûø?(÷Vü¬bû‚d‹v|‘v<…›—ˆœò› ÷_Øï÷œ–Ş÷‚ûÑûMvú>wÏè÷¿ûb<÷2P÷÷J÷D³÷ë÷;OûûB]ûû=ûVÑûòû0Ó v÷áâ÷½wØì*íø
ìôùùa*û½ü÷½*ıaìí÷áø
ûáÓ v÷ÇŞ÷ŠÜãëøîù>›oš…—‰¸…÷‡×y©K§Ö¹¤¶‹à‹÷6Ğû*‹ûßıaë÷Ç÷æ®i.ûŒ}˜R‚ø™6[a*ûv÷Š÷‡Ş¸a>ûÑûNvú>w÷@è÷÷÷VE÷$÷0QÚû2ÆûûJûDcû+û;Ç÷÷B¹÷÷=Ó vøŸw›ùIùYøŸ4 ü.‰&ø.)&ü.‰'ø.,÷+üŸåñø)ôü)æ-ûnÓ÷×ø!Û|w³æ@ã÷Ÿã7ß9İÔ€ø‡¶øt9@ù ‰Ì^^¤Hû4"û0ûDäû÷Òµ À«ö uûcZûHg¤Ä}3"œÍZ÷÷7Õİ÷Gù 7÷bûWH/5UØ÷÷»Îçé½Cû-‹İø±Ú¥î:â÷¯çèøİü˜Ë»³Æ«Ô³ïÂã¼÷÷3ŞûØû3?$û)â÷‘¸ÁåàÄW=Dmk&Q/VèûFc5…û-wÛøÇÚ°è÷ºèø™÷é÷}6÷û/û/6ûû}ûzâû÷-÷-â÷÷z.ûKX)++Xí÷K÷O½êìì½+ûN÷º vùaw›ú"ú2ùa ûüÛ‰û4øÛ"û6üÛ‰ûøÛ#÷Oıağ÷:øçŒ÷7üèñü@ vøøôÀóX¾Ğ÷1ù ìà#"ĞÀàŠHsc]Ó›«»æü vùawæì÷Pùa*ıa- vø†Ò÷w÷œêğø†÷7ü†êùREp$qxû€-xÔ÷IÚ÷ËÙµå9â÷¦ñ4âòø•ø÷k7÷û6û1+û%ûà2÷ÙÁ¦Ä®‰nûX`H)‹êEa´Õ„4û”ÔI÷ÖÆ¨Åµ½Î¨÷÷ô%í#XR.6YÁçñ¿ÊßâÃP0-xÚ÷¢×÷oÙ±èEæ÷ŒæGèêø˜÷`ÙhÀ;²ìË¬¥´Î÷5Õûû7?ûI¨aÍmò5ck[/ûî4÷!÷$éã÷ìû÷ÑHV[BEW»ÌÌ¹´ÑÜ¾cKò¢ûÚ5XZ1.QÁâ×ÇÀàåÄV9- vøíá÷êøøöØüy5ø@1W:UûOûl/}#ê­÷4¢ÒÁ÷ Ä÷ÀÚĞØû*‹ÓøÕªøIøhÓûÕ÷ÍøÕü)A÷¶ûÎüF- v÷>×ø]w÷ßãø÷>×%ø]BûÕüR4÷Æû>ã÷>3×ûu÷t÷ÔŒ-x×÷ĞÚ÷*á«å÷½èø”÷x÷(ëûTfk^ª÷V÷½áûÿWüÖ†µ¼®À‹æÌK1*LJ/;\²Ù|1ûœ×K÷÷1ìé÷-d v÷Ùá÷pááìøÚùáü„ıaì÷Ù÷ôáûô÷pü‹õ6vâóX¾Ğ÷S“íà#!ĞÀàŠHsc]Ó›«»æ÷ƒv˜Ñ÷\Ñ¡Ñ÷]Ñ²Ñ÷]Ñ÷Ñ÷]Ñ€ùå÷8é?×,-??--×?éê××éûJø°Uÿ€üıgÁöøµê?×-,??,-×?êé××é€ø#ûşT^^ST^¸ÂÂ¸¸ÂÃ¸^Tüi÷şT^^TS^¸ÂÃ¸¸ÃÂ¸^SI»ø{ø«–Ûü÷6ø÷6Ûü{ûdEü vø/õâóX¾Ğ÷Sø/õà#!óü'í#!ĞÀàŠHsc]Ó›«»æœ vùawŸùùùaûû^ü÷‰ûbø÷ ÷šıaò-xÚ÷ÉÚ÷EÚ±ä2ò÷§àAåòø™÷q÷1èû@VpOdˆ•÷?Çæñ‹ìË³fC˜à†Ç~«i­e²Q¢R‹û5‹*û#‹û‹ûváû÷7‹ê÷ìñ÷1†0RJ94OËççÄÈàãÃP--ûNv÷T×ø"Ú|w®æ÷­â7ß8ŞÙø‚ûcùn8A‰üÉa\¦Gû4"û1ûGãû÷!È³Ÿ¼³û™úøYûUF14VØ÷÷ºÍçé¾Aû-xÚ÷œÔ÷wÚ­ç÷ªåIéôø÷bŞi»8­øÃ ¬¿Î÷6Õûû(FDû3ƒá÷ “²¶ãİ½`DAYd,~…‹z?Œ›“‹ô÷Âc39MU+*`¹÷‡/û6™ÓC÷(÷/îã÷ü‹õ÷Åõâó÷Sø/õ#!óü/õ#!ûÑ v÷{å·÷ˆ÷´÷{åûˆ1÷xâøÜà²îø‰îùv÷û÷uû!÷-ûdûdû"û-ûuûv÷ û,÷f÷e÷ ÷,÷v(ûA%û
û(û)%÷
÷A÷Eï÷÷+÷*ïû	ûDÓ‹İø½İÜíøîù5ø÷gû÷ûJû·ıa÷³÷R÷÷÷z(…ûA< ûûOø½÷I÷5Àûûüvù‡wz÷Ì÷»ùtIûŠı‡Î-‹áùw×ìø¬áûÿù*ıa÷K vùawÔè.æøŠé/çäùŒùaûû_üñ‰ûaøñûıaèø<ÔÇ‰Æ‹Çè÷_üïë÷]øğäèŠû	Šº;‹‹‹üZ- v÷ƒÕ‹øÀøÀ÷ƒÕüÀAÓxáùwÚìøëù÷‘ød+üYûFCûûIÓ÷øV*ürû1÷ &÷<÷F÷ò÷=-û½‹øÀøÀû½üÀYøxÉèÌJÔ÷¸ÓñÈ÷'Ô×Şø:Ìßùöø>÷Cû*÷ûVûeû:û:ûdûk÷:û:÷l÷÷Î÷ÊI@H8d/ûBû÷÷C÷K÷÷÷A÷3÷ûû$ FûCyŠšš¤§éÈ÷cGwMlÄj W‹û$ûû,5ÍAØ¶¬˜½»a v±®À¢¬´ÒÆ±İèÿû“y*>%A[j³ÄìÕíÔ¹²`Yu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
50 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 46/period/slash 49/one/two/three/four 58/colon 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P 82/R/S/T/U/V/W 89/Y 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p 114/r/s/t/u/v/w]/Type/Encoding>>
endobj
52 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 51 0 R/FontName/DJTMWX+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
51 0 obj
<</Length 4381/Length1 4381/Subtype/Type1C>>stream
  DJTMWX+Helvetica-Bold   @ø øøøøû>ûwú}úW
 ‹‹
 ‹‹      u²  ö €•002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  6  # " $ , ( 3 0 6 / %  + & 5 * 7 . ) 4 -  : 8 F U I P E T V M  1 ' J H S    D O   B C W N L Q G X 	 
  8   | ·	;¡X½+c±Èò2\éY…ğRÕ~è/FI·ß	X		Ë	à	ı
K
“[Û;f×w¯ó8€Ó‹÷÷U÷÷0÷×÷$÷®÷#û÷)ôù0÷màmº:±øÊ®¤´Î÷5Óûûğıa÷ÅŞÈ•­ôÏ±´ÑÛøû:÷ÁXdmGûC÷0÷?×®tWôœûºKafCûM÷U÷SÏ³iQÓ v÷'÷øQwŸù;ùOû‘ùaûAû‘ıa÷1½÷'÷¹û'3÷¤ûLç÷°Óx÷øƒ÷·ùù?÷‰û)*n_f6ûHç÷,÷4Íæ÷
Şµi1§÷(÷-~ûğûAû]ûû'û|û|÷û$÷^÷;öæ÷A°Ó vùawâùùeûÈø=÷·÷¸ûUû¥ûµ÷µû+ıa÷+÷‡ÑÓ÷qûÏ÷x÷4v÷÷÷u÷ø×÷xù[øû½û÷9øû oQY*ûAç÷0÷4Ùì÷×Æ_B¡÷(÷)xûæûCûiûû(ûzûv÷û+÷YíÌ«ÙÈx™0Ó v÷®÷÷T÷×÷(÷¸÷(ù9s”„À÷H€©:¯Õ©¯Äß÷3ÚûûÿŒıa÷'÷®÷/îšyû
ŒFo˜Zø†Ign:ûC÷T÷OÎ±hM÷x÷øŠ÷·ùFùr÷ú÷mû÷6ûvûuûû4ûoûn÷	û3÷x÷t÷÷4÷mû*Œû0A,ûûAê÷0÷/Öë÷÷Ö+û/Óx÷øöwÓøÖù÷øgû,üm/[^*;[Âåøeû-üpû7õ*÷F÷Tñè÷DÓ vùawĞ÷ ÷Ä÷ ù!ùaû üˆ‰û±øˆû1ıa÷ ø”÷¸ü”Ó‹÷øi÷×÷'÷È÷,ù?ø÷n'÷ûSûĞıa÷Ë÷J÷÷%÷{û,û(M0'û&øi÷$÷À@û/ûÑ‹÷%÷r÷%ç÷*÷†ø÷%û*û%÷*ü÷%û*û%-y÷øúw¡÷÷A÷*øw÷dø‘û*ü‘?snNKs±ò¦ûlûOÌD÷A÷'×Ø÷)œ‹÷÷O÷÷+÷×÷'ù ÷ü!÷O÷ğ÷ûğ÷+ø÷ü¢ıad vøã÷÷z÷+øèøã÷üÚû÷lüã÷+øãü vùawË÷*÷jùaû*ıaœ vùawùùùaû/û0ü³‰Šû.ø´û4÷†ıa÷#÷K vùawĞ÷ ø4÷ùùaûlûüÉˆûøÉûoıa÷ øì÷üì÷(÷øìüìÓ v÷Õ÷÷¤wÒø×ùùaû*û¤û«÷¤û*ıa÷*÷Õ÷«ûÕœw÷÷I÷$÷'÷6÷²÷"û÷÷¥÷#û÷%Õù	÷lòSÃû¬öûC·S™v ‹´À¼¬×æºhB•÷#÷$„ âû;ûA&8û"û*õo÷nÙØyîtªv‹^NYl&,Z°Ùƒû"C™d±a¿Såk÷‹÷@‹÷ç‹÷$d‹÷øßw×øøÚ÷ûøøßû*ıa-‹÷øh÷
«÷÷]÷ ø’÷ûÈ¨Ä÷ÏÊÅÀ»¨Â‹Ú‹÷(ãû'‹û'‹<6†û9÷î¥¬ÒÇ³bL4Gkû4û*jS„ûœ vùawšùùùaû=û!ûËû*÷ËûD÷ŒüSû¢÷+÷¡÷º vùaw÷·Ï¬ÙÚ¬Ôú4ùaû+bûCbûBgûD‰h÷UƒB÷èû3Nû¾”¿Zû«‰h÷St7÷ùû3÷_ıa÷ ±÷N¶÷N©÷PªûO³ûP´ûM÷#-}÷÷æ÷÷¢÷#û#÷ ÷p÷#ôø¢÷x¤÷P2ôû5û4.%ûDûIç&÷9÷ÚÂ÷¯û#cyny\ìAdµä„ô÷pæûmÚ˜«¬ÊÊ¯f@•ûÑ…õ÷ßïİ÷ ÷Èˆõ‰|„Š^„‘±÷³áï5÷%û û%C'ÓûÕ7³kò™Œ«d vø@÷÷>wÌ÷û÷ ÷]÷ôøµø÷CÑûCVnUoˆ÷‘ûıaì÷ ÷Åß³²ÕÆ§jCû×d}÷	÷Ù÷
­÷#÷•÷#øÕ÷÷?!÷û9û:!ûû?ûAó ÷<÷;ó÷ ÷@û# _S76_Ãöô¸ÄßŞ¸R"d}÷;vø<÷÷?w­÷$÷|÷û÷zø¸ùaüûû“‰Ê^d Dû5û û;û@äû÷Ï¾¦Á®zHú÷˜&^Q=E^ÊìóµÆÖÚµR -}õ÷ğõ©÷#û÷û÷÷a÷ Ôøš÷9÷dûá?‹ê©«ÀÇ¨uZ‘÷÷„;Åû-û;D ûX÷İÊ‹3ggxVÌ=h¢Âˆäû#ûëE÷0÷#æĞ÷d}÷
8vø§wÍ÷ ÷[÷û÷ôø³ø§øûûÇB`\IOm¬Ì÷İû ûñûÍC÷Ö¾§È¯ô@ü vùawĞ÷ ÷eùaû ıaüœ v÷—÷÷h÷øq÷)ùø€÷4áûûÜıa÷*÷—÷@÷çé÷û)‰Cfg@û÷h÷
í®o?d v÷Á÷÷7÷×ø‘øİøã÷ü‘ıa÷*÷Á÷Î÷ûÎ÷7ü vø§wŞ÷Ğ÷ ÷eøæ÷û û÷ üæø§û ü§dûmõ÷ ÷
÷É÷|w³÷#÷z÷û÷Úø¼¨øŠû<‰üËmX©Dû4!û<û?â#÷!Ğ´£Ä«‡L4hh>Kt˜´û,#—ŞS÷'÷’÷.çû÷„*eR:G`Çéê¶ÇÎ×·J1û™ vø(÷"|wË÷û÷ ğøø%÷"†‹Jgp<_‰ğæûü§è÷ ÷¨ß··ß–”Š‰Ÿ- vø}î÷w÷÷!û÷èøùZû8Td w(Ğ÷<ü}ü‹÷%Ë÷*÷j÷%û*û%üvùˆwj÷ë÷Êùuû	ûvıˆ÷-}÷÷Û÷
­÷$÷`÷!øŸ÷Vû!KjnSHgÁ÷õ³ÅÕº©pP˜÷!÷ƒ+Ôûû71$ûOû?å(÷/÷åØ÷d vø?÷|wÌ÷û÷ ÷]÷ôø´ø÷DÏûC_rH`‰ôØûü§ì÷ ÷ÄØµ¹ÑÇ¨iEû×-x÷÷mï÷O÷¦÷û÷÷M÷ û÷$êø˜÷gÜdÆG£ìÈ¯¢±Î÷0Øûû1:û&Š÷Ü­­ÅÂ®hTIel:v'ò÷‰²q<K^]NHl°â†ûû)‰æ3÷,÷(ïè÷- v÷0÷øQw÷Æ÷ û÷èø¡÷0÷<øQû4û—üDûĞ÷«û0÷ ÷0ûø3Š'Š#%ûEÈ÷E÷Æ-}ïJv÷zÜ÷÷¨÷÷Q÷|ø¡ u’‚£¿÷´ë;Åûû0FUû€÷½§£ÀÊ¨x`t|}i†ûx${XR‹*ü.ËMëÓ²ÆÉ|Œq”püz÷SRS[K`q¤²»¡Ò˜Ğ˜ˆŠ©œd}÷;vø=÷÷>wÈ÷ û ÷÷ƒ÷#zøÕ÷¥÷72÷ûE]rQe‰÷‘û ıa÷ÎöS®»rĞ÷á÷÷Dû#*]JE@[Éìô·Ç×Ö·O%- vø§w˜ø¤ø±ø§û'ûü‰ûøû/÷Tü§÷&÷ƒ vø?÷
û	÷
|wË÷ û ÷÷E÷÷>÷ ëùÌø÷CĞûO`qPfçÎ_jCF^pJg‰÷Øûü§ë÷ ÷×Ğ¨¯ÄÉ¢n:ûÒ÷÷ÒëÓ«°É½¥m@ûÖ- vø§w÷bwĞ÷ øÆûT÷Ù÷N÷bû?ûDû]øû ıa÷ ÷<ÆÇ÷ûxdûNv÷U÷÷Ù÷{wÉ÷û÷!÷{÷#êøÕ÷¤÷82÷ûAcsF^‰úØûıvæ÷!÷¦Œ­R¹rĞ‹÷á÷÷Dû#‚)^KEê?\Æé÷´ÆÙÖ·O$ûÑ vøEíÜ÷á÷ ÷ÑøEí0 ¿‘“µ²÷h€‹q#XZ%_?)×üE÷ øE÷ vø§w•ùˆù’ø§û#9üˆ<øû!@ü‰8øû(÷)ü§÷%İøŞü÷"ûÑ vùqw®÷$÷ÍûbdÔ|¨|­_ñv÷ ‹÷‹÷¡÷´îš®”Ÿ¸Ş&ûû0Sû*û;û3Æû0÷
û+ûÑ vùqw÷-÷$÷½÷÷4R÷+û÷0%³@™nšjµ.¢û‹û‹ûxû`'|gzleEğ÷	÷)Å÷1÷:÷ƒv“ò÷1ò†ò÷1ò§ò÷1òóò÷1òo€ùî÷?ï:Ü'&::'&Ü:ğïÜÜğûJø°Aÿ€ü!ınÕ÷ø·ğ:Ü'&::&'Ü:ğïÜÜïo€ø ûù_hh`_h®·¶®®·¶®h`€üg÷ù`hh`_h®¶·®®·¶®h_wŸø§š÷,—’Ÿ˜‹÷£—ü|‹õ
÷ Œ
_÷ªù
endstream
endobj
88 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
89 0 obj
<</OP false/OPM 0/op false>>
endobj
97 0 obj
<</A 98 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
98 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
73 0 obj
<</Annots 99 0 R/Contents 100 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 101 0 R/GS2 102 0 R>>/Font<</T1_0 29 0 R/T1_1 33 0 R/T1_10 90 0 R/T1_2 37 0 R/T1_3 41 0 R/T1_4 45 0 R/T1_5 49 0 R/T1_6 53 0 R/T1_7 57 0 R/T1_8 61 0 R/T1_9 65 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
74 0 obj
<</Annots 103 0 R/Contents 104 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 105 0 R/GS2 106 0 R>>/Font<</T1_0 33 0 R/T1_1 37 0 R/T1_2 53 0 R/T1_3 57 0 R/T1_4 45 0 R/T1_5 41 0 R/T1_6 69 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
75 0 obj
<</Annots 107 0 R/Contents 108 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 109 0 R/GS2 110 0 R/GS3 111 0 R>>/Font<</T1_0 53 0 R/T1_1 33 0 R/T1_2 57 0 R/T1_3 37 0 R/T1_4 69 0 R/T1_5 41 0 R/T1_6 45 0 R/T1_7 29 0 R/T1_8 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 9 0 R>>>>/Type/Page>>
endobj
76 0 obj
<</Annots 112 0 R/Contents 113 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 114 0 R/GS2 115 0 R/GS3 116 0 R>>/Font<</T1_0 33 0 R/T1_1 53 0 R/T1_2 37 0 R/T1_3 45 0 R/T1_4 41 0 R/T1_5 69 0 R/T1_6 29 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 13 0 R>>>>/Type/Page>>
endobj
77 0 obj
<</Annots 117 0 R/Contents 118 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 119 0 R/GS2 120 0 R/GS3 121 0 R>>/Font<</T1_0 33 0 R/T1_1 37 0 R/T1_2 69 0 R/T1_3 41 0 R/T1_4 45 0 R/T1_5 53 0 R/T1_6 29 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 17 0 R>>>>/Type/Page>>
endobj
78 0 obj
<</Annots 122 0 R/Contents 123 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 124 0 R/GS2 125 0 R/GS3 126 0 R>>/Font<</T1_0 33 0 R/T1_1 37 0 R/T1_2 71 0 R/T1_3 45 0 R/T1_4 41 0 R/T1_5 69 0 R/T1_6 53 0 R/T1_7 29 0 R/T1_8 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 21 0 R>>>>/Type/Page>>
endobj
122 0 obj
[127 0 R]
endobj
123 0 obj
<</Length 7516>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.16901 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(studies cited, a longitudinal study of HR)60 (T use in the)]TJ
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(Netherlands documented little change after publication of)Tj
-0.013 Tc 0.013 Tw 0 -1.2381 TD
[(the WHI findings. However)40 (, a sharp drop in the purchase)]TJ
-0.01401 Tc 0.01401 Tw T*
(of oral estrogens in late 2003 was noted, after publication)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(of the findings of the British Million W)80 (omen Study)65 (.)]TJ
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 265.1447 682.1197 Tm
(23)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.019 Tw 10.5 0 0 10.5 70.5 665.8197 Tm
(In parallel with a decrease in the use of oral estrogen)Tj
-0.02499 Tc -1 -1.2381 Td
(and estrogen/progestin combinations, we noted an increase)Tj
-0.006 Tc 0.006 Tw T*
(in the use of tibolone, a synthetic steroid whose metabo-)Tj
-0.019 Tc 0.019 Tw 0 -1.2381 TD
(lites have estrogenic, androgenic, and progestagenic prop-)Tj
0 Tc 0.01801 Tw T*
[(erties. T)35 (ibolone has been shown to provide relief of hot)]TJ
-0.021 Tc 0.021 Tw 0 -1.23809 TD
[(flushes/sweating comparable to that provided by HR)60 (T)55 (; the)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
[(ef)20 (fect of the drug on cardiovascular and breast cancer risk)]TJ
-0.02499 Tc 0.017 Tw 0 -1.23809 TD
[(is less clear)55 (.)]TJ
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 107.115 578.1197 Tm
(13,28)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 10.5 0 0 10.5 122.4056 574.8197 Tm
(A)Tj
-0.02499 Tc 0.017 Tw 0.93877 0 Td
(recent clinical trial of tibolone in women)Tj
-0.01801 Tc 0.01801 Tw -6.88216 -1.2381 Td
(with osteoporosis found it to be associated with a reduced)Tj
-0.017 Tc 0.017 Tw 0 -1.2381 TD
(risk of fractures and breast cancer but an increased risk of)Tj
-0.02499 Tc 0 Tw 0 -1.23809 TD
(stroke.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 86.4427 539.1197 Tm
(29)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.00101 Tw 10.5 0 0 10.5 94.5176 535.8197 Tm
[(Although tibolone is not included in the for)-25 (mulary)]TJ
0 Tc 0.04601 Tw -3.28739 -1.2381 Td
[(of Israeli HMOs, Maccabi Healthcare Services of)27.2 (fers a)]TJ
-0.02499 Tc 0.009 Tw T*
(50% discount on the purchase of tibolone to members with)Tj
0.019 Tw T*
(supplemental insurance \(86% of women aged )Tj
/T1_2 1 Tf
0 Tc 17.55806 0 Td
(\263)Tj
/T1_0 1 Tf
-0.0251 Tc 0.52382 0 Td
[(45)-244.3 (y\).)]TJ
-0.02499 Tc 0 Tw 2.44619 0 Td
(Oth-)Tj
-0.019 Tc 0.019 Tw -20.52806 -1.2381 Td
(er members may choose to purchase this drug at full price)Tj
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(without the purchase appearing in the Maccabi Healthcare)Tj
-0.02499 Tc 0.00101 Tw 0 -1.23809 TD
(Services database. Therefore, we may have underestimated)Tj
0.013 Tw T*
(the degree to which tibolone has become accepted.)Tj
0.01401 Tw 1 -1.2381 Td
[(Our analysis has several limitations. W)80 (e focused on pur-)]TJ
0 Tc 0.02699 Tw -1 -1.23809 Td
(chases covered by the HMO, rather than physician pre-)Tj
-0.017 Tc 0.017 Tw T*
[(scriptions or actual drug use. Further)-25 (more, we limited our)]TJ
-0.024 Tc 0.024 Tw 0 -1.2381 TD
(analysis to purchasing behavior and did not attempt to link)Tj
-0.021 Tc 0.021 Tw 0 -1.23809 TD
(trends in utilization to health outcomes. Since our analysis)Tj
-0.01401 Tc 0.01401 Tw 24.57143 33.42857 Td
(equated a discontinuation of purchasing with cessation of)Tj
0 Tc 0.07899 Tw T*
[(therapy)65 (, we could not separately analyze the ef)20 (fects of)]TJ
-0.011 Tc 0.011 Tw 0 -1.2381 TD
(physician and patient decision-making on changes in uti-)Tj
-0.005 Tc 0.005 Tw T*
[(lization. However)40 (, because patients may choose at times)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(not to fill prescriptions they have received, purchasing data)Tj
-0.017 Tc 0.01601 Tw 0 -1.2381 TD
(are a more reliable indicator of actual utilization than pre-)Tj
-0.013 Tc 0.01199 Tw T*
(scribing data in that patients are unlikely to continue pur-)Tj
-0.035 Tc 0.013 Tw 0 -1.23809 TD
[(c)-10 (h)-10 (a)-10 (s)-10 (i)-10 (n)-10 (g)-10 ( )-10 (a)-10 ( )-10 (drug they do not use. In addition, it is theoretically)]TJ
0 -1.2381 TD
(possible for members to purchase medications outside of the)Tj
-0.00999 Tc 0.08501 Tw T*
[(system, resulting in underestimation of HR)60 (T utilization.)]TJ
-0.02699 Tc 0.017 Tw 0 -1.23809 TD
[(H)1 (o)1 (w)1 (e)1 (v)1 (e)1 (r)41 (, prescription drug coverage with a modest copay-)]TJ
-0.034 Tc 0.024 Tw 0 -1.2381 TD
(ment \(generally 15% of the cost of the drug\) is an important)Tj
-0.01801 Tc 0.008 Tw 0 -1.23809 TD
(benefit available in the standard services that must be pro-)Tj
-0.00999 Tc 0.024 Tw 0 -1.2381 TD
(vided by all HMOs, and it is unlikely that women would)Tj
-0.035 Tc 0.013 Tw T*
(choose to pay full price for prescription medications. )Tj
-0.007 Tc 0.007 Tw 1 -1.23809 Td
[(W)80 (e defined sustained usage as a patter)-25 (n of purchasing)]TJ
-0.02499 Tc 0.004 Tw -1 -1.2381 Td
(without a break of greater than 120 days. W)Tj
-0.0251 Tc 16.45583 0.00001 Td
(e)Tj
-0.02499 Tc 0.64825 0 Td
(chose this ap-)Tj
0.006 Tw -17.10408 -1.2381 Td
[(proach, rather than a calculation of adherence to therapy)65 (, to)]TJ
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(identify time points at which therapy clearly appeared to)Tj
0 Tc 0.006 Tw 0 -1.2381 TD
[(have ceased, while allowing for less than perfect adher)5 (-)]TJ
-0.022 Tc 0.022 Tw T*
(ence. Because the analysis considered a range of products,)Tj
-0.013 Tc 0.013 Tw 0 -1.23809 TD
[(and dif)18.6 (ferences in packaging and dosage make it dif)20 (ficult)]TJ
0 Tc 0.007 Tw 0 -1.2381 TD
(to establish the number of days of therapy included in a)Tj
-0.02499 Tc 0.005 Tw T*
(package, we chose the last date of purchase as the endpoint)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(of therapy rather than adding an arbitrary number of days)Tj
-0.006 Tc 0.006 Tw T*
[(to the calculated duration of therapy)65 (. This approach may)]TJ
-0.02299 Tc 0.02299 Tw 0 -1.2381 TD
[(underestimate the true duration of therapy)65 (. However)40 (, since)]TJ
-0.009 Tc 0.009 Tw 0 -1.23809 TD
(we used the same method to calculate treatment duration)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(256)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
0 0 0 0 k
60.62 43.118 492 17.245 re
f
0 0 0 1 K
0.5 w 
60.62 60.113 m
552.62 60.113 l
S
BT
0 0 0 1 k
/T1_6 1 Tf
-0.01401 Tw 8.5 0 0 8.5 60.6199 47.8634 Tm
(Figure 4.)Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 97.8987 47.8634 Tm
(Percent adherence to oral estrogen therapy by year of initiation of trea\tment, 1999\3202005 new user cohorts, Maccabi Healthcare Services.)Tj
ET
0 0 0 0 k
60.62 65.8489 492 276.592 re
f
q
60.62 65.8489 492 276.592 re
W n
q
0 G
1 w 
/GS2 gs
/Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_8 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
21 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 62/Matrix[1 0 0 1 0 0]/Name/Fm6/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 0 8043.68115 4552]/CropRect[0 0 8044 4552]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-4.tif)/ImageType[1 1]/Overprint false/Position[70.019 68.058 70.019 341.09799 552.62 341.09799 552.62 68.058]/Resolution[1200 1200]/Size[8200 4552]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm7 20 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
482.68039 0 0 273.10889 70.019 67.9891 cm
/Fm7 Do
Q

endstream
endobj
20 0 obj
<</BBox[-0.14506 -0.24894 1.12286 2.651]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm7/OPI<</2.0<</CropRect[0 0 8043.68115 4552]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-4.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[8200 4552]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im4 19 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im4 Do
Q

endstream
endobj
19 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1138/ImageMask true/Length 15763/Subtype/Image/Type/XObject/Width 2011>>stream
X…íÍ®ëF’çÿ,6.{q¡ì¥1Ğ~/Õ€ú²Å½™µj5jÌË4¼8›Fù]¯Ñ‹ÁT^ÜÍ ~Át^xáåd¡Ö æ)‰ùAJ”H1ì‘'%’¿ÌÈˆÈd}ày%&Ùgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgöÇbóh wÇS²‡:Ü?!;Û³‘~Ù3:}2ö1Côòy¹ Ó'c§Xøó2¦Ó'c_cñE +:}:öUÉ¾ÜÒé“±oì¿-ıSÁ¿æOÇí·%»–x>ö¼dÿå¯OÇş1Şì2ú“ ¢OÅÎì©$v§ŠóGvöOúLìÿ^ä8¹XI<ûGö?¢‚}½•x>öuÁ.‘}½ˆYÄB±}Fö8N{áj%ñlì	í]°H'‹÷dì”âö,Ì‘
<{¤¢]ä	Ç³±×efŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}f{ºöòpÒé3²‡:ÜGÏÆş,EôóË~A§OÆ¾FÌÀ^>/c:}:ö%±‡?¿_ÒéÓ±¯#¾ôbE§OÇ¾*Ù—[:}Nöß–
}Ù{}ùaÙãà·ÿ$AÂHŸ‡=İmö_ş*@èšLgIÆÍìì‘è;î©ÄÈëù%»Œş(ĞÓ3…‘³Ç«’•£‘v½#3jöEçåb%Ñ=Ğ{²S`Ÿ’½¬ëäz+ñtì1±³P¬ıë1cÄ¾YIôcG6öX·Y'	‹^¸ú{‰ìéØÙÓËY¨™
ôdOÆîó©Šö,Ì‘pàÉØ*{ğ²œíÅÎr2£ó—/Í"MæIÙCÍñ¬ìĞOË	</»ÄÓ²§
OËŒº°»=1;½Å|^öœÌ“²£.ì®eçxVöqvW²gOËJ</»ÂÓ²'c.n®dgOÌ>êÂîJö0'ó¤ìANæIÙ¡9fö'dÏ–}Ì…İÕì
OËŒ¸¸¹–=1{4]ö„Ô]ØM—=åxZv-á)j'Ëhl0QöPxX¯dô˜×ç3û¥ìlfŸÙgö'ŠušìÌşlì¡ÖOÊ<7»Â“²#›rAï[¿wHr
ÓdËÉ¸e´“ºØ#MÆ½{á÷Œ‘²‡šcª¯#cR{àMr×3ÆÊŞaÇNsL”=S˜ê«X/{âã™ÀTÙ½a|ºì¡7”%
“eç˜è«X/»?É±É²û“\ä£eÏ<¯#s2ÓdO}.í†£e÷&¹Ñv~vÿ*VsL”İ¿ŠÍ&ÊîOğ©ÄDÙı	>U˜(;2…ivC°³é²{“ÜX»ìŞ$7ÖÂ.&õ°{“ÜX»ìŞ$7ÖİÊìş$§9&Êî_ÅfSeÏ&YØuaO}ù;U˜*»7Á'¾Î/»7Á3_çŒ—İ›àGZØua÷nÌD9™i²{“ÜH»Nì™Ä»Nì©/k©²'¾X–	L•İ›ä&ÌîMr©ÀTÙ½«Ø„cªìŞU¬ñWÓ`÷&øÉî]tIr3û$Ù“œÌ“²³œÌ“²{ü„Ù½InÒìÏÊLáiÙ'™ä:²{W±fŸd’‹I;°O2Éud÷®b'ÌîMğŒ£)C:vï*6hÊ;ÒI°g
nv‰¦,H'ÁîKğ‰ÂdÙ“œL¿W±Œtì¾WnÌÀÎ1v_’k¿ŠtëO#e÷%¹0'Óè­ÖŸFÊîKríW±ÁtØ3÷«XfjP˜{Úfu¿ğ§½‘²'È•	øCÿHÙYNÆÅ.1Yvß*6Uh²{<e<ì¾Ÿ(L–İ·UÛ&õÍ’ñ°û|»°óÍ’±§îĞÕ.øÛåÎhÙ“ÖÀúH5ÇDØ=Ó×PØea÷M_-0YöÀÃŞ&M&Ã.à,n$¼)¬ì¾$—*L—=Sè·cÇ¦Â¶à<K—¨õ—Ñ²{¼¡°kıe´ìß.ì&ÄîIğíÂ®½9ZvCåænöU#b÷%9-0]öL¢_a§9¦ÂºsV»kÚ½1ZvO’K¦ËîIrIË-R‰©°{’k±'Î¾	é¡ó@ÁÇîÙªm—°‰Âƒ³ï¨ş
òpq¸Ù=«Ø°½SÛê‡c§yê—=£S'»'Á·ÙÛğ`ìÁ.I½|^.èÔÍ*¸Ü¢½kõÆƒ±‡»˜}ÿyÓ©‡½EW“VkÛ}qèÅšNİì$×=¿wöèß‰}è÷+:õ°k2=$èùı»³³Õªd_nàc÷$9Cp$}xö8øm­àc÷$9;ÇC³Çö_	,"½4É–7Í¾\mö_ş*àeÏzIÊñĞìë»ü‹æ éÅIn´ìÑŸ„7’{V±íï“>2ûö0ß%K% F:\‚ô=«ÍºÌqr±’ğÍ÷H“™{–¯¢‚}¹•ğ±‡šcJìZÿ’}İ½w‚ôq×kŠmöŞ	şÑ×ïë˜1ö"6+	/{¦à’¯12öUœ;W]Ø=	~ƒ±±G{æH8¼ìî$ôLÿÀ¾cAGööËÖ»³õÙ;ïQ{“\0®ôß“=Ğ—¶İ“äÆ•şû²g
½^ÅN‰İä2‰	³»W±©Â„Ùİ	>qzÅØÙ#gc-ö-éTØİ	¾ıªõ‡³»ÓX»ìkıaÔì.¯ 3İqOwdºv“bw'9Í1İXçIr™Àtsœ'É¥fw'¹TaÂìî­ÚdGf²ìî$Ç¦Í)8ØY`ôì©khÃœÌtÙ×Ğ¶»I±;|»°›»;Ák	³»|&0avw‚Ï$&Ì­0ÂîöTa…İìÎ$Ç\ãgw&¹öÀ„ØI®µcJLˆİ™äZ…]¨0!vgíÖz=-vd
İ‹›pOffŸ{êÊá-öœÌtØ×P¦Sfw&øDÀüÆÍŞÊcµáËªö2v«ütÂìî­Z_ğ9{¦Ğ]R‰)±;“ÜÄÙI®õe…)±;“Üx^ÕÄ¤½Ù«Ø‰³;W±şİŒQ³»·j›5-ö^	şqú˜´?{¦ĞY‚œÌ„ØÓ~ü¸‹™ËØ“ì[Ğ_ÆÎúŒeŸÀ8öHsØ9Æ±˜¹Œİ™ä˜À8
úËØI.‘˜4{¦Ğyñ’(LŠ=ué¬ÑÖ<;»+ÉMİµŠm.^šçcgw­b›¯bv1“^ÀîZÅ6·°v1“^ÀîJğÍ÷´[Ğ_ÈL¢k?9öT¡ó¼æ˜{âH\MŸhöÅØÙ™#x§
“fwzÖğ‰DáyØ>‘(LŠİ•äš…\¢0)v×*¶YØ1…i±g
]»HaZìéL·ÙHaZìIcR;Š™PbZì®Ul&0‰I/bw­b3‰I³»|ª0ivW‚O&ÍL¡kQ;°DÚgßš½YØÎ“}KöÄØ,ì&ÇÎr2İ
»É±;’\sÇn`	ßœİ•äMCËÉX;‡doËîJr™ÀmŒUä;2·ew­bS‰Û:=‡]62]$&­JDÚQ2›¤
·—ËÛ%™³§ö
&±7"ZÂ.Ë™³;<Û‘¹¡d
¤nÎî¨`š…]×èÓ¹ÛìÂ$nÎîˆ8MvF:¤0…·ewDœækç„cP‰.tŠØ'¸1»s,Ù‘¹5{¦9,Ò|3Ãq?qÄàáØS»Óƒ7dÏÉÜš=±;}3ü+[Rë¹5;Ó
o%¿ş¯šãì;²o"Í×Uù¢îÀîèı[³sØšD×©8Rv¸Æ6S˜6»Ä%‹¬I°§
WScO·voëÃé7¹sãXdÆjÍñFâÛ@Ü]àÄù
Àb´VxÀâ™Â­Ùi!×1›Ü"É‘^™ä®bGj¶[Ò[Ê'ÒKá`ì›Ø{eY’^c4‡e>ædŞ.rÜœ=´zg,Dş†ôº$w{ º-´>‘¼W+pe’‹I/gG¶#c¾=ÇmÙ‰+“\Lz»=ĞgµSÒû½ŸH­C2 »=Ğg7fwğ%Ö!iN‹ÌŒcèùîàc9™[³Û}cX2¡Ù5™«ü•ì–èô*6|%ÇÑHd‡®#Z7O‰Áë’ÜµìiÑú†:Q|%'q]’‹I¯aOr2Ø‰ÂĞ’IX%µ¹cUbÒªôe·FœFaÇº<L?I%¬’ØÜqHvû¬ÓÕëvy˜~’HØ‡$'skvû¬ËnËÎ$¬Ò)É]Ënô™DÕ?r2ÃJ(p;ÉÙ4ÕdÎş‘“¹£h‰Û³'9cƒæ¨Î2CË×°‰ÂíÙ™ŠÕİNs.
W%¹«Ù£:bµA¢:CK`›n“ÜÕìÖ@jkØ†='sE’‹I¯b‡V°°×Ü.•œ]“¹"É]ÏíÉÙk7aç°'9Û³§9?{¢pÏDÖe«6&½Y¼+Ğ9Ùó×†gW¸¤_†dçèÂ^›ı­ä.jŒİè³m³ Gj•ß½w¼yèÌ“ÆınÂnõ¼´Æ6…‘Ú#Õû÷d¯bwµÇÕm=ß\Ì0‡/ı¯Y]Õ¸fÏ$“^Éæd¼ìÍB„q8ØÿO'öföLr1é•ìÌÒÃQi|+á¸`5¤~‡¾I.&½’İ¶YÜğºÆ·R÷â*ò‰ôò$ƒ©hG¨ —±‡Z¢CÙ•qt¯óR…«àŒ‡=ÙQú	u¸‹8.b‡V0ÿ]À¾˜q³'Ş÷o,ÔÂ™=İ³¡~Ù3:½ˆ=³<h¶›)\õàY^œäb|³D/Ÿ—:½ˆ=µ<h*`g×–óì5¿Çqy’‹uÌÀÂŸ—tx{b¹K"`_ÌhK‡™6û·¸<Éìëˆ/½XÑéEì¶@Ïì½ÎÉ8Ø9®Ü£´@Wö÷[:EDÚ?Ğû„ÃÊhMÖB,—l±+\ä
öUÁşÛRáBvh…ŞQ/qµæ°ËŞûàş˜˜)xÙwÄ¿å
—²gµ!µyG“]Àî¯ÿ»Ó%İ11õ]"SÛ‚ıW-a¯O/ôâÛÍşK§Kºƒ¹«_êì¿üU ¸Œİ{—öbÆÃş¾Ó%İÁœùÙñ±d—ÑŸ8.ôy[ w°7³ŸíÌCßSÅÀ‡í‘]àBöPø¥¹y!pá€µ]Iìñªdg©Ä…ìVğËŠ´Ç%:…Y‰Kú¥Ê¾äb%q!{·@?ØşsÇâ™‚}QÖ6r¹•¸”½cT¾Aw2‹“Ü‰]¬¯`Or2½£„Ä…UK5&
ØûÅs‰_ÇK±Pl¯`gš£?»Â…{°Wn¦Ù7â„±¡V—²wôÍ!sºdäyğ+“ÿ=£½FZ¦—²[ßO\ºÃìğÓ­.Í1E„hÏÂ<©À¥ìĞ
F KGÖ÷à§[8¼Ç3"´_§¢]DE—H8p){¶'cÀ“¸xdµD'vó»$¹˜ôÊ=jG gl¦ĞmR“¹,ÉÅ¤°[B*sŞ\K¸jço;yOâğ‰áØ-9Ÿ?SèïJ}¼‡¹/“Àn	ôõ½š~#ë…¼Çs‰Ø-[ÎõıŠ~/ \ÎÜ±øuùÄ€ìæ'p³3ão,¯´.ñ;±[¦–æ¸,5{–§ş;wx­“ÂnZZàrv…«ÙwˆI‡`Ì”µ±ê¢0À»X×¼JödnÎn	ô©„ƒİS/9ÍºØÕ'†c‡Vğ]Ov¦ĞIö¤q'¹ÁØ3ã(%Õ¿†
Y‘Z¥ıu³8.âÎƒ±§9™–°=;Ì'Rûƒ\+–™84;3ºW}.ÑœôzyOjóF…;°›ßO¸VY$Æßô–„Ôæ;27g7»W É8†E` I¬İ²'ssvh…¾Á¦ş/ÇUXNæöì™Ñ½2×o†w…‹’ÜpìiN¦Ï˜ø¦c÷;Û¯â\Æ¤Ã°›}ªàúk:vuö«˜£Ğàìæ@Ÿ(¸~““¹Z˜ã*Zâì¡ñ6Ì>&şxU¯{çÃ€ìĞ
†çr²{R`ç^ç¸`>É™ºØãÕö5i—ÒBà’ù“ÄîÉôôêŒÔ!ŸH»ôºÀ%I.&ˆ=1İÆSÜ| ½¼k:v®ù“Än9ZàŠiDÚ¥×.™²›ßOd7gg—$¹Ù¡ş(á’ß‘^<%®,xcÒ¡Ø>Qp]q\çûGàáÙ·IªÂ8ºOÕ>h‰’\L:{¢É8»6i"1Du£pA’’İèkÅM›4Q¢ªİ“éäbÒ¡Ø¾öê ‘pM‰ËÙ«7éœäbÒ¡Ø­à.Ù™B÷éØ«×ÉôNr1éPìĞ
î’µFy(vş{C1é`ì©iÚUÙ£»ë©ûxœ@¯‡=ÉÉ´îMjIzÿ*ó­bcÒÁØ™æpŞ¡ø¨÷İe•k/­ùdW³[^DWF9'3`½ßÁ±	>&ŒZÁóÒ^ÅM$pe‚·úaÙ®g{	•HL„İñv&á„’è”ä7ÎîÁnôîİ¥Ã>%:%9‡Ã¥¶¶˜t8v¦9.İ]ºŠôOrÃ²+ú;Ï÷‹Šı˜tHv	÷¤Pè±ööO‰«
ŞaÙ¡ú²‡¶éØ3Ã“ö,xfÏlsËº˜q†è>ì}“ÜÀì¾@oÈÃ†:÷¢^è›äbÒÙ™&Ó“İó“®ì}“ÜÀì¾ŠŞ0È­äl€$“ÈnLr•=øÚ.'ÆÎr2·g‡Vh÷;‡ƒİŠ‹4Æ=Ô°g†îO=2…ÄiŒÎxö4'ã`Ï8zxëŒİ³bÒ!ÙMİŸJ¸R‘-õİ²ãè™ä†f7Í­DÁØ¦77ùİ"GÏ884»)j'•[Ø9¿&fÇlòxÖğì
®MZ?©4›$'½®¨eæKÄ¤C²›}u`™BKÚ¿ğìñ™9znWÎædìÅ3€~K'rUŞ‘öKr1é ì†@_-hª>Ğµ\’¸úÕ…À=Ø¾š~Œ+Ö¿CßRÑ8ºı’Üàì¦­›J·Wıÿ$ŸH/ªÔë®Ğï1é ì=“p¼™¡vÒ‹Ş¹ÔİèHr1é ì¦@Ÿ*˜æ~ÇhÆr2×½Ÿ0_"&–=m?BRéÍášİ3T÷ıXÛ%bÒaÙÃ;·
{Æáš=W)¿gnİèYÅ2×œèX&÷ÈâöKÏnx„ª7¦CQß$gŠ²ÎKÄ¤Ã²¡ºib7‡"O†êšÅí—ˆI‡e7újq“pô‰RÜÂè¸DL:0{Ú¾æpİ ê3”°çveL:0;k³gW,W<]Ó¥¸1–“1éÀì†@ŸJ\ºï`Ò@»æ¸»!Ğ§
oËn¼ÄØŞ1í¤×'9ü#z-„oÀİ"5„€š,H{eşÉGá.ìi‹Ô“Ä¼¼uA‹|EÚ=ÿÅ¤C³'9™‹"uçZäiçäsv¦9ì»VæŸ°’sl˜.qöö‹èjagf—¸l…Ö5_˜.qvC oõ†ãÕMÇed—èq‰[°C+t~¨NIPK\Íí—¸	{Ö
,©Bß:ø’$çø^¦pöv\N®Y®$v&Ovu%¹˜tpv¦9ißÙ†»wM—ï%í¦˜tpöv wì¡ZÃğµ‘£M1éàìí÷Uö¯H»„áj£~Û•7a‡VhÜ¹Âş‰´KîSùëCïÆ¤Ã³gÔÃwd\ì™Ä ï¡]› Zâ.ìíÀ²›=QpÉÒN£{’‹I‡gg®qúDÚş…‚K–¤:´s’‹I‡g7l[å#iû7–dOæìí@_‘iŸ—ç	ËÉÜZám$èì‹7bÏvdŞBìs§ÿnÄædú‰Â ­Ğ9ÉÅ¤7`gšL¿Eÿ0Âz¬änÄŞ\^öV(¢Ù“\LzvÃû	{NfˆN'Ó1ÉÅ¤7`´Bß_¢Ó9ººDLzöş¾†/ìt®‹Á[±§9™~%„s@9®¼LkÆ¤·`ïè3çDz»òVìí@ÿ<â%ö¢¥óe2…»°·9i¿µF·|ÚhŠIoÁŞ~?‘“¾-{r'ööÖæp{Jó])N—èšûoÆÍÎ1öDÿ‰¬ù•œÂíŠÚuÏÍØ#­9Ì»‘‚InÎŞ¬{bÒ›°‡ZK˜_É…˜3°|$í”änÆ8Ø÷dn'9i§$“Ş„Z+˜3L˜“¹b3öâ=údOæì©>Á6^3ÛØ?Ş¢²°­äbÒÛ°'öóûDÛr5å$Ğœ:Ù“äbÒÛ°³{e	©9nÇN	†l—$w?öÊı|Tg—¸Erµ&¹û±WŠ›LÀÈ®0»€-ÉIÜ‰½1ïÎ”JtHA-ÙàjöÚîÈI¸Ù“Æ.,üÚËgËnÇéœ¬Ñ¥‰)èRv
'[²ş;Ä¤·a§¢–Ã\Ü0…)èâÅÎ¢V]w¸)»€¹¸a§^p¥ ‹Çİ^ŞÔïp;v*èÌÅMdf·å¾W±üÊtëÓ­\I.&½;ô¶Â.²Œ æpÉ–´k·“õnÕÆ¤7bon[;[AŸrÕíşUlLz+ö$'c*ìlì	Ç@½^óm[	“ŞŠicqc[Ì0Òî,àOr1é­Ø›EF&Ğmb~gCÌ¹1{ ÌÅæ¸­h“mK-ÉÅ¤U‰H‡{‚êì¢é¬p”LÀühÃ³to-Éİ”½è“SW¤FéúÒÍ/V0‡Ä}Ø“œLe0N]‘J˜‡Ka0öú½OÃ¡ş–ìØ™æ¨^;'ÓğşÆİwdšoõ{Ÿz}÷Ù;°7Âí¹¸a
fö“gÀ.`ıŠìØkŠsqÃvdLì9™b…]opfgŠz;ÈÃ]ˆ¡Ù›^¸Ç·–‚LD «DZÀx‰3{²£'	u´8†fOëŒ§ûÚØk)ÈÄ.qá|3İ!Æúc’ úùe½ ÓÙ“œLÅ%Vÿ»¡w,×SèŞï\“mßAàÌ¾YÇÄşòy¹ ÓÙYıö©Ä±÷s2ÆY*áäQè~o^¿y»¬Šõ:â´Í¯èÃ²WgW5¼ÆÇò,ËÉt6¦™•´Ù7`oz¦pª·qvÓ·*û**Ø—[:˜½èÏ%kÆqIai+Ë›L ÅşÛRaxö´æv¡@û	êp
î9ÄqeŠÿ½@ƒ=~Í%†gO4SŸ˜á$zÌ!_Çk–H‰*û¶dÿ«ÀğìLs\™¨ën¬Ğ]LåM 6¨°oKö_şò™NÁHÓí;Ä4»ïÈt´bEuÇâµz^•ì2ú£h%ä›-£‹làœCµøáqíaIö•=P«’¥ #½] ïÏ÷¤C%9Ú½¨Ë;ü-ÙWöP–q^.VƒÏ÷F ÷/Ô7\¤Éôq;Û}ì‘XE{|öÄÌ)Ø–ÌPI®HñdììŒ—u\o%†ggšÃÄ `cçpÂH°{sZÃ‚ØY(V7a·z	ÛÓ
–ä,åÍ™ıbÆˆ}³’=Ğ
ıFJÂ?vdúÔVNö$aÑW/1<»-ĞÛGJa¸$Gn'á`Ïr¶g¡d*pö´ßÃú–ådút½øHÖÎ{ˆ„ãìIÏ‡MödKr0”7ÕX·dù^¿Ä.Íí}q+Ï÷İ}eÙ†»(:Æ¤7Û£n?l¨àû~NÆY££g°İ“}ö@+TÈvd®awcïò&&½){=ĞÛ6§+’“µ’s¼ ¹{VÅõ*É'Òó†£¼‰IoËädÚ¯äş†Ô(_‘^MÁVà­Ø™æ0,U¤—Éd†¨ªïÁ^ôšã:ö¾+¹b_ô#Ù7a¯ï/:bAj™$¤&9{y“Ş–½è3	{ÊáF‰v8cÒ³g{2­7j	‡]`höêÜ•=ÑdN'G'uNö’‰DovÍñ6ì¬ÊÎ®fgıÙŞ†½è£œŒ{—:1{èé
½×ÑÕ'¸+{-ĞŸØ™ÄeÕK@:Ly“Ş˜½èO…ªzéçy÷eÏ*N|Ú‡eƒU/Ê›5Ù·`gš£•¢¤—mÕö3&½5{¤9—] •Á¬ë¸ÂC1<{NæØk>©¾Ë
»ËØ5Ç[°×}R9¶%xáã­xötOæ5ğß‘ç‡S~÷ş=ÙëË›»°'9™fqãJst½ìÏÎŞŠiVqsÑªä?ö+²}cøŠ>îÏ^­«NÅcênö.(o>‘½?{ Ú»Vµ©P7»DÿDËµÄ°×ıÙ’³û7¢òõáŠ­ğìÙÌkÄ•8…	3{åëF
‹R<™û³W½;U8Õ{
föÊ×‡dçxv¦9ÚÎúš°’ÌnD:@ysöj gg`“¹`›’^Pa5§XLz{ö@+:­tIŸ=øTà"ç“xöj ¯8tëiN_—pçj\ôoÁ½ÂVº¤şõœŒ].Éï¥»d÷gOÎÀ•ÂÎ:á+_·Ôu–Në5ò1éØ™æ0d¨ÌÂ˜T¾c…ÿº
.d¯ıìNìÕ@Ÿ	¸VW­]®vërœçĞååÍØ«[7)‡¯º©v•qı~!{¦9îÎ^õ¶„ÃWİT»Ê2åÉ\›âïÅ–‘ú‚íï'9we¿+qöD“1ıYÀìœ7	;÷ggš£K­ubW¸ÉÔ“_‘½3{m¾:ç¹PÈf?©õGÿ!Ù;³Û¢—ebk­9z*¾Z]Ä¤÷`¯úzä%cè)í'³t›ÏÿÎÏ“Ş…=5;w¢9Ìì
}÷"º±ŸŸãnì‰q€-\Øı<„ÍÎ4‡q„9Lì¹Vği9Ù1°[=Œî@á?U7µÇP¡%F1ßm¾ù §‘)‡§P©Œá%òæìKÒ©³Ûı?ˆ´V{’“é·è"sËIïÃÎ4G¯—Ï©%:Ö¢ÀØ+	ô^l›»S+Œ=Ğ
½^¼3-á-or²Ï^©è…ª¬IÓYÁ[,úbÂƒ°§{2‡=õB)I…›‚×—4ÇØ“œŒ‰ıô÷æä’l¿÷‹ÊÎ4Gëu¤‹=©€/€rŒıè+¯#]ì¼>É|´Bë•œk¾{ßËÿAÙÏŞ¼põ¾KZîÉíÉzA cY+à#¤Ïäd½ qÁ»Û—8Ÿi~ìLKLƒıü†1UèÇÎ~Ş¾H^£7DHLƒıèÙ)êe‹ÓË”¬gbpŒ€=}E^|¯”C‘	øj&ÒÇg?úFqã*Ï²W_w~ÓFVG±“åd¼CÏñèì§Š¾Éh…kVjŒãÑÙÏ>¨7X=;ÕşÉ$ğèìç@ŸIt|§Ê´Ä$ØO>Uè¸h	µÂ$ØMÆTÜ$öÑµ·Œj¾ƒicqi…Ëw®‘>:û)Ğ·Šû„ü;Wå8›ıè»VÅ„'sEQHâ±ÙO¾YØ9SYÖpótêò¥7eOOØ,n\ŞéíPò°ìINÆ´k¾zÄÅ¥Vxlv¦9ÌsXçd.})yx/Iö‘ÙOï2‰Îk–DKL€Z¡^åœ{EÂ÷#Ï«¹œ>šı8­™æèìİR}­É>2{vôLst­n¨\ÿ@Öïô
Íädª^—LòŒÃ¿¬ıú¨ìLsT¢Ñ¼SÅı§uÍÇbİ£oïV¸‚ºi¤[×|,ö@+˜ÙC­pİKI­»|ëíØ_½7h¤V¸î¥dÒÓéïÎ˜ì©ÂuåE;…Gf?z;SpÌe‰.ÑîàTÊÎ4‡™=Rp©D—kïÈ>.ûk ï÷˜HåŠlÇ`ò¨ì¯[7™Â=ÜEdd½=ôØì¯c“Jh>¿“ğ;•ÂC³g{2å–zšVŸ¹Eâ¡ÙM¦ÜR×9}vg?üÎ+ÿåwïÉ>&;;1hÍÑÃ_:~[‡K²Éşèö¦×í\±ôóŠ>“ı5Ğ#¹'[ëJ»’]áQÙÏA+Ñ'èğ‚¡[i‡`ÿ›ÄÃ²g¯£Mõ·Dgöi!ØeËœ‚]ÖŒôNöN;WÀ&åxXv¦9N[lÙ£.;WEaKö1ÙÏ[u­Eg(pmiG	¿NªÇc?zÊ[9ÙîQ²T&:^4&½3û9Ğƒµ¢İ ¥–9ÙeOOÃG/SNıĞ©´ğ»Õ¯êtıÇcOr2–HïÙ—ğ×ŸwÌÎ4Çy_™l÷()áÿÒËòïÜ›oÉ~ô…ÓsôX
Hxå]ø¾p‘œÌ²Zá\èpÔ‚ÃÂ¿"Û-4ìÉ>{%ĞƒiFõWi÷‰l7vÿdŠIïÎUÆ¤ùˆÉ¹_Ì#aQçôñxìiNæ(H{°w™ñGöf¯>{¨9:$ËË›ò‹ŞºéØììÎyLfÌìV°…·H+\[Ú×IZs<{5Ğ¶ê«Ï\	„¦Å¿@÷/ğxìY/­éœL—º¨ÃÀK<{’“©Œ‡í¬í2Kç‡dgš£J«Ğy?6èUÜWz#öz OtNöÜVí«®‘Ş»ô‰IïÏ^Ùº98§@¥-';@yãıfLzöz oì`d­}ÙİÅô¯Â£±gõĞ®s²]ÓXíËŞÙåè¨˜ôØ“ÚØ2­%ºV7ä?/;ÓµT¬Ğµº!öÿ ;^öÆ^UZ;­˜|Fstò
ÆŞØ«bº:ÇÓZ›©`è|#	(<;­D­+*~Î´‚û·=àIlnÿVìY½ş‚†ª›÷ôárz…>¶'óHì‰V°9=U7ïéÃ,4GwÙ“>;«W(õÚ;ÓïÉ:7"%ÆëóQu‚—N/QqŠ!ëœğ½ØSúxv
Ö¶uG¤ÿ•¬+IhÉè Gx!şGb—°­nÂjä³°§×¾ÁÊh w!Ç]Ùë|‰@uB×ì™æèÃ¾'Ûb$ËéQ^öŒN‘Ş‰]KÔÖå¨Î~Ã£V‹ŞTdõŸ{Ùµ@›É$¡——/ËŞ•İÁ“ºãd¦ú”ZÓGó&‰ŒØ÷Ÿ—åıîÉ®9lòÔ5îÍ®.›¶-öT®#°ğ?k:EDz§‚^ëFğ­¬¹Şƒ‘umï'zÇ®êêkbç‹@¿_Ñ)"ÒûôÑ:§Ïª/ïÉ¼²'¾â(9¿“Ó+´&–\•ìË-Ş=iÓÙ9ùÙÉ_­Ğ'Úi3ûoK…{²§œÊò×oØ#ê<…­LìqğëaÓìk¹úÓT64:°—Sl— ~GZaßì¿üU `§»ße-W>©Î%v²Şß÷˜ğ`åİŞEK´Ø¿üåÿrÜÑç¬š>Ì{Õïj±ÏîXNŸ}¶Â—Zì2ú£À}Ù‘6œ>Õ9YË†¦q§Õ/àéjY°oĞšïòİJàÎìÍ·é4ğd»³û÷òÛòù[´â¼\¬$îÏ®9jñhG¶>Cœò4ìê76{¼•¸7{Ò KkÏ´ö‘1ï7šìG•½¬ëäúØÉÉ«°ˆ/hj§–eM¨Ğ‡=%[c§z^lß€™®MØZ¤÷­õËš(§Ïîì	Ù
{Ì{›•ÄİÙ	¯F—hÍQuúj_~Ï|_©İOÖØÃ]òE?s•JÜ¢›æ°9}H­š>]³fÇê½çùºHÉ×ï9Û³P2¸?;ÓõaËš‘^+ø¦|N¶û,ã¨²G;äH8îÏŞÜ·Kkì4ÿkç¶×šÿˆÎò«@e¾¿É>­í½"[óy4õO¨9º:ıg…‡ao®dëgæÖf®«AÂãg/<;ÑiÊ¯³—{s¡Ì=ûù5¾hEöQØ­Œ›v‡Qõ²—Aƒl'i¬aß˜æ«ëÉ#ê‹}ÄŞØ·ycöÖJ¶-I=İÇwô9>vÖHsÀuùDê‰µ÷yãao­d‘“öbˆ=§Ïñ±'Z+Ô\X ;>n²“Ë6öívŒ>ºÏ÷ã”ÇÙ³æJ6O8*²"ß I²7Šzâ¨õE™öd<[™ÀøØ›+YÃ~MªÉ¸3%×
#doõ‰Ö
ÍaÍÉº§ZsŒœ^Ó‡mQß© ZÀû•‡do´n9}ªk½c™9#do¬ÓÓúé¡s¼£šiÙÄ{#ÍQW4¼¾ˆı¾O´Ì]6
v¦µB´A‘jísiÚÂÈ|ıóˆì-GeêêEñ…ê7Œ/2_ÿ<"{ãõT¦›ìÅªÓÂ6uÆÇNS<§Š‡s´ò „Ÿıİ;Œ½¾’MxõÌlŞ£’¦ÃŒ€=©†vf(biÆ+xC¦J5ÇØØ¡u7£‡‘¨OoÊÔ?3½½m°wİşS#{Nµi°#[ÿ’‚—}Ç4}Š½¹’-Øs²=Ù“‚]bdìQ³˜Kš8¾ºIWÙ%­Ÿ=<;9}İY™Öš£';íö{ 1*v0]ŸàE9“Óg•¬»bzO£OÇ#b'Öº³êV(tb§éxDìE)+Q Zs4+ÀÏd\>O/o™Îá£,vÖpú¢Ğ­÷Fé¿‘q±Ó®.+^S	Œˆ½•æÂÖ&F%\‡ÆûkòïÛÙcOš\©.P<5P#Ç? pú—cDì4\õÁj…¿ƒshç¸ÓlÉöL`4ìí½hv@i²7'B}¾—/ñ
v§‡Ä¤Ä4±ÃØ€Z¡ËÚ¨Ù“Í–?GÔkú¬ÍƒæÔ°ì†|GácAG#aO›Ñ.PD!Ğè­9ü>T¼®HÆÂ˜¢¸®rµ@'/’Y£/˜™Öî·MáuGö¬`W{¹’Mé Æ®9*ìÅ—¿‰L+¶Ç8ØÉé5½PFÃªìôPÂ?çy¦Ubv’ÇcÓúÿ56Õºîõ@BÏªĞmÿ.Ñ;Œƒ½LaîĞm¿:u%±÷2½e…¦Ók»æğAì‘V;2½£ÏÆÀçôÙÜÂ~-`}‰~Ï_ŒI½ëMOµÖ¨(ŠÀØü¦yiÇ¨ë$FÀèF1sÆ¤ àOó;VìeĞÑÃ³ h×®uOì¦¿7E²b=ŸÓÑ£³ Í‘ììoÚbHkç1Ù™nÇ¶ÔÄ^„†NS>Ğå^Æ'¼£“‡f§QjÃgøG˜z©1f¡İÛb/#¡Ã‡f§ÇlïO$a{„ékZst»èwZÿ‘š= ÃÈÓãK˜bG·ÔY\—cìMTÃVù]nQdìĞ‚F©=òä¶íòŒ¾É©pE·¡¯”1é²g¼ôe{{àé›|Jì§™\â…Ïæôiğg‰ğc`Ot)g¡SÍa&ÑIR­ğ*Ì^¸x£t)?}¶„|>Ô
.©0
öW¯ç¨¼ˆèÀÄnì•ºZaì‡qÖZ¡ê
{Æañ/û9Q<8{{äSŠv‰€¥Ÿ¼>?öÒÉ«EN1º©„eÜ«±ÁÂ~şÆÃ³—[uÕ —h­Œî|è¤“hLìåpVà‹ó]¤`q‘ÜÍ>*Ÿ?|NG¯ózŸT†¯1ğİbÒGg'Øj°/ö'“JhC|RìGo><Å«D×‚µ—xDbgºì)G'ÚÓKö8&ÄêL«U¢9‡­ŠÛ—¯hÛ›[#fOte]“I¦-ìa~x=­éx*ìE„;á¦‰>¸Á‚N›ä¢[}“‚ı@«5GÉ^v±§
­€ÇDôr:{9–‡T—
¼îádZs4"^²dìç9ŸI”§Ä–i­9êÁ!ÙyG>&;˜.åÏZáU2İßœ¢Z›%&mşğq%Õ•ˆwf×„2hÍÒÉ4Ø¨gNu¥è9ÈïHNÏÁ8¦Â~dÕ
GItí´"‰Öšƒ	@bìGg>u¦ì>‚‚İº76ö©±²ÑZ^Î4e#»˜ûa&*›WçV…?ä0¥qøÀØÌW¡³Bh”Th	ñ”ì§*#áAFÈ^tñ»qtKŸ?{ED:böL#æÑa3Ñ×¿NG`?Œñ«”BGç“ºĞßKöˆcôìĞê”èOUŞat°ahJÙ0ñ³g¯£y.m]Î€@ÿ‘NÂô‘=ÈÇÎ~”D×g}¦µ°íZD9ÀuNL:VööU8P€‰CFãhÉ`e+Ç«Œš½x^]÷ü×?PO´ÙŠ÷t4yvã×÷ô1öZÀÏÌhdé£.ÔZf…‰°WÓ}^ÙµHô)Ö¾+0!öb0ÏBt‡Oô±Œé+'I5Ç«L$Ó'ùYWÙs€Õ"ù½*º.9Àôñ Ñåğe‚ìz~Œu{ª«?"ûq¢Ÿò]ƒı5¼3ÒÉ±“¤º¾Â;dóTÙS­iĞ÷¦È^yûáµU¢?Óäú)Ç4Ù_Akë[¦+ìSËïNxıC'­½	²Qjõ:î
Óeô›ÛZ‘,cİÁ&Ë­ğšáê¿¾Y=IöL Uëæ9Ù‰³'Ç2F›dÒì©Õz¥DOÃşßqÜMƒÿTìÁ2v‚~ZvdúyÙOÿ9Ùƒÿ¬ìÅJ‡ŠÛ'e´Â³²£¨ëŸ•ı¸ÒyJöŠÌì3ûÌ>³Ïì3ûÌ>³Ïì3ûÌ>³Ïìãcwò@tøtìÑ¶±Â]Äñ|ì,'ö—=£Ã§cD/Ÿ—:|>vş¼,Ÿ}ñE +:|Röå–Ÿ}U°ÿ¶TxNö8øu/ñ„ìÛ’]KPºÓO$ù+û/ ıŒì2ú“xBöÕ=• ÓOÉÎ
vO¬{Gzië‚Ôñ^œô6­v¢ø5ÇÉÅJÂõM?İß^Ú^J÷;ÒKZOµ\o%”]<'{Ì"ŠíVâ	ÙÆ^¸ZI<;ËY¤¿“©Äó±G{æH}9DÂñ|ìİéì×¹-û¥tıØíß|Kv·ÅşL2³Ïì3ûÌ>³Ïì3ûÌ>³Ïì3ûÌ>³Ïì3ûÌ>³Ïì3ûÌ>³Ïì3ûÌ>³ÏìoÈåHE´ƒ¦cs+§VóÍì¡%L¯”‹ÖpŒÃØŠDPkÈanME¸´‚­•*0>•`*ÈC½‡‡id’í	æVºÒŞrP‹TEôkkné™Hó¬h8,­’åV°¶RŸï+“]¨íeO—2ÃŸŒ­ß}‘Ë%>Ğ±á~’ÛmôC(wtÒî·ï©•±à‹„©õEl6Œq˜Z#¡ÔbŸªhãÀ|åèGµ^G/éÄÉG?Jµ^DßIäCÙãğ;¹]³ˆéÄÄ®ŠV¡`j¥ÚÆ6ö$E«=üQRkh¾2±o—Q(üìËğ'±ıÈ¢ï$²¨uËÓ±áù¥>ÄáOâp—VkÑmÅè¤İçÁ¹şñ„ÃÔ~‘×Ñw¶Öí:zá
&v®ÊÁNüì[qƒ¬Â²5Èé¸-®şÄ×tbj•ë¢uK'föµ}yhµ°/ƒ/bU°o`bÇv³@BÁÃà'¾ÚF?¿ihİn¢ğÒ¡I~/ãe °¤Csë:0²_ÄšZS£ü"Ö«ğ{óS­Ñe«XÈ@â¦ì>°¯éĞÜz){pvrÊÕ&úØ[-q¾ [ì+:4<áb§Vs«X®B‘qXè¨õEs˜[ùzşqEIC†ØÃ?`ãäù\²[.üY”ì[:6Ò-ÖŒ÷=°ÿ…ÃØzd°<órş	XØ£e'öè'¾v°¿ìÜÆ~ s³3	óó‹ØÁş“ ºÏZÂÁniì‘€—ı{;{¡Öˆ[.@cGt
ÆÖKöDÀÜçû¿p˜ŸJì?*X¹`·´òÀÎácOB{¹Ø£’N
öV)˜KŸ’ı'K+Ñıs+/Ø…‚±Ïå¯bOìì»’=”°·¾ÖföŸ,ìIÉn›MIÈv®`ìsQ²3:ô°r²Š¸c¾'ºHÀØ¸¢AìŸ¿ç0Ó¡p°8²[z†weß‡®8¿/Ùmø@tKŠfÆ~;²¤cc+EòÏß˜ä#±¯B3=³ƒ=EÉĞ¡›=ØìÑP°·Ú.²`OéĞô„Á!¿¯éØÔZ²ÿ,a¦s°Oµ^…?˜[ñ‰Æ<†<>óñÃ89$ÑYëº¢ukevD·Ä':¶´®C{¨‚¢®ûYïèÄĞ
¢³°Z£s+öPE]Ó¡‡]„´Z‰~€‚¹•o·Ì¶w¡Ik±§cKë:´±Ë@®×Ñg3;õ¹(V:fº²•Ø¹Å+º²3Šb‹+Ø[mìŠØÜÑ±é	ù¡XÇ­èÄĞ«,è"{«ed™E¹=±±Ï¡È%{öm8Ñ­Yô„©.vznEt?*ØZiışY˜ŸŸ²X¿‡–Öëè…ïèÄØºµ¯ß%Šõ{ötìÛ”­±åŒã°oKëaßÆøü	 Š}3û±5úQÁØHÇ¾@¹oãgÿ üYÆqø“€™ıMZû6ú!”°¶2~Q0ÓÑRÓÅN“6úQÂÖÇÁ	3ûz½ğ5»ÙS-h_Ó¶O[´Šdoc×2U‘Ìñ*)[i¯UÂÜš)–#ä0¶ŠL2ú­€ù©{ËÆ§RÅ>-:±gœí é¸-YÙª,H´*vàíìåş¼ù	‹ÑŞÂ–­ôTÖŒÃÌÎTw`OèB…Otlk•°äG-•ë%OiÁD°CJÇ¦'²:6¶&EkFÇ–Vzæ”OEán¿¥c7û3¿“šÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö™}fŸÙgö›°/‚}¸ötÔ v¡2¶Ğ/"…¯è°!L1‘òD¢İ"“¢EÀÒ´$‘	ÏJÜŒ=ÜG»0§£&¡.[ìa^´`M‡M]"S‘(´9TÑ’JZR‘ÙÓ²%“¸û‡èŒ”š„Ÿ_ş­££Ã†D?Gÿ“}ÄG:l^lõê¿É[:l¶l‹–BKÖÛÿ.ÿ*B–|¤_ü&ŠıSÅ‹(¢£&á÷/‹Å2ZĞa³%bq¼Æ²Z®ÔïåvE‡Í–ÕVıY~»±å‹ŒZ²ÙşùË/bƒáÙrV³û’”Ã1btx’oph¡NYšfÃj¹İ(µ©²ÿİ×_£hYo6RbK‡MÂUÑRcÿ: S´¨/_Ä·=(ÙÑr±ˆ8*şIZşZX­W¾A!ïÂ?{Tc_‘ì›oäfs89ÈWß~‹â—K;û·ÔÂ*·	É-òŸ„Ø`xöL¢üı"úWVgÏH‹	_°/":j°SË»åûú|?,éy7XÑÑ)–~‘8´ìœEş^P¬GÅñ"2¯-šcpv­P>[›ıx7;{T²¯éÈÏÎ¾”!Z¾…‚…ı?TØdNìC³zG–ØYôo,Š8*-B+û¢Å“	75Ïã(9
öP¡p4G!Û‚ğï*ıµ$óÚ¢%†fõ,±G/?°è…£Ò"Q>Á¢Å¾Á±¥Éh2ÅÓ–ì;:2µ|ITæ(d×bş‰*Z¤Â ì©>Š vıƒqlQYÑ’ÔØ]È®œI=Ô\ÿ¨eª]Á(¼¶ätPÖÆ=ÔÅõD&×GÂß¹éï¥ì¨¢åeÏôQ$ÕuúEÓãã8×ùeK\c/9´æ…W|¨±Gú'ıE+½KTÉ.qæÈ?2Dœ8jóéïõ.”Z}B Âxm9J~lÁƒ²Ó¥Oìˆxùt•–?—-«6û–ñ‚}ÕbÿE{&Q°‡öı½hùö	uøØwŸò‚ğGû¡Ü4¤?[¾”-»6û7/ØU‹ıW­4±G%;ã8³ë¼d8µP¯Ñ__Ùé;+¿˜ØnÁé{D<³Ë²EµØóo
v4Ù¿+Ø3òyVnıñÌ®KvjÙÈ3{D>_ÜG}BIøE+4Ø÷HnÂ^Íq¨±Ÿó{ vÑa#Ç…rAuİ‰ığÄ
Å6ßÈMí‘Ø/EBÃ¦Ê^øv#¿³ÎñO1àŠºÍ­àdE±d‰6ëyÁq=Ñ
åÃl7UmÀ±¶ù€íFÉÓ|¯®ã@_#Q«mÖ(êylp«švñ½o~ %BıÖ° Ã&;/×qvú£úg¹¥£3Ç·
eËVıYn6h—u(ZB‰ÊŸÑr‹şòñEáFk,¢k®Ò—¤%{ÎöQN‡vÆ£bı¾¦Ã{JkîûWß~‹²æ-Öïÿ¬Ğ’-Šõ{ P¹MÀQ¶d´~ÿ‹Äàì¯khÏvÑš{0ú{Ë¾Í¡¥ÆşêKûD¦¢æ¿¯-åÎÑ×êsbdÆKK&p»=«]¤Ì„ßíB8ˆİ²_—í™H¸‘}Ÿˆ”§Â„§0³-)Ç­ØŸyŸvfŸÙgö™}fŸÙgö™}fŸÙgö7dÿÿŒ#9:
endstream
endobj
6 0 obj
<</FL 1/OP false/SM 0.01/Type/ExtGState>>
endobj
71 0 obj
<</BaseFont/DTWGIJ+Symbol/Encoding 70 0 R/FirstChar 32/FontDescriptor 56 0 R/LastChar 202/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 549 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 250]>>
endobj
70 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 179/greaterequal 202/space]/Type/Encoding>>
endobj
124 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
125 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
126 0 obj
<</OP false/OPM 0/op false>>
endobj
127 0 obj
<</A 128 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
128 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
117 0 obj
[129 0 R]
endobj
118 0 obj
<</Length 7512>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01199 Tc 0.01199 Tw 10.5 0 0 10.5 60 730.8196 Tm
(new user cohorts, and \(5\) entry of tibolone as a treatment)Tj
-0.00999 Tc 0.00999 Tw 0 -1.24286 TD
(in parallel with the drop in estrogen-containing products,)Tj
-0.02499 Tc 0.013 Tw T*
[(primarily as an option for new users of hor)-25 (mone therapy)65 (.)]TJ
-0.0231 Tc 1 -1.23809 Td
(C)Tj
-0.02299 Tc 0.02299 Tw [(urrent guidelines stress that while HR)60 (T may be appro-)]TJ
-0.00999 Tc 0.00999 Tw -1 -1.2381 Td
(priate for short periods of time and at the lowest possible)Tj
-0.00101 Tc 0.00101 Tw 0 -1.2381 TD
(dose for the relief of symptoms, it should not be used in)Tj
0 Tc 0.058 Tw 0 -1.23809 TD
(women with a history of cardiovascular disease, breast)Tj
-0.02499 Tc 0.02299 Tw T*
[(cancer)40 (, uterine cancer)40 (, or venous thromboembolic events.)]TJ
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 288.1499 643.0197 Tm
(26)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.02299 Tw 10.5 0 0 10.5 60 626.7197 Tm
(Increases in the proportion of women in our population)Tj
-0.02499 Tc 0.007 Tw 0 -1.2381 TD
(who started therapy with a vaginal preparation, particularly)Tj
0 Tc 0.034 Tw 0 -1.23809 TD
(among older women, may reflect increased attention to)Tj
-0.015 Tc 0.015 Tw 0 -1.2381 TD
[(symptom relief, in concert with greater concer)-25 (n about the)]TJ
-0.01801 Tc 0.01801 Tw T*
[(long-ter)-25 (m ef)20 (fects of systemic hor)-25 (mone therapy)65 (. T)70 (otal pur-)]TJ
-0.006 Tc 0.006 Tw 0 -1.23809 TD
[(chases of oral and transder)-25 (mal HR)60 (T dropped, while pur-)]TJ
-0.00101 Tc 0.00101 Tw 0 -1.2381 TD
(chases of vaginal preparations appear to have continued)Tj
-0.022 Tc 0.022 Tw 0 -1.23809 TD
(according to previously established trends. In addition, the)Tj
-0.02499 Tc 0 Tw T*
(number of new users and the percentage of new users start-)Tj
-0.009 Tc 0.009 Tw T*
(ing therapy with an oral drug declined. While use of oral)Tj
0 Tc 0.02699 Tw 0 -1.2381 TD
[(HR)60 (T among current users appears to decline with time,)]TJ
0.054 Tw 0 -1.23809 TD
(there was an especially pronounced drop among estab-)Tj
-0.02499 Tc 0.009 Tw T*
(lished users after 2002, indicating a tendency toward short-)Tj
0.013 Tw 0 -1.2381 TD
(er duration of therapy with systemic agents.)Tj
-0.00301 Tc 0.00301 Tw 1 -1.23809 Td
(Even prior to 2002, HR)Tj
-0.0029 Tc 9.30462 0 Td
(T)Tj
-0.00301 Tc 0.85805 0 Td
(utilization in our population)Tj
-0.022 Tc 0.022 Tw -11.16267 -1.2381 Td
(appeared to be considerably lower than estimates from the)Tj
-0.017 Tc 0.017 Tw T*
(US. Our estimate of a baseline prevalence of estrogen use)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(of 20% \(2001\) is consistent with that of a 1998 telephone)Tj
-0.02299 Tc 0.02299 Tw 24.57143 30.9619 Td
[(survey of Israeli women aged 45)-25 (\32074 years, which estimat-)]TJ
-0.017 Tc 0.01601 Tw T*
[(ed that 17% were current HR)60 (T users.)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 468.311 721.1196 Tm
(9)Tj
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.01601 Tw 10.5 0 0 10.5 473.837 717.8197 Tm
[(Despite dif)20 (ferences)]TJ
-0.007 Tc 0.007 Tw -14.84162 -1.2381 Td
(in baseline utilization between the 2 populations, the ob-)Tj
-0.013 Tc 0.013 Tw 0 -1.2381 TD
(served drop in utilization following the publication of the)Tj
-0.019 Tc 0.019 Tw 0 -1.23809 TD
(WHI findings correlates well with findings from US stud-)Tj
0.01801 Tw 0 -1.2381 TD
[(ies. An analysis of US phar)-25 (macy purchasing data estimat-)]TJ
-0.004 Tc 0.004 Tw T*
[(ed that approximately 42% of women aged 50)-110 (\32074 years)]TJ
-0.005 Tc 0.005 Tw 0 -1.23809 TD
[(were using HR)60 (T in 2001 and noted a precipitous drop in)]TJ
-0.01199 Tc 0.01199 Tw 0 -1.2381 TD
(purchases by 2003.)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 396.8231 630.1197 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.01199 Tc 0.01199 Tw 10.5 0 0 10.5 402.3787 626.8197 Tm
[(In that study)65 (, data were not linked to)]TJ
-0.022 Tc 0.022 Tw -8.03607 -1.2381 Td
(the identity of the purchaser; therefore, longitudinal analy-)Tj
-0.02299 Tc 0 -1.23809 TD
(sis of purchasing behavior of individuals was not possible.)Tj
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
(Data from the National Ambulatory Medical Care Survey)Tj
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
(and the National Hospital Ambulatory Care Survey also)Tj
-0.02499 Tc 0.024 Tw 0 -1.2381 TD
(demonstrated a substantial decrease in the number of visits)Tj
0 Tc 0.157 Tw T*
[(of women with HR)60 (T prescriptions between 2001 and)]TJ
-0.021 Tc 0 Tw 0 -1.23809 TD
(2003)Tj
ET
BT
/T1_1 1 Tf
-0.019 Tc 6 0 0 6 338.1274 539.1197 Tm
(19)Tj
ET
BT
/T1_0 1 Tf
-0.0209 Tc 10.5 0 0 10.5 343.8781 535.8197 Tm
(;)Tj
-0.021 Tc 0.021 Tw 0.50706 0 Td
(again, these studies were not designed to allow for)Tj
-0.02499 Tc 0.013 Tw -2.97164 -1.2381 Td
(person-level longitudinal analysis. )Tj
0.019 Tw 1 -1.23809 Td
[(In a study of HR)60 (T use among women aged 50)-110 (\32074 years)]TJ
0 Tc 0.093 Tw -1 -1.23809 Td
[(presenting for mammography)65 (, the self-reported rate of)]TJ
0 Tw 0 -1.2381 TD
(HR)Tj
-0.00011 Tc 1.32886 0 Td
(T)Tj
0 Tc 0.086 Tw 0.9468 0 Td
(use dropped 18% per quarter following the WHI)Tj
-0.02499 Tc 0.011 Tw -2.27566 -1.2381 Td
(publication in 2002.)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 397.2628 474.1197 Tm
(25)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 10.5 0 0 10.5 404.3788 470.8197 Tm
[(T)70 (ype of therapy was not addressed in)]TJ
0 Tc 0.03799 Tw -8.22655 -1.23809 Td
[(this report. Analysis of data from a lar)20.9 (ge US phar)-25 (macy)]TJ
-0.02499 Tc 0.02499 Tw T*
(benefits management company also documented increased)Tj
-0.021 Tc 0.021 Tw T*
(discontinuation of therapy following the WHI publication,)Tj
0 -1.23809 TD
[(although switching to other for)-25 (ms of therapy was not con-)]TJ
-0.00999 Tc 0 Tw T*
(sidered.)Tj
ET
BT
/T1_1 1 Tf
-0.007 Tc 6 0 0 6 350.1498 409.1197 Tm
(27)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.009 Tw 10.5 0 0 10.5 358.6618 405.8197 Tm
(In contrast to our findings and to the American)Tj
ET
0 0 0 0 k
173 745 379 10 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 251.5303 749.5293 Tm
[(Sustained Impact of the W)75 (omen\325)75 (s Health Initiative Findings on Hor)-25 (mone Replacement Therapy)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(255)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
59 42 492 18.963 re
f
0 0 0 1 K
0.5 w 
59 60.713 m
551 60.713 l
S
BT
0 0 0 1 k
/T1_5 1 Tf
-0.00101 Tc -0.02699 Tw 8.5 0 0 8.5 59 48.463 Tm
(Figure 3.)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 95.9782 48.463 Tm
(Administration method for new users aged 45 years and older of hormone r\eplacement therapy)Tj
-0.00121 Tc 41.48446 0.00001 Td
(,)Tj
-0.00101 Tc 0.52687 0 Td
(Maccabi Healthcare Services, 1999\3202007.)Tj
ET
0 0 0 0 k
59 65.288 492 298.033 re
f
q
59 65.288 492 298.033 re
W n
q
0 G
1 w 
/GS2 gs
-0.00002 TL /Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
17 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 57/Matrix[1 0 0 1 0 0]/Name/Fm4/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 0 8200 4943]/CropRect[0 0 8200 4943]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-3.tif)/ImageType[1 1]/Overprint false/Position[59 66.753 59 363.32101 550.97998 363.32101 550.97998 66.753]/Resolution[1200 1200]/Size[8200 4943]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm5 16 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
491.98004 0 0 296.5679 59 66.7531 cm
/Fm5 Do
Q

endstream
endobj
16 0 obj
<</BBox[-0.11992 -0.22509 1.12403 2.44547]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm5/OPI<</2.0<</CropRect[0 0 8200 4943]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-3.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[8200 4943]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im3 15 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im3 Do
Q

endstream
endobj
15 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1236/ImageMask true/Length 6185/Subtype/Image/Type/XObject/Width 2050>>stream
X…íİ]oã8šĞG£Aq/ó6bÿ_ºAŞŸ’Â^ìİB‹½Ñ`Œ2Lîºş@cG.µ*˜ºœ?ĞÀ2ÈEßU³Ğ«Æâ¾¶óiKIª’ªÃ‡3Š^úM,ñX")zº‘—w²€   @ €   @ € Q„Ö8íÓ‘$ai¼nÕR*‘Ş“º(ò\K… qÔU1eJ*‘x—×ºPTz1€s¦R'©E¤ ‰s:n€Æi¯ÚxÒè¬» ˜;Ä€#D ìÕ(0F„  OÖó€1â‰Ğf&8F„ #ø¬–g‹HrT—OƒcD¡®‹27R‰ ÀÔ›¥î¤‚1¢5Áó%±1b|„¶Ê¥ñ\•1@ €   @ €   @ €   @ €   @ €   @ €   @ €   @ €   @ €   @ €   @ €   ğdŠR<7@+A¬ enô‰QL$  @ € ²€   @ € c€   @ €   @ € Ï@{ãt«–ˆÀø© À¬ÎKm¤'@º(ò\K%N ŸÕ£LI%V —WºP‘¸5ÀI´ ‰ ˜J¤‘„Æi¯Úˆ>¹È~wHƒ‡½ğu Áã! ûÙ	Nİ *ÄP>Â(°÷ ì9ÀÃg‚{ _<Â³À^Ôğ4¸× íJÀ©Ä	0wSoZı°¡}˜:óğ%±}x”UaHûƒ@ €   @ €   @ €   @ €   @ € ØW€u+—àYHKnke ì	@ € û
 ätN5 [A€2àíñ‡ÅG	¢ĞÇ|”€   @ €   @   @™€ €   @€w²€   @ € c` n9Ÿˆ úO• q œ~ò‘x@€   @ €   @ €   %  @ €   @€€à×­Z7l<5€õ;‹¯à¦Ş´ª“
Æ@| õ¬,µ‘Ê“h—³WS‹¯
Py®¥ò4êYñ•|V2e-€Ë*7€®ÔIjA€8Bã´WmÄ ÎÅ >¹¸ğ»» ˜{ B€Ú] DzLœ©b ¯ô‰²ˆ ˆ Ş<H%N€ÆÇı4˜4~V—…É¥ëLpµ"¤Ÿì’X[Ï¾ö³€q«‰ ¢íŸöª0ÚzF X€   @ €   @ €  À< @ €   @ €   @ € ‹€   @ €   @ € eN @€   ŞÉF €   @ Œ€ ì	@ €   @ €   @ H† Ÿ Ã`* S  @ € ›ƒDĞ£ßZD}lA €   @ àÛ¤ÎxİªuÃÆ@Œ ÓÖ,u'•8”“#”ÆH%N íê¢Ès-•X|V2e)@æ\^éBYÄ`*}¢,"(œÓ•:I-"˜€Wm¼ Uì ş@Äà® æˆ i"ï“ÆË03@hW¡‰²ˆ Ëëˆg‚IXn¤éŠüinÖ–3SJ%V€iÜKbpÆ­fBˆ€Ëâ  @ €  À @  ĞÉ   @ €   @ € ÷0AŠÃU1á"uKérC€çğÛï¿/âøîÔ·í¢ğí@ €   @ .R @ä ó°µT€ì#øÇ¯¿üæ/À¯rR§ñüB àÔ   @ €   @ €  ºÜàØ‚   @ <} ¤´\H=xÄ°"8œÍÊ2“ Z€zVæ™  @ € Lğ  @ À·G  @ €   L @  @ àÔ   @ € x óÆxİª¥T"pSo–ª“
Æ@| Î×³²ÔF*qX_Ek©DÚ	zŸÕ£LYDàòJÊ"^ Sée)@â@¤‘L§½jã˜[7 >¹È~w‘Ô.z€‹Q`î&«‰ĞfPqÔQÏëÍ³€TâhÚ¸Ÿ“S?«ËÂäR‰ó
n÷’XhŒ[Mm'Èeq€   @ ` € èdO €   /€’`Ó^Ä	ğÂ˜·o– ^ y›Ÿ$  @ €  €d°”€ ‡õ¬$@&@ €   $<@ € ğíp ¤XHér#€	RHérC€c€   @ € ˆ`ÎŸ” \œÅA™ïÀ<œ§	 	RZ	pPæ ÀD€   ŞÉF €    Œ½˜)²‡& °ø(Ás˜‡óVàŒ Şw€   @ `@ Èš  Àâ£  @ €   Z	pPæ ÀD€   ŞajµS>m¥‚1À¼1^·j)Œø ‚›¶f©;©`Äà¼¡ÌT0âh|]y®¥‚1á(à}V2eŒ\^éBY c J SéeŒ(t¥NR`Ä	àU/@â\Ü iã5€²î²¬€ø 4dÜ "ŸPëLY c >€ªb’gJ*ñxDş4ØbÖæ3]Jc :€$´S÷’˜7n5B´Cü^€   @  _$@'{À€ øI€   @ H† K	pXÏJd€   @ @2Áƒ   @ ß   @ € 0 !x€   @€S€   @ À„óV¢Ë-@ €   @€y  Ğ€  @[Ï@ €   @ `@€ {àŒ Şw€   @ `@ Èš  Àâ£  @ €  À €‚vÊ§­T0âĞÖxİª¥T0â˜Úik–º“
Æ@Œ r„<×RÁˆ`në"j€`]^ëLY c >€ÿ€JÊñ¤Ö™J(`D	 +u’Z c N ¯ZX càë ´D°.xú`ÄyT€àg'˜U_{&øÄo¬EP“¯ı0ô”Ôêq¸ÌµT0â˜úo° ò”æ­ñ½Kb#É‚ˆ7Nû´Å5€õ›ŒL¼ËâëÒ<êL0‰à)w‚  v :Ùcd·ä·ÃˆøğØ/€è;A€ û°b$›ó½`)ÊüYÍ$>¯î ü*Á.@VæÏÀP²õ „‹¦œ¬Ë²ÌŸÕ³@°ø
 ûÔ	Z|” #Ù¾@+~xb ç©o°.¿?w€NLêYù¼d‘éX—¶•= à/¸*|q¬bjñ( @QæoXJ0Ğx|É(ğè à Ì êzV |÷¹ ›Û-7= Ò€¶S‹'pK°”àQ<r ÊüA¡[ Ö©û€/xô+ +ó»nné¾l¸àÑû€ûÀÿ„óÓ¿hJl ²¡ÁUS0`!m;ûj ì12ß¤\§ºÜèc9Ñ÷Öåì«u‚ìñÙëK	>ô¸ phğh e¾‡ áâ²¿1B=‹yÀÕ-à°àp Á½äİtü1 ÃÀU'Ø /uÖ°.ı —à4\Ğ¿“m ,ğ¸ ò&²Å
PÊK8”íD$xş²‘uªËÍ@'xõ0´›:ë°ì-ÎDJ	nèd‘Ñ6
x<l´èK}ñ0XJp'ÀSšXü #ïÀN  @èŒ “=FFÿÁOƒG‡=–p@ Ùööhp+ÀCoè;A€ œad4D8úIN„öï¸e"tPæwDß	€ œ #£ŸÌ×ã= DÎ8ğ>X\¶’"óğH·@ô @ N„02š"œı$ÁîÇ|XÏÊ€bŸıep"”O„’.7Ïª­gÅÔâş_ZN„,8
Ë2' Jy‰ OèiğQ;AÙsADs"Ä/F}'H €!ŒŒvèdN„¢ˆ¾$ b=FF÷H€º•= <ıUá¢Ìù½ ‡ÁR~7x ;A€ ¡3š"ßè›!t¹ùV"Y™s@€R‚=¸nøŠ_Fß	€ \FF?Ç‘¬Ìù8Ìy@)¯€[ Ø	€ Ñ\yÒ"_ñi°“=¸ b€ZŸıXDØ	F ÿ[~Äkù5ÀúÇ@¬ ™²ˆúqx¢,€1ë08I-€1íp ÂEÑ-€ø:AÀbpõ›1úøg\%/ŸÔlV–™¼´›ú¿O¾m+\.Ê¯ÇgWÅ„ëÇzëÑĞÎÊ©E?À§!€·r¬òJ@iô;y©`¢+öÆ<`¢+Í@±XİCeŒÁÒàRç—f_ù“le}Õ~vêÃ©İ©ğ@ùƒÅâR’íóSÿ$Ûç§p7@®åÇsø¸@wò#f€«%±HÒV~ÄpçX÷=¾ •{ğ=¾¤Xì/À?ßø²b±¿ x€½.   @ €   @ €   @ Ä ´0Û%‘W‘:Ì$Hõ½›ÃÚn¾„îM%;ejåİ^É7xØM!õ’2;eın«SJ¥Áã.€ŒK—˜7Ø9ßs«<‚Ä©Lâ­bÚ¤Ã´ÑK‰·›rj%Ş*¡Qíê@C©i'ñÍ’˜¦ÿÜÏS*\ël}%—óRÁa»hyµ1Ë$X¤PH¼İÊ¥|îL'qJï¦’àôê@‰ÃPjzÕ”Ë!Ø¹—Ï¢çÜÏSi¸@]hõÚ{ìdôkç²,}Ó` ÕP—êØúªÔo•v“ÊGo}`Îgyºh‡¡ÔDâíáMSU#8àqÀ+øÒ¤WK|³”jÑø"W¯ì¦^¯R}İƒÏuÚ8AµLI¼ÕÊ¦.FêµK†Rv[™:_ç*m<R€Ç] œW.\!ñÍR¤‹¦ªµJRÒÕì7Òé{WL”ÅN*_§
9¯íVÚz¢U?€­ëUªÂn÷•œº"Sošİ/O$U(›8ÜÀ(OM!•›å0]¬®á0J–ï ÈÁ›bœZl—f“ê±I1©•†—q¢/¥ú pºjå;Æ@Ê^}'[OI»Äé,9³™T¶q¤••î@òa•’¸çsY·= «Ô™¤vp zSoá=zÊi“é	RMÚà®+à?@/@º°“Jà°›ú°J¥ÿ%a/@6ÉİVVÃ •zßJÔ×ÊÉ0À$m”Å r·|9 
	wZ™­k‡¾ZHK¸3x¬T‡ŞÔ¨‚Ãî§·˜Z¤eq/€¤@}Àd}^ØM¯Rèù#ä›V^;ôv*—p·•é¨J‡A€K`İÊäCh°û	m ´„wÎÖ M!qO+ıêàH!“p •Úb(ÕI¸3G¨R9PáĞ3°VJRíLÂíV¾orøäĞ—º?€ÉÓ^ ­6©¾ËÅğu¾I%K	w[™Ê&C ¾° ñØı„k #á Ş˜ôÌÍ$ŞÖ«A€Mª`¶(%HM%Ü™ïU©¨rèK­Ï!—xûcx½è¹;ô›5Àµ?z'[?@;Õê´ (‡Úa€ó”¶ ğŸ`’5€­%ŞN¥k€BÂ»†‚
.,%ŞşÀ¤•›ƒ÷¦|oúM+—¤”ÅÎÖT©È9ô¥Öç0’xûcHÖ HÜ—º/À¯ipóŸ%ŞşÀd60
´kdî|`›½•¸?Õ`l•şˆ^ I¼JfŸ°zk‡Lâ­AÆ¥v`8µìş”]Ï‡¾TrÖôÎ‘r¬ôïÎ£7õ#<Fo•*YÏú üç$2‰·pR[÷¨F­R=³zi
İ 7uÖ?KI+5>…NâµõL#‰·o)i¥L…{ Ö©Ï¸ö«—7ß
@k8ô¦jİ0=°J¡ ÅúY t÷§0’xû–Jä‰'ípI#©ë™w²ƒ«ÇáæÚ¯^´Ò¦Íêi0qHõ¼Â(9u…‘p7•'ï]Qï$«ÇNíñıFJÁ¹\*Û×aâÖOƒµTzS×3ïd»À]ûÕË+6müúY©>€túŞMJ	ûSõLYì|`(´zíà0:õ¹T¶?ie®Ş4»ç~²î°>v…‘‰Û =©FR} -Tj]UHØŸê[,J£ôu‡¾T.)ßs«eŸÄyô§4*ÜgMpu™{‡Vº¼H?Xô¤>Ij àØÖş•„½©ÊçFâó¼L} «”œCÓö\¢µ×yòÉc …
÷™øÕÊjƒ>+4¡1m$ŞIÙUªoì²+K¿ó`1ÒT¶q[-²pHaî±ÓÊà¦NÉ²¸COj¾JU¸Àæ{‹€¹ÕS½ I'‹ÿı Cß¨Ğ*Şï.RS‡VšF¾™7è³Y¥*Ü	À¯Æ@ €   @ €   @ €   @ €   @ €   @€{•CÙ†^{!Ûnip­$ÍĞ¯E ° *8\o,æ¡9Â @‚Åj/Û%@^6û
 ƒÇõÆ® *|.€{F UÒTøå7‹í[ i4\Ò<€#4›2‘í&ÀâÔbÀ*ø½H[ı¦=Ä%Àûnªİ¿Ú¥nµı·ïÎÜü…¼| ¼9}Ñj×à M–/^©Ôçtƒ½PKóayuÀ\ûyÓ™ÖÈÿõáoòòÀ›×ÿhç¿é¥ñ.Òîe°AÉyÓ`ï tgŞ\ÌC³|¥Ûùi;m§ni‚Ÿß X|hçgºÓ×VWÀûp,,ò'Ø;€Ñ(Çè:€¯1©N›I]U>/'éu€×{ør¡G7¸€yºxsœòIUaï FºÃ`•¶Õ©›LæŞeÙdúwyù
 i_.F£´mp Ãàâõ‡l”ÉŸ`ÿ Ôaº Û£—~¼8Ì²ùM µ\è€D ç{í éöè¨Îİ
 Ü øE/ÿº½0Ï@®Mòña…ÀÙu FÅüÍèEV7¸ğ!ùP@…=]8º 0ãÉÑàıßååK€î ›§£‡“Û «+ Â>½ ZF5Àâïòò%Àì 8ZÔ® Ö£@ö, ª upv€BµóÃÃZ^Ù»™`»Õ	–«Nğ_dVcüN'h½œŸ^è¶ÁÕÓ`)3ÁNÉ}p© Ü˜	®^.õ‰ñÍá!æ“—7 gg¶Pm8ûóíl¼ØK€" *çëŸ<ßšàg $®Â3¸G	qÌÄ0µˆàY~1B €    Àÿön?…
endstream
endobj
119 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
120 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
121 0 obj
<</OP false/OPM 0/op false>>
endobj
129 0 obj
<</A 130 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
130 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
112 0 obj
[131 0 R]
endobj
113 0 obj
<</Length 6734>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.03 Tc 0.005 Tw 10.5 0 0 10.5 60 730.8196 Tm
(45% in 2007. Most new users aged 55 years and older start-)Tj
-0.03011 Tc 0 -1.21429 TD
(ed)Tj
-0.03 Tc 0.013 Tw 1.11632 0 Td
(with a vaginal product \(62% in 1999, 82% in 2007\).)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0 Tw 8 0 0 8 70.5 690.0697 Tm
[(DISCONTINUA)74 (TION/SWITCHING)]TJ
ET
BT
/T1_0 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 70.5 669.0697 Tm
(Analysis of annual cohorts of new users of oral therapy)Tj
0 Tc 0.049 Tw -1 -1.2381 Td
(demonstrated marked variation in percent adherence to)Tj
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
(therapy with year of initiation of treatment. Oral estrogen)Tj
-0.01199 Tc 0.01199 Tw 0 -1.23809 TD
(users who initiated therapy in 2002 or later tended to dis-)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(continue therapy more quickly than those starting in earlier)Tj
-0.024 Tc 0.024 Tw 0 -1.23809 TD
(years. Of users initiating therapy in 1999, 47% had a dura-)Tj
-0.021 Tc 0.021 Tw T*
[(tion of therapy of longer than 1 year)40 (, and 33% longer than)]TJ
-0.0251 Tc T*
(2)Tj
-0.02499 Tc 0.02 Tw 0.71952 0 Td
(years. The corresponding figures for users initiating ther-)Tj
-0.008 Tc 0.008 Tw -0.71952 -1.23809 Td
(apy in 2005 were 34% and 29%, respectively \(Figure 4\).)Tj
-0.009 Tc 0.009 Tw T*
(Median duration of therapy for the 1999 cohort was esti-)Tj
0 -1.2381 TD
(mated at 319 days, compared with 178 days for the 2005)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(cohort \(p < 0.001; log-rank test\).)Tj
0 Tc 1 -1.2381 Td
(W)Tj
-0.0251 Tc 0.83877 0.00001 Td
(e)Tj
-0.02499 Tc 0.022 Tw 0.66586 0 Td
(defined switchers as women who purchased another)Tj
0.00999 Tw -2.50463 -1.2381 Td
[(f)-15 (o)-15 (r)-40 (m)-15 ( )-15 (o)-15 (f)-15 ( )-15 (e)-15 (s)-15 (t)-15 (r)-15 (o)-15 (g)-15 (e)-15 (n)-15 ( )-15 (t)-15 (h)-15 (e)-15 (r)-15 (a)-15 (p)-15 (y within 4 months of their last oral)]TJ
-0.015 Tc 0.09599 Tw T*
(estrogen purchase. According to this definition, 5.3% of)Tj
-0.02 Tc 0.005 Tw T*
(those discontinuing oral therapy switched to a transder)Tj
0 Tw 20.82577 0 Td
(mal)Tj
-0.03999 Tc 0.02499 Tw -20.82577 -1.2381 Td
(preparation, 2.2% to tibolone, and 1.1% to a vaginal product.)Tj
-0.035 Tc 0.02 Tw T*
[(Proportion switching to vaginal or transder)-25 (mal estrogen was)]TJ
-0.03999 Tc 0.02499 Tw T*
[(highest in 2002 and 2003 \(T)70 (able 1\). W)80 (omen who had recent-)]TJ
-0.03799 Tc 0.02299 Tw 0 -1.2381 TD
(ly discontinued oral therapy accounted for 19% of new users)Tj
-0.02699 Tc 0.01199 Tw 0 -1.23809 TD
(of tibolone in 2003, the first year the product became avail)Tj
0 Tc 21.95289 0 Td
(-)Tj
-0.03999 Tc 0.013 Tw -21.95289 -1.2381 Td
(able. By 2007, this figure had dropped to 12%. )Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0 Tw 10.5 0 0 10.5 318 730.348 Tm
(Discussion)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.099 Tw 10.5 0 0 10.5 328.5 709.298 Tm
(Changes in drug utilization guidelines can lead to a)Tj
-0.01939 Tc -1 -1.24286 Td
(n)Tj
-0.019 Tc 0.019 Tw (umber of responses in the community: cessation of treat-)Tj
-0.02499 Tc 0.008 Tw 0 -1.24286 TD
[(ment by current users, a drop in the proportion of the tar)20 (get)]TJ
-0.005 Tc 0.004 Tw T*
(population commencing use, and preference of users for)Tj
-0.00999 Tc 0.00999 Tw T*
(products perceived as posing less hazard. Several studies)Tj
-0.006 Tc 0.006 Tw T*
(have documented the substantial drop in prescribing and)Tj
-0.02299 Tc 0.02299 Tw T*
[(promotion of HR)60 (T in response to the new infor)-25 (mation and)]TJ
-0.02499 Tc 0.013 Tw T*
(changes in prescribing guidelines.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 452.3335 621.248 Tm
(7,8,18,19,25)Tj
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 328.5 604.898 Tm
[(W)80 (e analyzed utilization of HR)60 (T products in our HMO)]TJ
-0.024 Tc 0.024 Tw -1 -1.24286 Td
(population. Our ability to link purchasing data on the basis)Tj
-0.005 Tc 0.005 Tw T*
(of a unique member identification number allowed us to)Tj
-0.021 Tc 0.021 Tw T*
(follow trends among users, thereby characterizing \(1\) new)Tj
-0.022 Tc 0.022 Tw T*
[(users, \(2\) changes in the for)-25 (mulation used to initiate thera-)]TJ
0 Tc 0.035 Tw T*
[(py)65 (, \(3\) switching to alter)-25 (nate modes of therapy)65 (, and \(4\))]TJ
-0.02499 Tc 0.01801 Tw 0 -1.24285 TD
[(changes in duration of therapy)65 (. Follow-up through Decem-)]TJ
-0.00301 Tc 0.00301 Tw 0 -1.24286 TD
[(ber 2007 allowed us to deter)-25 (mine whether the change in)]TJ
-0.013 Tc 0.013 Tw T*
[(patter)-25 (ns of utilization seen immediately after the publica-)]TJ
0 Tc 0.13699 Tw T*
(tion of the WHI findings was sustained. Our analysis)Tj
-0.02299 Tc 0.02299 Tw 0 -1.24285 TD
(demonstrated the following phenomena temporally related)Tj
-0.01801 Tc 0.01801 Tw 0 -1.24286 TD
(to the publication of the WHI findings in 2002: \(1\) a 22%)Tj
-0.00999 Tc 0.00999 Tw 0 -1.24285 TD
(drop in total HR)Tj
-0.0097 Tc 6.34133 0 Td
(T)Tj
-0.00999 Tc 0.85122 0 Td
(purchases between 2002 and 2003, \(2\))Tj
-0.015 Tc 0.01401 Tw -7.19256 -1.24286 Td
(an initial drop and subsequent stabilization of the number)Tj
-0.02499 Tc 0.02499 Tw T*
(of new users, \(3\) a major shift from oral to vaginal therapy)Tj
0 Tc 0.088 Tw T*
(among new users, but not among current users of oral)Tj
0.011 Tw 0 -1.24286 TD
(medication, \(4\) reduced duration of oral therapy among)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(254)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
0 0 0 0 k
60.343 38.713 492 21.777 re
f
0 0 0 1 K
0.5 w 
60.343 60.2399 m
552.343 60.2399 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.01401 Tw 8.5 0 0 8.5 60.3427 47.9901 Tm
(Figure 2.)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 97.6215 47.9901 Tm
(Rate of hormone replacement therapy use by age group, Maccabi Healthcare\ Services, 1998\3202007.)Tj
ET
0 0 0 0 k
60.343 64.13 492 287.332 re
f
q
60.343 64.13 492 287.332 re
W n
q
0 G
1 w 
/GS2 gs
/Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
13 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 62/Matrix[1 0 0 1 0 0]/Name/Fm2/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 44.758 8200 4798]/CropRect[0 45 8200 4798]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-2.tif)/ImageType[1 1]/Overprint false/Position[60.343 66.279 60.343 351.46201 552.323 351.46201 552.323 66.279]/Resolution[1200 1200]/Size[8200 4798]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm3 12 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
491.98004 0 0 285.28839 60.343 66.2796 cm
/Fm3 Do
Q

endstream
endobj
12 0 obj
<</BBox[-0.12265 -0.23232 1.1213 2.54381]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm3/OPI<</2.0<</CropRect[0 44.758 8200 4798]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-2.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[8200 4798]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im2 11 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im2 Do
Q

endstream
endobj
11 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1189/ImageMask true/Length 13696/Subtype/Image/Type/XObject/Width 2050>>stream
X…íİÏã8'ğ¯ZR
Áºmb¬~„<°^«¥ö²1‡õ`!â·©Xì¼ÈÃD [—êf˜ÈC›‰:´ãÑo¿”íK–Ãò…Åß$)ÙVĞÔÇIQİÓxL˜@    €  @ 4€* C˜àn¶0À‡€Q¢† ‡ 0`€ñÀ’B@ “
 )0T€Ty Ub° óNğ;¦a¨9Àï˜†	@%ÚaÀ ?¨ä³Å€îÒøÙbÀ Y‰Á€ÒÅŠĞ`¸&˜s3\€e ¦  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €   D,Z"Ñ€CKä  h€  @ ¸~€oNéûØ¦p‰ûm‘˜I.ÃøÍ¥z–Ø,*”yˆ]ö8ã6@‘š™²yÌm™T 6Ï‡`ªÖ.tP—ÀL5:ÁhP Š<€Ã`‡Aõ8l ë{‡D.5¾t&Àï9ìi(‡aŒâBi(‡apÜg>ØUáØdàÌOÿˆáüÀ9?7Ã¸OÜˆ›7ãéjÊÄaÀ J—±ÁLl‹œé*".|L¹İÚO0]-À·ÛbÌt 7~åï"NFE¢1X€ÈdQÁm—øÓÕÄ6CÁm—¸x'°@.3æë¿¼ˆ…¿pónñÀôJæë¿¼ˆÔÄ¥Üt‹œéÚ wÃÍPbN˜‡Èâ€ïï |ä…÷¦cp8ÆøĞCø6Kv»m`z‡ b¦|À¹•§¾ ?ŞmåœéİˆˆKõlş¼_?pê;îï/  !@‘~.•ÍùèË”œú>Îü÷»h¼; %À´` -à£y½ÏöX¯@ï
%ìS« ±À-Ó»ø.š)‘’{›n†®|>Î’!p,¹{$€¦÷±ó+KÉı#¤Lïà1>àÂ	Sw€‘À€òØ}ÇÍQãÄš 8v¤ï ±ydqì¸az 8İçæÊb N÷× À`ÄÍ	â²½` `ê À)°™q{ ƒw À…;n‡
0âÒ—Æ© 4zÅ…âæ4qº’wÈufQP"Ì®ıq{•± Füi® ¤"~
œi‡«ˆ`ÑpÇeo\m¬ |¶¾¬Ü'îõ¨SDÂÔ€Gç°£LÜ-_œ.”F 8ÙqXPºŒ-N¬  À(SÆÃàSß{îö0èÉ%0c•E¿´˜ro}€õÃ *Ñ ÀUÇ„i¹æirà†i Ñ
@bP¬_Ü@cºŞ	r3 Œ×‡Aœ!”A Ò6 á ğìùï" } ˜òÆoÈ ‘ƒ™ùˆlq€D£ ±8±¸@?†ÁÁ@lÊ|À ëËâgà,¼— g‹ÄbØ Ê"´€ 0d€¾  €3El0l€Ë€© Ê!´€Ğ	 26Ààç ²6@l1l€Ä! ûp}À ?€ 0t€ÈaØ — S? 
f¡¹´6Àà‡Á  ,à0l€M S? ¢Á8 ƒ  à"Ã@ .3ö	`Æ,´€¾ÀG`ğÃ` ø€L™p‰‰@Ÿ .2
 L}ü%:ÁÁÏÀàî™ÀJ¦ 0d€Sè†0øa0 à–iĞ Lƒ(™@ }ÀpşÈ4h€¾Íb¦¶øS[üˆöõnw
h´Æ˜©-Z#6x§ Ê 5r¦¶_º`ÖÊbÿú\ µhÑhı¥gÌÚ ºÆÚKä­¿´´E"ÌZ"ÛĞ2Ş@{Íc±hı¥…YÀ†–Ñ€Ü¢ ’öš'âĞé†–!%³Î„&k} ŞPs%ó–_º aŞ-FLg¨ŸÎ
@"âOiê[¿ãü9Šæ«r‘ùø&^)Ñş4Eœòl¾ÀQõçÎ™|C£ÇÃ`£¡¯ (± O'ó;‘ckñ™”<oUÂ7¹(ãOSÄ¥|S| *‰ÿ†Á»pˆøqîbø“É¥ôç­¡ø¦x€ÔøÓä	gj	¾XôÀİs§€g nO€|	P..…v ²÷ÜÙ¥d2Û à/%5€‡Å5Ñ12¦³Œ¹³©tÕóš\ÄV3İªHybÒÚØ´¥˜õt"ğfğ5×ÀŸ %àÏà¹—€ç[ÿ„gù;?˜øÖñûjÔ³Àª?çÎş1è1€»çÎn!‹ö‰FëDH6üAO DZ3„•–a°ËT8ß e:?Àêy®díS;Ö–Q2k!ŠCŸç›,ÚÛ4Ó·Ã©‹w	 v¹eñÃDkË°©E¯6 hgI,ÑèŠé¼ o¬\"R¦Ad½¹:jÄÃà´yà =ízpÃt^ à©7 çŸœ	 ¶è-À˜éä ã;¦A(«°è2h\eà»‡>œi|ãáé€ : œ àÎy jÔêtØ1ÎP2ßÚSH§Ãp¾Ûáù:ù€¸>î°5¸BUrs• i½»@§^ğü ™Å™ ĞO€Üá\ i/Î6`_ûª œo&Èøˆtˆó¸{îÀ¹s>€)Ó fL`È}@É4èQ ömC(˜zpÎ™ ğ½@/çÈ†p¾õ€—»b¦7j½Ò5 Öí`Ë5m:öTç°8h®pä©0Îo»Î|/€s¤R2+FLg¨ÿç àã?æoEÆt­÷]zAäL×	³!ÄÂlÈ ['ÃÓ¹ –?Ê¹Æ¹ z¯ I9Ÿ¢@ıKô›ÅYR¦M¡Îp£¾8œ`„L£ vşeÉ“q8#@†Ü`3€ÅÙ \jQèéY´Xô L.ğ(}¸"É.ğôÖ=a¢q>€yEÔ§S$mc€ªÏÀ.w;ü·YÁ=¨¤øéØÃ]Á¬¥•KÉ|cXœà×Ù”{ /™µ­
óËbg˜T iÉİóÜüf"›ï—
fgW 'hñ†M7Àœ@æ}À4>€ÁÎc…ª3ŒÅàø£ À,vî#‡3ğuàïdO DZaú1r‘ÚÕ1±q8@*âĞzi”Ì{ À€Òñ‡ °‡ÖÇÀ%óÍqÏt€È PU—ê‘”ø(¸×yx\ÆÓy 5Õ‡®%kç)Ë°h}@¤ñF”Lg0U}˜1k¶şy8´Î„X8=2À«ÂÑ†ªe«ïó¬kÁ·šñ}fÑ‹>`W€¸j*o6é×ßş6ğûÌá3õ ‹öNÍ`1îµ„C×ÛÄ³ƒ»(qh°¨6­Qò£fA3fo|ÓY&BSf» ¤R0oéÄ)i„©.‡_Ä‡F³)•ÌŞøóL…ï™íµğD×‚o{˜GîŠ8ìöˆğL ÑÎ ¹Ì˜¿ŞÕo‡•¾–5·H4Ş\7Æy ÆÜÙ`q=§òf¼œO\É²AÔ úĞ6d­÷6[cÆãÖoŠk*ó¶apùNğ€Ü¢¥§Û­ífı"hù‚ÕyÓE¢F}ç?â¶ĞØ4\ÈŞœr\ ®7eV{ÔO°åÆPcõrrxsÊiqÑQ ™wvû7OÿEÀ óÀÄáÂ Â¼÷¶…A5px3rit‰Á[q.€Õ*­¨ªÁJ×®¹Å›Á#ê‘Æå°Z£@Ê_–©sSß
àI³è€ÃF€ÖÉm&ó6 ƒ-¡dãúP[‹18@æĞ@cş¾Cû%®±-2©_—tà;ËÎÑ¢ıä˜m‹\^2¦-ÑŞÔP «W²Fkû.™mmÖ²50ÏßŒ¹Ôåê;S[ŸÕé÷JeÑÄâğ ©Ì×‡’}éÙ~T›æâpôXŞ(¯Ğ —Z¼=<‰€K; L™NPn(™Ÿ Ri,›âÎ1ÎZN÷ø6•õ±¥=FL'¨uFµõ€ó“O¾@Ætú›¡ ÈN+ [¼ qr€_gSîµd§ŠT =8epˆ© 
î€]O§Àt¹>à´Ñ	à<+B—È»t‚g à/áp	€¬Ë0¸mÙğ ¹8ô@œ ‰Å% Òn 'ˆ.`Ğ€Më'%bÑ‡>àR œ
9ô¢œ1»  §Bµo¾Ü0x! ¿µoŞ—z4v†^€ÙÖ†²:M»2€Mëëõƒ® ê2`Ì‹  Ë8xÕ ¹ÃÖN.r¸ÚK İ­Ü8ù‚w.–üşÚ×·Å™® )y3m­äÕˆæ%È7ãé” _î\ÀƒÑÖÉÀÓ	ğß.Pƒ['L§¸Ôİàrôƒğã`nñvŒ™® Áá²·Ã—ğ÷ƒ)[Á–ÁBãZüı b+ØÒN®ÀT³¡Áø! n‡à:Ì„® c¸@i\-@ÊP¶ŒLW¸,>ÿqK¶ƒmapËâóûÁ. ‘Åu®¡š¤Ûr¸V C¬4.¶0ê,.€Ü¡C;q¸^€.?î5¤3f—í-.	àÇÁËŞG—ğã`‡˜2
 àör ].”w9v{@zÍ Û×D+¦’Ù•t¯¹¤µ¯ß÷L'¸Ü“¡îãàÓ‰ .»Ğyüé:ü8l½R˜®Àƒ‰ÁÖµ3üåÂ}€•Åå şCfÜ¹ @^ ›u8]pq ƒú€¦Sõ—Ä†K±8À¥G®÷ƒJÄá*:Ş*‡«èv?%âp ¹Ã°²ÚLl€ im  ÇÁa$¢1h€nã ùÆÍ5t•H§–²;@~á©pÇqP‰t‚Ú@.ĞiTB€;î\Ûªğ|Œ-º <pç
Ôe,.ÀûÁ¤ö+lb‡+ˆ:¸kà8˜”Ül˜Ä.Åä.n¶ü‘ Gp¸8@Vğ*@—©pì2ÍÍµ¤³íÓa%âX[“=¸¶aªDn°­§Ín®€Hs‹­%š)+ˆÅdİâ÷Q¡Ì\ ÇÁ´û•]¤ö›ã\øáhàÔŒ›nñ'eº¼ ë~Ü>Zé3M`òHgÛgB+}¦.‹ã-ˆÜ3»0€*·Ï„Vã>±ßss¤‘{fà8¸+€¯ú‘:Á1w.‹Î5v³9óëˆÄfÜì fóÈáz  ;ßææqmø~ï yñ=óFÎ¸PÜ°û÷Î˜íßÇEjPİ%pÏKğ~pç~ãª a¶c¸ÔO‰Õá ,åâ ±küùš ¶¯µ]7œu( úp7ØñéÚï	Òƒr‡ äµŸ¡kÌ”ÍÈ,z í0M Ğ‡õ ì3.î	®`ŸqĞÿ™¹€}ÆÁyçq% {ƒUçqø(Ğ‡y€•Æ>w‡ÏúïùØS‰ü?nŞûL¼LöØ¯ÿì€*/Ğ‹©0”ì}	`Ñ€X~b>`€}ÇA%RF 8ô`¯ûÁÅŠĞşë£“şƒÈ†íwêP€¾ƒHKfûÜE‰w~ªĞG %ÌöŒŸ+õ ı¯¦÷>
ì;`Ñ€}ÇÁ9@äğîr‡½c´ç@Ğ§K`ßqp1“¾€´ÖŸ@úq7¨2f¾7Àów=rT{!ûÍ…zË/Ì…4Ş9@$u8 Õxç zw´kª±ÀËßC.Õ‹]"‡C ²Ë¤R2ß7nö	'LËyª¿¿$€a~Ö©À
€ÀáÂ şÖçÈ-ª.øò ñAO¹9Å| ÿ×¿ÂáÂ Ña p©ÆşSáäò |ÔípP/ª±ÿ< ¹|'ÈqĞáü Å@,..Zãş {,ˆÜs§p ¾cºà88c~Î¹ĞÄŒ¹ã"ò'%w/8øõşöÀtïÅù£ƒ~}<c¶?€ß¹hÀÛ!fµ ÆÎKb÷Ü¹ Å|ßa° yÉìø1ÕØ`ùp4é@:cvØTBcç©pÁÌ˜éåJfçœM^î `‹‹$Âìœs!ÌŸËˆÃ¥bÑ8p.µÛTÀ,;àâòSáÃ.ŠØ©Y]r¹Á¥æ÷#çˆ4ú²*üÚ!°ËíŒ(¹í@¶Óï·a.¤±ÛDˆÛŞ >î6N<€C Tıç8@oeÜ`9îÀÆAtŸ
x Ü3õàã çB3æ; ô©~?¸ÛT`âÁz¡Ü ë@z€„ùû¡Dãàè>š¬õ»—ˆEãàøSjĞ vàÒ ßcßÉà½püˆ³ôk"Äqğ[ÉüĞD™´–Ã'Ğ«Ó¤‰ÿÆ~d"/­E³¼3@¿f‚Åà#á»Pr„ÙğN ÉŒY ‡#Lº¨~ÄõîÓî µ7.ÀÖ~‘½G)c3‚Kp™|Œõ8²
ÿ´‰Ã•$v9¥ïc›¢HLõ"o°è@ÉÍq 2.‘š‡Øez¦l©‘u€’Û+pÙã,5óíf ëo©^n°Ú´4¢ GXyìë(pÙ¶Q  G`ŞeĞC€Õ* äö| ?¢W  À1®® ±µè@."(¹=À‡~dr”k 3@ı ¤Â°8Üq€C _ë\ùÔ¨Ó	c²v÷yy€XX§#\]—Å{0ï-Î÷ mtL'ˆzü,G¹!ê ‹ŞDìš-ÎĞ³{å V»0‡À^€ùy r‹şp$´8€Cÿ 8:;œièÛTøå!óó ôo0Ğ8À¬— éyæBÕDè;}˜qs ;æNÿ ~12€>Ë@Øg€+Cé¾ãÂÈÆşƒ~aD†€¬^³S Ÿ3Á3Mû{/p¦"ĞËÛáE°2À÷¸.@ÆqÀ`È &¯wĞƒpéÉ¯~ÌNô „ˆÃpRÑJJî€Ó „ƒˆ9È‰Ç^øÛ´ìÄ7DÕ³Á1³>ğìı=±Á`Rñ7DƒHD¡äŞ —Äæ€†’“.Œ@õvEˆK'HØs€ìäc=˜w§¼*€¾®	caŒ I½üŞ ¯7Ñ£À¢ß J„ù	z;~½†Àk ÖKÿ¹@¯G18<İ8P=š1ë-ÀCõĞ`ˆÏ— §¼&Gøí½˜Fûƒ¦N JJæï À¡}eÇ 5FL[ã‰“A‹ÓÄÄßb5 h”ô‰EkdL[ãé„×À„Õ¶8À†Z*‹v íñG¦.
L
0cvl€*N7 ŞàĞ¹F×S]Gí’’YK¤*¿Ã¯z²k`r€l€ÅM€Ù‰ 6fÂ0•ètñJ
öãY‘VC£”FlıÉ. ¹¸”eõ€=U;`¶ğÍ^ « âGøÒÊ¬ä¶Ï ¹ÌÕ˜']._r_Xw%€Ô qş·j]ÂVùqÛg Öğ€Eæ²€¯ºŒ®ş°êxS 4bo€ªŠm—@.eªç?au	ğ»8Ú¡SÁÕ=qµ} ‘]é]µ“¢µ:u)ØP²S§¹@ÎÚ	À¡½sÔhÛE¸épmy§Å ÷Ì0»(ÙğÁZïZ2ó}JÁÍ):Á{î»ª†;LäSÙğÁúüÂ PÒ±Áì0æÎ 6=ÅãÕop€ª.~%Rm{
ÀÖÉk€y+€Å†‰£A§–/WÉ)Î Ş ĞèÔ½ÎæÅlø‚‹$¦Ø6=Àxã`Ş©œ-.p elì6%óN7Ãş@%‹™TÿFM+>G‹d6oH‹©Ôu$İÖÚØSÍ~İp@j°=¦ó© IåØéÌöàõÍNğÄ ‹»MM„#÷ƒÕ½À! y{w
€\×Ãq2‡½Ø3iœ	 õ—j&Çí'kUØ	€ç(€Òèz¤o©UğG8`= ³†’£~§øñöPrü™I·¥Gnø\à;û T}òŒ;gˆÈáub)âĞ€\s¦4vyğšÉ'Õ³Á=ª`qx¤n7WágÜ`ÌV€˜©-şÀ4(¹= [@uÃµ{"¿ Ñh[¦9 7gˆ?¼}	(M5(¸9B`°=‡Õ~pÆSw‚›j–3éæ]Ôio}m^¿®°8Àß_n ¤› b»xbs¾HKf+ıàÊËSİgí÷eüÕÎ¿våÖPêõŞ`şàe7 }	€| “ã4É›wƒ™Ã¦§•GP³­Óƒ£ßT  òöj Ö
7XÔoDkoì°ùn_1Ÿwó0¥ç}¯·‘Áqïñ¶>‡£ğÌ¶Àû`=ÿÊ
ÀÇpØPpsä~pÂ´€nñ%ù*€NÄáøwùÌ·Ô›Ér0µ8€’“lzzÔ8_‡Æ£%ï–98Æ oŞÖ”8;ª¯ÙvHó˜L¼@óİİ§Âx ¨[éRÿÖÑg9%ómËcª
=7ß=Àæ§š‡˜o¼,¶.@–Ü¬]ş28 şsÖ4ÎÀ^¯GëÓä’›f¿p8ÀÆ©°Ú ­Uä·:¾lu²”²¦î5¯Rƒ+ Ø~$Î¯‹eÜ«_"§H7Øæ§ Ø^jláÏ˜©Ñ5Ê¶¿| ü6æoM4ækÍ)Ô!m`òÖÓa¶JægêıålÑa¼T­Â™Ìg'Ø`ãLğì÷ûj¬„ÛFÊn “;f= Pâ°ÇÅ¢dÜß=<@~Ïì%.wı³Zß¤d3¾Ø9ª>àÙK\ ÑmTÄa Æ²@$cîô@9t;NÄá%ü|UI%_î“>D‚§ìğ=ªF±ßXĞ+€Î‘‰Ã
@9GÙ«'œ¼K€DP`óŞ/“½úŞXtê,¢·Uä‹Ka60î¹Ó€È¡ë‘3fU¤ó­ìÑNzàï÷vx}‹§¿rˆFG€yQöÓì÷iÔ"••± Û³ÛW€ÈÍÉz ğ'´‡ÆjLyõW5ÿ©¥$bÑúÕ­ ,&`±›“ıéÂ}À´f°ò·O€ÒX",û%íÓ(f5€ÜÁÿ©‹¿Z\`ùÛv›'å"¾á¬„ÌÃBIÁ—ë‘ŠÆk¼>U.şlÑ€Z}ØaÀ,ë¿%‹~ •_®Gæÿ¦°€q‰vè€ïŞÚ"qX°üÍj!Ë(ùb=rÿ7/1ašÇ¨? %³N ™´¤² >&pè@ôŸÂ¼%ÔzËğ'ËÚûJŞŒ‚‡,£ "Ì["];ÑêzßÕb9+îZÌz àoosYŒæJ6-ù¤J„;k2İ2‡U€•iÅÅZ€f-«¡Ì?¶{x¹ª[ æí]£¥Î ùâõ@•¸<€‘% Ïùáå÷,ùiK#€êí KØ¾  —Ï²xÚá§­òÀ½î ® 3~ÉJ'xñK€gdYË–K@|uÛ.ÔF¶GaŞÒ¾š Å=·=ŞàşZpú¿¸Ÿköƒ%ó6ZsÛ'€LÚGs»şşŒ?ëêI-gÌÛÆ‡€q[h‡~ ¬ŸÍü¢697ëº @É½ƒ>[ô oğ£ÃC[%	wš}Ãz1÷Í§*Õ%qËpñ³EüÓc?oÓhoÙ8„;M ‡f”Í‡
˜€<ã»ƒ> ,*Ô€õe0¾c|»æNóx‹ ÓœÌ¿/å`¢Ño ´ (íÿë—ŒA@£Ãœ¼|_Rú+ä=$şÃr±¦ÕpU°`}èjj\©Fì°·Í¥±õÁóV õ{šH Şå»+‹¶	”Á6€õ @#úPõ×3æ;´şÑ;¨7Ú×µÈb- Z,iá¶µuØkà\FZÎ”5OÚ/ùót‹kàxĞ~xƒÖ‘Õ¡=Ş%€¿¥ÑhhƒQ"×À_´ıL	Ğrğ]q¸*€TZÏÔ_-oó`±¸* /PrÓi™É†æ=´.´Ï‘xè†ƒß3 O«dŞr½³k˜p[o %·W€œ?õˆÛ&Œ«–Q ×àïì2næ·Ãu&Æ˜i>f:4n‹¯àåL•FÛÛË†‹hl¼'˜0]Àß3Õ#¥9€Fm¨œ1»*€TcíºV– øàPï&¯`T}fĞ2öÏªEÑÚÉ.§Ì®àûj$³h{.–ˆİ  q- óe Ì¢}öçZr1¸.€Ü¡€İ}+€Å5èê^G¤¬&‘©Æ½Å[1ÍD4`OËùñúªğûPK 2ˆ-–¯«&ğC.Âw]õ®ö¯?xß ‹»İ%@âü.cVığqQµü¸à] Ïh.Ïp€ÃUp¤­¸l#€ÅõÄÕVK@©ü½¨ Vú€Äú®`Æ=¾2@&ÕP*ÅÕÒï–@¤›÷¦wÀ%Oæm3>6€Ö÷™]€’Ú­Ş0o9¾dve ­ë£%ó–sEwƒËb üpm ; DÃ¸6õ0¸.€Ã" 0€  @    €  @  €) €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    ô@Š 0p ‹N ¹Ì˜¯E$âĞ‰T¯E&Â|=¤½øMÅ(ÖâKæmÅ;l ğ @É|-b‡öZ´h´:nph/Ş {-Y|um '8}0è^K ƒ–HE˜o«ájñWĞZL£†«Å ßp¢>`SÍÓöb5< @˜ïPÔ	@XHVB‰Ù.ç/Ra˜Hò_ğ‡71_Hák¾räòÃHDòú‘ó2Ö¿È}™ó#}™¾˜êÈå.Ëd¼–¹üv%Ëbjõä‡ù ¬O&Vù,#‹wIdÆÈı‡N‰¯¶¯yãH›ú#«bò•#Y¦Îd^Ìë‘n^æ¼WYÎ´jYLíÈyÕ¼Ëë‘éJ™r‡. ,…ÁÜäâR™±
¯ JJÖT‹ØLœª>ô5ÏW¬>,”T5_=r^¦¯ù¢²Ë#}™Oó#Ó•#/^Š)^¾İd2/æõH0ÿp#@Õ	|Çôv°TÆ¿’ee2Sós”ê+S~şÈs)R)ùâ©:Òe+Gº¼:’ñz¤Zé‹Qõ#—Å4\”Éø¼zäcu$£TÕ‘fõÛ?Ë ÓN J5¯Ìóš¿Vá y$_ğÃ:ÀüÏøa “B5 ­ê¥Lß÷4ŠY 4Œ«6ŒUrûVÄNÉÕ^HJnßŠ¬P²èu&VmìSqêNĞ%rÎN°:r['è¶]ü
%ç«Ew˜ì:4h/Æà8ó ÜmR™©Í }ší<4ÓN ü‰Jî]!À—­"‰Éøçr­ [g‚±¸LÜ»¹ØÀàm€Ô˜ë½Şº*œ‹SÆÏ—ÖÿÌ×ĞÂ¡­†:²h‰1–™¶«F£uG‡¶âya¢%î1b¾^¼­&¼{øQòG|Ï|½hh‰ÿ-ñÁÿEK1¦½øïü_´Ä÷íÅğ`şÅÖZN˜ºø•Å5¯
¿ø	¶Ápøóç«WÏà „·ƒÈü]®üÉĞ Qu¯áT«Ü .$XÀ¯¤àúŸo Zº¾@ èÀö]ëĞ	€÷óÌ‡ ü™+¿œÌCH}ßï¯Ìøb  lÿ°.€âó$‡ápo¸ .½Ú@7€B`Æ!$ÃàfØ  1l€’y    € 0L (!Ü"Ö2À" 0€  @    €  @  €) €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €  @    €~dp6À}1p 7:ÀxØ ‘<€5h€Q 4@\|Ç4h ¥1h %ƒ
3á‰×û€„©-î˜ÚÂ¢5"ƒÖ8Rñ›ŠÙôş-S[´ lêşÈÔZvzS»©ø?£5b¦]ŞßXü„Y·yÀØ©†Ø¹xÊ¯Ím<p 7:Àtà y1p€Ìbà Ãx³ˆ°S{ğ¦ ‹ À @    €  @    €  @     @™¨@ÆF<ğÌ¸S®VœXÔ£ôÜ©G²8¸ä~í}Çâù~³øtQ—?¡¥ør‡ú“£EñÜ_+&Õ™pÀ˜K“Ä .¤6.¹[{´lcÖC+‡zMD§ş“D£;?84jÈoß_+ŞUÅcÊıfñQ	)øbµør^ÑX/&3¹ht È’H,j¹XL^$Íš‹S¬‡á	ÔQ1™ãÁJ£~¢eÄƒYŒF½!ù÷³Å7Û’/ŞÜHçÅ³ª¨Sló. ÷‘›¦*şâĞ Hm1VŸ4êo#}±ã1_¬şOv:U	”FıÚKãÏ<X}²¨k?›»±J4êÅÏ”Š¾Ø&@U|’h‹fñ_X<«Šz1÷JÁº×êL˜6ÄŒGO’'Ó4wêÑ“46¨µE{?ROÆİø¢^C7NiÔOT=}vÓ‘Š-ïz´Óµâ#;/Wp½øGç¨e,Í×<%u€‰İ _lˆf‘Oâg3å‹Õ¯tJs£´QóØĞû“)¦Š/Vâ&rn2ŠM®Q‹iòI»"Eõ÷Õ§GçF£Ø`­ø'S¬Dóâ-êq—|Ò¾GuG<ó”&|± Åv4ÖS¾X½ºœÂ7§FÍ¢µĞë <x4ŠhÔâƒ¯¡K¿‡E->&Ÿ4ncƒõâÍ”½{£øJë³EKñ…Râ#ÃƒŸM'€d›Ñ]ü³òEà/VİFõ¸'<˜Ÿ6â›MÖÒ…?Ø¢ñ½?0ˆšÅÇ,£çzñ£ø‹ÅzñS§n¸Wş¦Ïæ=üöp úÙ4¾òÜM ‹ÆeWi9ÅİfÇ‘ù«FãD?ÁY¬X…Ø ­øV€Ûè«Ckñ#î­è1¦Üİ€qìC£y€_šp·vü7{C ¥±^CÛ ~ÂG«´ Ü©‚»Íâo£¯bÑŒ„»õáay€—b&LÇ¸s	wë547H4Z D€F ÑV¼šr·Yü& ›ÜŠF€§D ‡ ì1ÆëİwäØ	ÚtY4úïi\hÔ/¥ÏÀ6ß†R@lĞh£•/JîÖ‹¿óÅš ñ_üWÛ|_%¾øôÉ¢1Ìòªî`'“Ä4çRxt.Å)ò4nH>·ŒT°ÖÔ's€¦;Š;_ümóDçÅµ÷Ü¯õÕ Š
 rèà&Éó‡æLğÑ¹,-ïOã6 µ`2P;­9@&rw¾øñÚ/=/M€É ÙN£€E—{÷ªgSp¿1vE¾6‡í´ }l¸Ÿ¤Ü­O@ç Mßx0r¿¥ø×qmé¸ phãbƒN7C¥’ŸMã+ıÍË$iv;ÊL[;Á,jˆŠ9À÷ëïßà£]PæÎÿ±Q›ªøÛÈ6¢b ‡úc«N06èt;\&ÿù³^ˆäcú×¸´¨ÿº}|ˆlÛ(ó@?Î¸__U ‘Åzñú®hï‹¿åÁ·ÜoÏaÇjŒº `„ªËl  ¡ ‹úOÖ‰PTDvÔX_CÜ¯ÕĞ*¸€Eñ"ÜoÜ±Œn£5€Eñk O~' ~)·M ‡De¢Ö©pìXÃIlÆO‘èÂ©Ø¡ùK+ø©pdÑ,>® 4ÖŠ÷#Ò˜/ÅORpX+†Sá×.vÂ´y0¾ÖwÜ¯w‚ü‰F7‘E½ó"À']L÷k?EäüÍP¢Ñ8ÑDóD‹ÆûH´sÕº^¼™f%÷k]/|ñ~n³^¼¿r¨w½¨n†Nó€ñ$ùÙL¹¿6àí°A½©W5,¦Š/VÜd›D£Ñ¤ÍÛaeĞ\¤Lı^d±Vü“)Ğ¨Í¢øgÓ ¨ŠŸ¦ªQ
Œ’çÎ n:IÖD<€åGlPo‹œÚÄÆİøbµ-jT"‰F£-ÆŸ-D4š?Qòh§“´1
D¾ø'ãš Uñ*y¶÷|QsŒcñÍb’GË!¢#€_±qX›˜âN%¶8RÑ;óE½†Ó©JĞ8÷ˆ?óà”»Í÷ŸÍÉÅ+}±- Ói’<Ù‚/jÅTuY_óSpëîwèÅ)®-Z¬Ít¾¶jËÌ¼¶(šrÒñàD£¾<+~=“£¾jÉeØjSc­xˆiğïç‹¢ëÅ¯/Š²˜jQ4á~—‰iYü²xfã’ûµåÙ™?X+‡F­ˆhÑ)gTkï#u±p¿Qs_ü:€K}]r‹€öÅGk¥_]7Šû[~`WêŸ/hÔÃTFšx$EäZŒ(±ÕÁ¿ã~­—ßßYÕôåûìÚ¢÷Å·=á„T¬×’Å´>‘™0‚ßqw+@x4 @    €  @    €  @    €  @    €  .oÅŸñ1ÓõDo„sxDãx ‘Æ">$ó\Ã v€ˆã÷LUä&µğnø!>`y ÄçÅë;¯…2U‘ÍªoõoYl˜ïñ >¢jN‹˜¥¥?];¬F,âÀH™æ V|Å(ƒZÜ01î™ª'1ÌKøÃ_ïğ[ƒ’¤%7› ’³@lóEA‰Æ1 æ¥Åu óúN@ãÀùVµPL¾¦ùO¢	0‹æßTU]ÄÂo- e¶8>²XT˜- ›; šqâ°|Î«ñòN Ó˜ç*:¶œÔ ^[¦—rı±cûãë Êb£	³ ™h,”rçx IÉl æÕPoX8ğï2ƒ:€Æ*@bbÆİ› ·fr18€f€Z–ºà¿Ô ô@¦á?ÿ7fUÉ:6`L“‚yàÆaã	³ "§Hçeß¼”úFój¼V®ğ?V”~yçux€?şß™Í»„Ø X~Å+À­Ã"î'ÌŞ °XüÃ‘²yÙ£q,	Ôx4¯ÆÈ¡à/6-“")xD1ïñ~3hø	â2›™%€SwÌ ÓDË¨$Ï„eióy6w¹•!Ø¡rÃØ°à"‰Â‰…ŸíKÁœ ¬
ûk¤ó.nìPë+Dßl6S3Uğ•+ßê?—…?şS$.·¹á%`áFwÌë ã©âwÆ%26Æ"åÉXÈ¯f*« Ä/¸çpoï	à²™Ë/ÑWyâßï D¾ˆÌ|¿u{«~JŸnÆ)ßà0xçğÓØ¤"¢Ç<{?FşJ¿¬´U şj\á $–ªMİŞqS]t.©¾˜ wé(ùôI.+p7NRŸlüåoæÛ[à¥’ó(£gë>ÚÜÁ“QšêäI~ıùÙaO€Tä[™Û‘RÉã³ÆíX• Ooêğ³ÄfÂ{ ¬›N'jäèÜJ>?¬´Õ€äéù³›:øßX¯dR(‘¯ÂwïÆ£‘zúY.áÃ8M~"€ù»ıÍº/•\DôhCğãt|3QZ=şíéçÇg‹=2‘ß*€ÜÜ±&	¾ŒÇH3q‘s¯sÎ>„'VÖ}¼'£ê*ù»È/ŸŸ Àãg{W@ıd’_¤ŒÍøoÏR‘_E<ÀíŠ~Öˆ¬¯òmÿä§ÿd¿š/•\"ëœkL€q¢Uô·ç_¢¯û|[ Œ3<~µ@eâ"ç^Ô ²ÅÇ»±J5àğO"¿Ä¿>´ ¨äùñ³Î xJõ Óu€éäöFÅ?D#`<Šÿ9²±ş§o_sx©ä ¶ÎEÖâ(Æ7w‰¾ÁoÏ?=~5ØÀ-.L”JäKIZ$ÿ*ß¬ÃÚ%@ )¦ÓL|ÄvB‹Ú äùù³™&@D€D¼ãÛ/—À¯"š3àÑˆÑ,CAÍ*€DO¿}çĞ¼xÕÀXŒ‘c5øù'ùj°àò9@.ê&[â#4€¿X‡–> ^ªÀ xˆ,¬´ë _E4¤^Ò%Àİ·gq/•lÜ`e"ä5K|5Y¯DøG)™¯Í=Î-Ïd|œˆ|u¼¬şğ6ú*‘AdUdaı„Aa0²*-nüg‰†Âôvq	LÿÇ“†Cs"¶ÎÅRÀMÇjìÜ_bƒƒ 4*€Ÿæ y øÀã€±°ˆ¬â%`ß P5€Ÿ"?8l ˜½¨È•
±Á!7CÂ°É¿#ÑşßÃ•_q+w¯5€IáO|Ì#ÌPOæåöeÜfÎc~3‘CdÕÓÿ- €¬üo(…Da:&€‹üÉÂ¡y/?ZçÃ`¢´z´e¢cƒ â’ğoHŒ¯Íø6­¾m ~Š<î£ÏÎ~¾cbƒFÇÂwø
àÓ'Œ‘«	`’ÿ…
@án‚»À—EÍ»ÁøÙ:ÇªÚ)\1Viª“'S&&68x= ²ñ/e,ÏŒÓ²šÁ¡@a”;U¦ÅbA$æ|Ô  Lñbr—›X8i¯j´›ä_f±|*‘"›ñß(ş$–%g¾¿CsA$ö `ÅA üTX?°Ö à# Éséª©°†Ã€BIêSá¨D¬Ñ
ğ<‘BL\&R]m ñ¿”±ü<cûÈŠjx¢¼˜¹sX¹¬Jf L[äÅİMu3Ä¦x(À2ş]töX,—˜š‹¢>¾ãâÖL~EÊW~RÒìTfÌÿE¬r,ç‹7jšUü« ª••„8“\yM-V¿Ü¡º%aš¯¸Œ7Îø™ÆQ F±F§p·Ìºt¯ÚakŒ<¹íZ•ku3ëğè°@iô N±¼Æ·°bÑá[™õ@•Ì:­!9tĞØĞQó I×ªd›ŠÆvö‚Y? Âãñ  ®	àÿäé&Q
endstream
endobj
114 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
115 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
116 0 obj
<</OP false/OPM 0/op false>>
endobj
131 0 obj
<</A 132 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
132 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
107 0 obj
[133 0 R]
endobj
108 0 obj
<</Length 7237>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 60 730.348 Tm
(Results )Tj
ET
BT
/T1_0 1 Tf
0.011 Tw 8 0 0 8 70.5 709.348 Tm
(ANNUAL PURCHASING)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.08701 Tw 10.5 0 0 10.5 70.5 688.148 Tm
(Purchases of oral estrogen replacement preparations)Tj
0.03 Tw -1 -1.25714 Td
(among women aged 45 years and older peaked in 2001)Tj
0.097 Tw 0 -1.25714 TD
(and dropped steadily from 2002 onward. Purchases of)Tj
-0.015 Tc 0.015 Tw T*
[(transder)-25 (mal estrogen lagged substantially behind those of)]TJ
0 Tc 0.04201 Tw T*
(oral estrogen in all years, peaked in 2002, and dropped)Tj
-0.02499 Tc 0.02299 Tw T*
[(thereafter)55 (. V)110 (aginal estrogen products accounted for a rising)]TJ
0 Tc 0.03 Tw T*
(percentage of estrogen purchases\321from 5% in 1999 to)Tj
-0.02299 Tc 0.02299 Tw T*
(18% in 2007. Likewise, tibolone accounted for an increas-)Tj
0 Tc 0.10201 Tw T*
(ing percentage of oral drugs purchased\321from 12% in)Tj
0.011 Tw T*
(2003, when it was first introduced in this population, to)Tj
-0.0166 Tc T*
(29%)Tj
-0.017 Tc 0.017 Tw 2.033 0 Td
(in 2007 \(Figure 1\). In 2001, 20% of women aged 45)Tj
0 Tc 0.007 Tw -2.033 -1.25714 Td
[(years and older had made at least one purchase of HR)60 (T)75 (.)]TJ
-0.00101 Tc 0.00101 Tw T*
(This figure dropped by 29% to 14% in 2003 \(p < 0.001;)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 60 516.5481 Tm
(c)Tj
ET
BT
/T1_3 1 Tf
6 0 0 6 65.6288 519.8481 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 0.013 Tw 10.5 0 0 10.5 68.5523 516.5481 Tm
(\), and further to 10% in 2007 \(Figure 2\). The most dra-)Tj
0 Tc 0.082 Tw -0.81451 -1.25714 Td
[(matic changes in utilization patter)-25 (ns occurred between)]TJ
-0.02499 Tc 0.013 Tw 0 -1.25715 TD
(2001 and 2003.)Tj
0 Tc 0.116 Tw 1 -1.21905 Td
(During the period from January 2001 to July 2002,)Tj
0.172 Tw -1 -1.21905 Td
(women aged 45 years and older made an average of)Tj
0.166 Tw 0 -1.21904 TD
[(14,793 purchases of oral HR)60 (T per month; this figure)]TJ
-0.007 Tc 0.007 Tw 0 -1.21905 TD
(dropped to 8982 for the period from August 2002 to De-)Tj
-0.01801 Tc 0.01801 Tw T*
(cember 2003. ARIMA analysis of monthly oral HR)Tj
-0.0184 Tc 19.83248 0 Td
(T)Tj
-0.01801 Tc 0 Tw 0.84252 0 Td
(pur)Tj
0 Tc 1.27796 0 Td
(-)Tj
-0.021 Tc 0.021 Tw -21.95297 -1.21905 Td
(chases from January 1998 through December 2007 identi-)Tj
-0.022 Tc T*
(fied significant seasonal and autoregression components \(t)Tj
-0.0233 Tc T*
(=)Tj
-0.02299 Tc 0.02299 Tw 0.79059 0 Td
(8.5 vs t = 28.9, respectively; p < 0.001\), as well as a sig)Tj
0 Tc 21.16238 0 Td
(-)Tj
0.01401 Tw -21.95297 -1.21906 Td
[(nificant ef)21.5 (fect of the period of purchase \(after vs before)]TJ
0.12801 Tw 24.57143 33.87133 Td
[(July 2002, t = \320)-25 (2.8; p = 0.007; model r)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 6 0 0 6 492.6687 733.897 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
0.12801 Tw 10.5 0 0 10.5 499.635 730.5969 Tm
(0.97\). Mean)Tj
0.07001 Tw -17.29857 -1.21905 Td
[(monthly purchases of vaginal HR)60 (T products rose from)]TJ
T*
(1)Tj
0.06 Tw 0.46485 -0.00001 Td
(197 for the period from January 2001 to July 2002 to)Tj
-0.02 Tc 0.02 Tw -0.46485 -1.21905 Td
(1287 for the period from August 2002 to December 2003.)Tj
-0.0096 Tc T*
(H)Tj
-0.00999 Tc 0.009 Tw [(owever)40 (, while ARIMA analysis of monthly purchasing)]TJ
0 Tc 0.095 Tw 0 -1.21906 TD
[(of vaginal products for the entire study period \(1998)-90 (\320)]TJ
-0.021 Tc 0.021 Tw 0 -1.21905 TD
(2007\) revealed seasonal and autoregression components \(t)Tj
-0.0069 Tc 0 -1.21904 TD
(=)Tj
-0.007 Tc 0.007 Tw 0.807 0 Td
(7.7 vs t = 17.6, respectively; p < 0.001\), period of pur-)Tj
-0.01401 Tc 0.01401 Tw -0.807 -1.21905 Td
[(chase had no ef)20 (fect on purchasing volume in the model \(t)]TJ
-0.0251 Tc 0 -1.21905 TD
(=)Tj
-0.02499 Tc 0.013 Tw 0.77639 0 Td
(0.821; p = 0.413, respectively\). )Tj
ET
BT
/T1_0 1 Tf
0.011 Tw 8 0 0 8 328.5 587.3969 Tm
(NEW ESTROGEN USERS)Tj
ET
BT
/T1_1 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 328.5 566.6469 Tm
(In 1999, a total of 9394 women were identified as new)Tj
-0.011 Tc 0.011 Tw -1 -1.21429 Td
(users of estrogen therapy \(excluding tibolone\). The num-)Tj
-0.005 Tc 0.005 Tw 0 -1.21428 TD
(ber of new users per year declined to 8266 in 2003, then)Tj
-0.02299 Tc 0.02299 Tw 0 -1.21429 TD
(rose to 10,352 in 2006. Although the number of new users)Tj
0 Tc 0.26199 Tw T*
(stabilized, the type of treatment used by new users)Tj
-0.009 Tc 0.009 Tw 0 -1.21428 TD
(changed markedly with time. Among new users in 1999,)Tj
0 Tc 0.065 Tw 0 -1.21429 TD
[(60% started with oral, 10% with transder)-25 (mal \(patch or)]TJ
-0.028 Tc 0.02299 Tw T*
[(g)-5 (e)-5 (l)-5 (\))-5 (,)-5 ( )-5 (a)-5 (n)-5 (d)-5 ( )-5 (3)-5 (0)-5 (%)-5 ( )-5 (w)-5 (i)-5 (t)-5 (h)-5 ( )-5 (v)-5 (a)-5 (g)-5 (inal preparations. By 2007, the pro-)]TJ
-0.011 Tc 0.006 Tw T*
(portions of new users starting with each of these delivery)Tj
-0.021 Tc 0.01601 Tw T*
[(methods were 24%, 8%, and 61%, respectively)65 (, represent-)]TJ
-0.02 Tc 0.015 Tw T*
(ing significant changes in use of oral and vaginal products)Tj
-0.026 Tc 0.021 Tw T*
(\(p < 0.001, )Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 364.166 426.3969 Tm
(c)Tj
ET
BT
/T1_3 1 Tf
6 0 0 6 369.6545 429.6969 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.0262 Tc 10.5 0 0 10.5 372.4979 426.3969 Tm
(,)Tj
-0.026 Tc 0.021 Tw 0.46869 0 Td
[(Pearson\325)55 (s r for trend\). Seven percent of new)]TJ
-0.005 Tc 0.026 Tw -5.65897 -1.21428 Td
(users in 2007 started treatment with tibolone \(Figure 3\).)Tj
-0.03 Tc 0.00999 Tw T*
(Choice of delivery method varied widely with age. In 1999,)Tj
-0.01801 Tc 0.01199 Tw T*
[(78% of new users aged 45)-25 (\32054 years began treatment with)]TJ
-0.02499 Tc 0.02 Tw T*
(oral medication; this figure dropped to 50% in 2003 and to)Tj
ET
0 0 0 0 k
173 745 379 10 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0.013 Tw 8 0 0 8 251.5303 749.5293 Tm
[(Sustained Impact of the W)75 (omen\325)75 (s Health Initiative Findings on Hor)-25 (mone Replacement Therapy)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(253)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60.351 38.316 492 21.7789 re
f
0 0 0 1 K
0.5 w 
60.351 59.845 m
552.351 59.845 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
0 Tc -0.01401 Tw 8.5 0 0 8.5 60.3506 47.5952 Tm
(Figure 1.)Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 97.6294 47.5952 Tm
[(Purchases of hormone replacement therapy by type among women aged 45 yea\rs and older)55 (, Maccabi Healthcare Services, 1998\3202007.)]TJ
ET
0 0 0 0 k
60.351 64.747 492 275.927 re
f
q
60.351 64.747 492 275.927 re
W n
q
0 G
1 w 
/GS2 gs
/Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_8 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
9 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 61/Matrix[1 0 0 1 0 0]/Name/Fm0/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 0 7554 4598.96484]/CropRect[0 0 7554 4599]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-1.tif)/ImageType[1 1]/Overprint false/Position[77.805 64.747 77.805 340.67401 530.91199 340.67401 530.91199 64.747]/Resolution[1200 1200]/Size[7554 4610]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm1 8 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
453.22159 0 0 275.9888 77.805 64.6852 cm
/Fm1 Do
Q

endstream
endobj
8 0 obj
<</BBox[-0.17167 -0.23438 1.17866 2.63531]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm1/OPI<</2.0<</CropRect[0 0 7554 4598.96484]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-1.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[7554 4610]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im1 7 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im1 Do
Q

endstream
endobj
7 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1150/ImageMask true/Length 18438/Subtype/Image/Type/XObject/Width 1888>>stream
X…ì½Mä8šnù(•å"®3—Ñh/cş„¸`Ú/ÚÊ˜óObĞÛÁK4p¯ååb €›Fù¶Wa–wÑ¸Å¿¸¾tlïâ¢’ 6ä"•(•Şû’ú0™¹ùW¸¹›™¤×ƒ”(Q2‘|ù¾/ë£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£ŒòxòœÓPäÓÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈÚÖï0Ö9†ÃZpkTp6Ö˜8k²ƒ¬‘‰sa¥•e¤±k’˜¤NYe±QVI»&ÂÈ\ñ_æ°QVE»&ÒL§io–5#‡]e¦H§îÈ¥›fÍ9ß-ù­Iáfnf§ıg<ëÄ>«Ã.²ò’£6ÍªÈb÷X3÷¬’võ×Ç`¤±{¬'dkVQğ…^Ûˆ©jXeÁzlû3«lX7êç”œÕb°;¬îqY#ƒb}[¢3†c‡a¸©ÿÛ4«F£¦‚¼ÂöY§éqºt³¬X°Ê‚3ş%‡-Kl§ÇŒš§›eUË¬qÎÙv}ºBæÊñŸÅfY%§Æ\äŒ‡rÁÙv}ºB5¬6ËzÀ©q4¼%UrÖËØZG#™³°ªª{ûÖhWŸŠ5«}d5kbÑ®´ağòP¶è)ë…Á`X?Z _sBV-6}g=àÄK8g~¾Zô“µš°Rƒ³Ê8T¤ÑgV¥Á“CeKhô”52àqkÁ¬}·5XY´ıÚgÖ°ÎäÒgˆ~î7kLµàñçŞ²
N$ö|QÁ²ÜŸ÷“UÃÿ_Á	"Z½d•æÈ/3Ä§ÈÃÔuè/ë±g-ùsø©kÑ_ÖëJµ‡óµğº‰3¼à±[ŞëFYƒFªÖœ)'ˆaà¸±%N8±åï¾²†…¦ğ++'fÍ…AŸY³Ò÷ë‹à½ƒu6ÖéIÏY'œ¸KO8V’[„Œ{Æª8ùáû-*EÜç5'ƒëÎ´^`2è/«ÔÀQèÓiÏmDÅ1ü
Ë©
QpÖ[İX#îNß¯%g=eõüĞ5‘C½«>G_Y……WI6v¨lQÎÇ~²&a©‰ü‰é)«àäÃ‡q®(œ
kÑsVixe•eÅZíê$œzÈª[LŠº¬;'‡œ6b49Àd¤c'‰®DYÉ³/­Vë7kDŠˆÈ†õ»)b™õ¸bİ¹ø¦Y"U¬¡Q‰7ôúba'#¿Û,ª*fœúÊªÁyÍzRÇbúÉ*		¯­5kV§şÍ×Ò³–Ò
ígì	úÉêõpğX¹Kc“øCoç«ßÆqHò YÙıloìõ;Å
r‘ón‡¬Yûº¾²òõş[D£÷¬ÊxVöéøÜÏ\jlsê¡ÿêYOølé‰Aã:rëôgh[oX¿æÔJÅš•œ!¶àîvèë§V¦œZVÆ9g½aUœ:ò¢eMø´à¬?¬^,=«JÎ*V
§}a%¿¶ä)çõŒ=<ö“5vŞœ"ô‰ÕÂOÎ¼à¼fEÄİÄ¬½aÈ¡bjV^i‡:\aĞÖ„rÎ¯à®D¬=kÌ¦¢Eåşô‹µàpEâ¼|¾Æ¦¢EÍªÑVÙhÚš!HÈğÖsßækË†mÅ* â¢ÿÊy/Y¥Á*ë¿pŞ³ùÚuå²°‘Sàî#ëWœ|g:?U-|ä~°ÆÕšs
ò
5kL€ø{eK4>¹wØ«MÂäŒúÂZÛˆÂƒ†5#9wüºê÷~°f«¬ŠL”W¬Q8î«FÅúAø?=«$ç’ˆO!¨ä¼/cX£f5 >{VÁv³HA¹'ºI£Š¢½3õööp3_!úÈšHÓ°²ŸÛGÖ0R›PÅò„Ú¼°œµöa [¢ŞÀëkàZ?¸ê¼Ş°~›'29ô†µˆ¿‚²-+ga=cU>xX;±AÒFi)ƒŞ°ÆkÁ‡kQ•ÙˆÒèkbP± ,Ö&p¡Ñ›5çÔzı¤jVi±Â*4z—ødÇAÃjQ«¬}bDÍêOƒnâTo¸£7¬M°k;)+8ë„úÕ¯Úû5¨í_ò§­ÉØ·ùjƒ¿
¿&"ºÔŸ	§½b8µrÄiqG×±oéY;û7ëŞí¿&9æ´l4‘yÉYö 5öœUX,¤’mÈ‰l¾ÊúÍŞ²J‡ÃÙrÈ‰\±:†gBc?YÛe3,.±F‹n+VA\'&Bëì‚Ä&rÒòŸÁ]Y³‚³vÇ 1hßæ*Ö„œïóf€gœ:¾Á¶$1UñîÌÚ „ÅÅBXÔò,ö¬¶à.µÀb}mYƒ-Š4±K½äweí,›^ë²"ò†G¾q|E£K‡J¦œv@K“¸ô˜QïÌºP9+¬&°Ê5¬‡œv€Ufº©K»mº…Õ`±ÂäÍü-äkA|Œ¤ÅŠÅ±İ1ü[“87s3;½++/›]ÖzZ&.¸âëŒ„ÁŠÅ±]ÖÈÌ´÷`]ÃÍü9Dç¿¢u×¶Ë:™[iÕ²JrMYxÖÄùWç‚Ó.°Ş“•WÎZVÛÌ_Uræãá±Áªœö“•¡¦|¬m‰†5#Î|<<±¸vïcË¬G-+Â;©n®vÂÇÚFlÆp8¼B'ÌÔYØ°¬é½YyFÖ}èmÿZ7ñÁT‘¥,çl™Uc7Xç-ëİıœˆ4ZŸÎixVû‚“ĞYÁÅõıl•Õåî~¬<c2hY+6Ï:ó¬†By=«ÅVY©t37»+/›	Y´»ËªÚS&2'Ì*×³^U[OÎz/‘7*î¢ÕEDúÜ¯ïƒ’º†Õa«¬(R¶ıïÁŠç¼¬æ|¬¯,ê5çsˆ7AI-k3‡]ÃüëÁÍIîÌ:©b,Í TP»µ'şJ|•5sØİ¤
Ì•Sö¾ú±ªbg«|§Q…+ù°ìÕÖGÎÙöE1«Á(ƒ»²¬°
©ÑYV¯²FMíı‹­•j1_#ÆTÈš¸…ÆŠ·Pr¾¯¬‚»R£Ó¯ âlÅãå|/YO«8a»%¼~ßyş™?Y
iì'ëq³ç¸{x‘…xÄağúÂæ¤ÃŠ™àcLs^ux2ç\X?†#‡½c9´ıú‚O<kX…Ã•Hçu¬|ÿX3‹ªËŞjµrš±K~ÂÄ‰ÅukNì°w¬SePuë[0kUš°åïû56XgûÉ¹`fº r«M8]{Íê¹ZVWùkÏ9]1ÎÚ}¼½aı†ò8?iÂeRiDûÎà†ìßš3	`Ïš”|Z™/c*xN\¿o°¬ÊÏ¹<Ê§Ä§!Dê×Ï¢Zµá´w¬YÅZ¼Xa-of9í+x$5{:#óVş^b?ä6ÖÈ/.pPš=Xƒ.« üv¢¬19ÔVSF+á©$“\Xf-øâõâ°/¬	1™ÊDÕZöÅgŠlry+k°6öƒUøÅÅeŞ`&‡°ÙØq$‚ÅEç®G¬’Âªê×ÓŒXT°û˜”È'¬¶SXı£êMWíY3bÉ[ sÜ ‘Ã®È!§›$°FF5kïWËà¡_#‹ÛÄa_XÃ|­ ‚ .û˜"yJ–£=’CN7IĞÃ+Û^&œ !‰ª~îkL.Eâü|+ÖúEDG|Ö#ÖË‚ûµ²õ¹ìå„S`§úÁÑîQë×W”\î²–@¦‘¼7èë;Bd@.D‰¬’¼ÖÊ¼ít“Ì±?cX’B|©‘“$(hÇ]YˆK‡›„kíK¿–’xÈÔr„©Ô@BnBhâÒá&)8í+rIU”©’ãª“AØ½J.öõ{¬E€àÔÎVÏV³É‹ıcuX'åœ?ã–²bÍÅ¥Û§c½Æ#aÖD#è)‹ª_ª@ç7Ë;Èœ­e¡‚C5_ƒLƒIûhKÔñßÛXSNÍ“{Ë*ÖGÁFƒác8T×4ZÏ€4ö‘U®k·¬‹~½Âj°¬Š®²š„C£AyÔ×ĞZåÍ!ñ]eÍÈbkëÊ-ÆµCËÊNÜ$SN;ÇJäp•U·®Ü‚µà¬ş>rº…õ˜Ó~°Š+†C²¸¢Ü­¬‹Ê»ÎºÒ1_‹c±8I‹ÊXÜ3Öµó•å%9€ĞË¬Â ‰ÆŞaE7Ë„U³FÖ[8w–Ugë]NU\YfíÌ×}#ŞÀªQMæzÂºšK~^²`µÄ³u}Å=c-8[ã}
İ°ÊÏäëHâlÏY™ëJ¸©ğ¦“ä³:vè»T‘ÆN*Ÿ{øt×°ğYÍJaq2èHÉiïXsÎVYùš4hW%ò]JKñUrìáµq	ÖÚ Ò«¬±¿tƒÌ8íëíÖ£RlWXÙçÃM’qÚ=Ö’Óò6XŞï`İ”¬²Š¥ÒŞ²ÆËûD³.ë&yëŒÓî±sZÈÑB3rªYsfUK£VQÎùé&O·L.ò¯ø$„„›1ì˜U®ÄÊ÷Í–à´<¢e!4¬<QÉñ¸%öUj´ZH‡eS•Ò ‘=Aƒ%=×²í¯È_Û_ÖD#&íÙ,»†U•ÂsÅ>ë«°¼lš0f=Úu"tiäp=¼¬6è¢.«È+ÛÊâëënê¦Îª•sw¹°v»1qŞÇ[‘Ûì&ÉiçX¿®[UÔ¬yÃjÑ`Yÿ!V[X§c…Òğ³±¨d•Sø1L|¥«!8]Yœö••÷4ü6³zİD|e!½`åæ^­(o|¸•¬È§}›¯u«¿Õ(™UQÅ:GGƒ\+_+œvõÛ¯9ë¥gäš˜‹N,X5öU:¬Çœ‚ä<kB‚¨ÄJÀ"Ñè«Çªly?_crHœ_sùlÿ»u=kµ]î¾Š«Øwæ³kUÓ³>÷>šºäDd2‡^²sâIFÎÓEd¥æ],Ü×õjø6œvõ(Ö 2ï·0+;nÊTİ8ãôåªIpÚ9V$@æ¹Ì"qÈb¾ò@é¸O;Ä*Œ)“æñË¬iTñ¦™AÒ`GYcúÈˆÕ²a|Ã^lú5¡ÏŒH±MJl‚Uhìè|ô+id‘„Ú•³è„5z ›,‚5\0M‚KÒ¨¼q‡°îâú9Ô¬õæ†"ƒ«›•¤±ÿ¬U$TQyPÚ¬	š‰‚³vÿÊ¢/¬’
Îë(¿C¥IKÎúÀúgVAá°ÌJœµ‘´öşş±N9kæ«k¬±`U9šøû÷’DcWXO8«äûÈyW->R·ó5k”Ôò¿ëšc°+¬ÄY3>£6ÄÙfPdPf‹kÉù½X-vDdg|V¬6±GÌÚÜŠˆ,úÁjĞeeƒ?v‰=æ1,ê.(«ÁÎ°Z,³²BNÌ	û3­=L:Awí-«Cİ}€0eÖ'İğaF_®‡wGdÛv¯|Y¾	İëYÛ°pVO\/Awí©(*8ï°Vb
‡æ{pÖÜìôñş²
‹…¼à„W¨YKÎéôñ³\#IS%hN{*òê®ä%¬9gÌ8íÄFÚğgĞÕM±Á<ä•fj.û9ê°	§{ş¶'‰QN:ÅÀÒú
îboV>oÅâ!?g±Åak2§ò,ÏÖ³NNğµ?ßĞ§µØ&ë<MÓ4O¹ğ2Xe@øó°*ƒ4º©ó¬‡¤±Äj¸[ˆÚßÜÖß2«›¹™zÖL£ËfÍ™õ%6¦
±=‰<«´5«2¨ä ]g”Û¡`ıÃY­´ªb•õ4æTŸ¹²
º79ÕTÁ‡°Î;¬œU¬ëlÂ}glÃ*¾PÍVÅùÂÖ4zË*ëùú,ø[Ö›dMLÃÚÆı•ş:ØõRW¾yb±©5Çb«¬Úµk§àªõ$58¾d6Éê°MV	7sË¬dQ±š7ŒÎ-úÁ:[ˆµ‡Z±húÕ³Æ-úÁ:eƒ8O+Ö*‚VmIyÖ*œ\ôa¾Š<Ãïóãü÷-k
eİ$«I,6öi-¶èç”Y¡œ²Ê‚Y›­ÈrÊ‡6FºAÖí†˜Š,oc0u¿J*ùĞÄÛ¶;ğKjİÄ¬%vSåSËñ™ĞgıeT0klĞÄHøØSVÖÃ% ,¦õŠ(±1±Ø-Ö˜\É¬'¨V	¥±©5Ça×X/ˆ;3[‘Ù$kµ¨íëçÌzFª¬aÕè!«äœm¥·d•a_À ‡¬ŠsfdAtSë÷ôn¾VÌ$96„õ7¨·”z¨‡UĞElæ±wÒ]•sŞ»õu‚Øb•5¡‚óÍ‰Æ¬9‰Ø¹):¬‚JÎ7¦İÖTäm¿j<
kì°¬Q.È’X7®Îât#{u»ÁZª’Y¿æd%r¾¶á~¢~í¶YÊˆMÂ„YU|-è¦Í±2grß2« "íY57iÁÊ-Üğ+Õæ¾ÜÃlDbõ+uÄTäk´9VÿJ9»aK‘ eP!9_Û¬è_¹XÌv€5vpxV…Å.°2êš–(.¯Õ×ÜV+U²f´õ€Ó†dº;c8£u¬¼»)™yİ¤±+º)²x<¡İYs$} È!ÈóÇpH| «äãNØMoË&&$c‹MKÌsU|²öpl}¤?¬4±ÃæYíÎØşqáğh¬‚‡İğé
@X<"kG˜_—È™ÑâÑæ«¢‘Án°¾â5Á¡ÒÃ0Ø<ëN(áŠÕÖ¸oKœïëc6G>æËïÏ=æ0óºI¦|²¬1=¢—Û["4‡4kïÅÛªà“cêãFcşl#î"«·]Åö/ø¸cóõQX3½KóµÕÃÂª4vhÍi××!°f9g^~ÒØ¼1¡±K¬Ê¡^56¿ÀrÚ!ViQ9ı•ŠUÔãÍ ï¬íĞU!ùŒ³aıŠS¥¤C
ÅÙ°.lœF!oR¾G‘ñaÇX£f¡İ¨Alw’5n¨::n'Ç0;œoš5ß)İ´ˆ!<ë.­9Ê9ì"ë£ŒaXì"ë£è¦³›uÍÙQÖÇ±%x‹#á|×X3‡GØ
c}Û?±;á?­°>J›÷(ï} ë£Œ5Åıª±s¬	§Í³îæ|}œ]ÉH?ãÃ0X9…uÂi(¬;j7¬#ëİE Ö«Ô‰Á0X#Ò‰Å0XcÒÂb¬É€ú5!f¾&ƒYsb‡Á°F9gaÅ€Xã’³‘µw¬‚tä0ÖØa 1²±ÃÈÚ7V";†5²kFCYs2rL,œ,†cKÈnÂ`ìa¾Ã@ü×¢rë^p+ÿCÊé‰%6ÒVxVÌ=îsœğéKb¤“N9eñD¬/=ë%Ÿ>±H3MÓã<ÍŸŠ5„a‡ÿñô¬5Móô	YSdo¶ÀªL:uáï	YÙø@O-¿5ó‰›¹™>%kDDO-‘™K'­zZÖ˜Ys>>5+“>9k2 VADÀz(iÛı*¾ğr"‰Èa›¬¢àO!™$"‹m²>ÙÎleÍ™Ø§]_O¼ÖØëÄÍÜÓ²Îúy+¬é4Ÿºc—>!ë7	]l‡•-ÿ4uù²²-a¶À*r•gyæ2‡'eÕ™Æ“û9¥tÊ)«,”Jc¬V2é³–½­5òŒÓX§!Ä‡CàGc8¬ƒaU#kY36ÒbƒÁ°&ƒ`¥b0¬ñfÎ@X9:<VJhŞ Ä`X²æ‰5Ì×°=<Ö°¾ÉFÄ÷íï0ÿÕò¤õ};„Œk¢‡Ãú•_xÂÄa8¬Y_GÖ‘udİ3Ö#NCar
ë	§‘udY÷ƒuHkÎÈ:²¬#ë.²
NCa•œ†Âª4FÖ>aq¾öuHkÎ°Xcƒ°ÍnÑÖÄ" ;ôŸU8äœ³¾³Ê
Rœõ›51ª?)K.õœÕf9cŠ¸Ôs?ÇCfü4úŞ¯Äşôõ’!#ÿ,zÎŸ1kLv¬ˆ™Uk>„ùŠÖMŠŠ!èa\òš3Ö˜˜Sq’%—z¾æçä$
.õÜn"räè}¼‰>1'9Äz3¥7†'­ETp©ß¬3«Áo.õ›•Í%¡^o²c.€5& {‰³FDNš˜×ÖôµêW¿kF†Y‘cŠ¬9,§Øœ„U”!^p®ÑwÛ¿hX¥Fß}ºœçl—C`ëbæMÿYayeÖÄ
¾³z{¢bå³Ş³FT´»°}g©D<VA„äÌ`(¬Âb8¬ÃaeU¬1İÄ¦bì0VeUìĞVoK$4VA:v «²ì²›Èb¬†C1Ö{ıg>Äæ0„õuP¬!tê0²>FìÒIëÿ°V¯›^ğñiXsåü¶ÃÊkf||9Nsÿ·%V¶%nG'¦ÇiêÒ-±²ˆŒ/8=«[bõ»’™æá…§a¹™n‰5*˜Õ Œü¬©“Vm•7%!-‡ùôÑe–Û­²ÎåØ•ÕxŠõu»¬Şğn¬Á0X^z,’U\Ü†z¢’M
‡'0ÒÚùº=VbVÖQ¯‡UÃº­1éŒ
>{t=(´Û[_ƒéDZ=I¿Î'næ¦Ûf•OÄ¬Ät¬lû³äÛòsjİô4kNVdyæ2‡-²òV<ÅšãÕ°²Ø«·%ÊF”Vi°UQû[«>7ä“øt»Àú‘×WƒA°&çF½³ëi©N-Á
A2±
ëƒaeK"¶küÔZx‹¬9…5&ïze¾œE—œƒU2ë”Cañqóµ|ºMØĞMCaxÍ«ŒnBf1”5™Á`X¥ÆpX9½Â0XŸq²«÷uÖÕÙ.kÁÙ@X“’³°>ñ.ÇVY%i…õ‰w9¶ÊšÑ¥|+Y¡1V'†Âš+‹ÌW*2‡èaß³|2ˆõ•¥ ^bvÛ‰)Ÿ÷ŞfT" àó°FÜµ½g~eTâ-;>ï;+>3*q÷jôŸÕ[%€5ók$‹°ª’m	E`•E–sçæ|Ú{V‘«b(¬‰“%áA°ÆV”¬›Ài›Šaèa–¶%†Á:eQc¬~‹³°ªº_»-ış;±fÕÌ£ï¬Y¦<î:»¬R#LÛ×úÌÙLğÁ³=n€bû¬q>å<Dd>zÍZL9¯£Šıfm:S‘ÁpX-ú­›šÎTDäĞó~5°
«‹ê1ü¨ÆÄ!§-‡&˜5çc`uè5« "¬~ÇÃ"æ³Ş²J*x'&°ƒş²**=+÷(RÏY¹_}î (!åĞëùZ±Ê2¦³&a¡Q9ï€Y3_êñú
 ã0ñ?1kD%—úËjˆRãw&æ“ş²‚¾aVğ¹_x8ï/«†dÄÿÄ§U£¿¬k&FüŸöuÆ¬<Mßiô?gV¯Á}Şsİä-	Ïj KÉÇ³ #r`Ö×T(>ö˜•Q0Ÿå™A¿Y%QáY-92è7« *ƒ /È¡ß¬ÉÇŠ5gäĞgÖÈÆ?yÖ"NÂ`î/kLÑi`U%DÏY¶üÉaÅîN8é/«ğ¬…÷H€5
ë+[Š¢ç¬Ò³ºà²3k>³*Ò>ÖÄ:ŠLê/kÆ¶Rfª~É½eõNÔº)"‡È¡¯¬ÜÌÊ'ÜÁÌ›£Úàé/ë3>ñ¶„'Ÿ÷“5ŒáJ!!,.ySfJ!­´Êb—tSµĞòà•× lléÎ•óØ¥5§j™»Eùá2Áqšæ)Ã±%8N€ÅR?o"J™2¬KwÇFlægd°4.)ÜÔÿíŸSp¶¤—6Ç:±3;İ_İ¡+ß9lŒ5¨áé²ÆEF^rNUñnÇXa±ä¹×º)*8{(k¾k¬+Q
U³–œ=”õ/;ÎJÕ”T‡‡ÍWÕ°z›lY«å0Ì*ÖìWA¿T¬’‡r¢ÑgVI?7¬Âà¬n·Ö×UëøWâƒ7¤ÅÃX'næ¦;ÌZT5£ÊáÊæ½X§éÔ»tgYóL£fÍr>Yâœî.Çlù§i¾;~Î*«“õ¦«·5îó²\å™ËvU79	pLF‘‹¨Äªu`p«ºîeÎ«ae±«k ´×Ã1Ÿ/l,*yÎi©9]}™•Vi°«v“ 5D`ÕXqø0Çš~Ì4ö ¶¶ºCÉ”õĞlCi¬Üe=Ãÿ®öcøD{ÆgÈ,c­aõzQ]íÇˆ,ö'H_¯‚µU\ÆöJ?Æä°¬) £ªû.¯èaÉWJVûñÖM¯dı‘=d¾²¾zVA§¼BË^p¾o¬<OÔÊ½[tVÕVÁ¬’¨¸ÒÒÄ{Æš8XÑç?áˆÏB¨·ÑMÊ³Š•~¬Xƒ=e•D	'|æõ.§jÍÉˆïVl«¬ÂaOÇ°¢ç¤=ƒ×Ìµ-AU¶Õù*öŒÕw« Ñù[zß@Ô6"±Ùeüà”Ïö•g¤!:Kè²bë5&«Y«~lXmx‚ïúlÏX#–â=‘MÈïîÄ¾ßj#C³.éáÄñEØ
âlïXİ«… áFIÌ“Ã‚•ïùûÑ~²Z$¯Sù.v¡ß« "í{~¡„ù^fóGÀş±$<"¤ÀênD)„h9uXUéııdFA!µ¬ªbûs9’2ó¬ß•˜•÷Dö‘õÜø€ )°úIZ±ÎSŞ¯U³9,±>ggğªo¿¬˜úiè}"çÕkâµUÚ¬rÀstw§MĞ ’U{Çzìm¡jnZfÕ•Ù«Ÿã%ÚÕ˜LÃ*°¬ü‚‡-1«gñ¶„"¾D&¹´¨ú«äY¡4öL7yÖ)b‡ˆ­ãY¼fÎ*V†;s“Î^t5†%9Vb™Á~±â³]ämÄĞoa(›¯áŞ:…*×°Æ&£Ê‘Å~±Æ%“–€²×TÑÌzVDÃÚ¬»MÄ“8ì‰\{Áöˆ5)ñ­g{å÷^7q•»ÏJfhHnÖœÄÖ÷”ÏøÂ±Š²RP!äı{çY¤©XÅE^¾‚Yc¼ğS‰SÄ¬o¨È°W¬²¬T¿Ê¡H+Æ"¶£tâY½ó&É!1á›çF’ƒòk”Æ>±ª’³oQkŠµ¶VÑAX¾
?uc#Èb"(èä=bÍ<k«es:UÕ´|†øÏ•
.qßæ>dîu™¶€ ò‡=b%òa•.ë;
ñ'ÎjGµbU>PlıÏ&r!ˆÈaX#â5Õ¢‹ø£*k75ŒÙRäü ğİù
ÍN|…}Š#zû×bÁ~©©¨lF¤R`¥‚š­Y~”|­ı‰ûxÒ…Á"†êî1„›y"HrQ8ä<Ê}Ä<³‘æ+İ ã^ôkmŞ7¬³²Óã”iU9? $qü¢gb"*°oóõ£Ã‚ÕÏÏ‘ÉrˆzZzö#E%÷«;Ağöü¦@Ág{Å}rXŞ(ªe•Çl¥›bºø…+Ö(/ù®gUŸüııaa^eÑXŒ¯­X°*ª×œ¨ä!ìÇpùêÕ‚U¾%‡}³%¬Ò@0ëqeÖ°È|• (ìÁ|ñ³Š°Ìî“È$™FÃê#áÜÓ•¹¤ˆo"s¼ÍWCDÊGÂÿ3 ñFãëfãgolÿ¼Ù—«KIXHò(ì4óÍĞëß)¯‡â°È@iĞnèíOçÚ}¹Š5c´ğn«$‡KùáëYCYZ´µûã«›Êº­ÉY…Îô¬:¬¯^…‘ÿ($úÒ¡İ€ßÖH#!‡çNÌÊsSWáˆ„“gµì¿JÒÈª¡-Ô5—wbShxÃmJª~6b³ÿb˜U‘z¹²—÷-> Î+­ìÇ¨0©Ÿ¯“·¬Ÿ5Ç`2Ï| {Îš‘Ô¦Ú_] ‘Â‘ËÈy;
a ì'«o}‹$àYC÷£ó$K”û÷Ïhìy¿zÖgkÆ_ 3¸=kFÎÛËÕ ØGV´MÍêP/3Êaé{pø8qŠ¬ ÒÕbY;ëk§»„Ewæàb+Â.H3÷’Õ`…UTãx=+ÏnÖ\ûÈÚ±•Ÿa»‰A÷{ä¼-À;”~!*ö¸_»¶?qæû×`å{8Ô;]•-‘‘Á^²fœ6b 7X‹€\T>^; öuÆ©–Õ¨ÖX/Ü§Êb1 öuÑ6&ÚŠ³µ2¯}:QrvûûvY"‡*jÌÙuB£ ûÌŠW¨¬ƒ«ßÁpÎÎ© {ÍÚ¨cƒ«Ë°«X» ¬Šnf…EOX3r¸…õnºn„ÈaëŒóa°F}dÍÈa#ëõ^è&‹¡°®]szÊ*Hc(¬ëmDiĞCVï¦®aµè!«wS×hg‹²z7u«CY_b…áĞGÖõ!8‡¡°Æ!¨6Ö„
Î‡Á*¨ä|dYGÖıĞMÃa¤‡‡d7,Ãš†Ui†Ur
ë§¡°ö3¶6²¬#ëÈ:²¬#ëÈúäb…F€5rÒJ«,Áªrå”Ã Xcwœ¦yê÷AzÏš¸”a]:V7õC`s7q3;ëdn½¬=3–Äz4 Ö´e•{-ó–µÿı:$V"7ÊúJä­¦a°fEzìb#õ’çƒ`{ïU9‚Õ«áaÄ%ğ0BK!°)8²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈ:²¬#ëÈzƒDDa‰FÖ‘udYGÖ‘õ‰Xå«¤‘udYGÖa•DƒaUÃb¥‚YƒŒ¬#ë²–	gam%°**8ï/kĞÂÃdåùk1V‡~±ú°°¢‘Õ¡ç¬/>F„U„+ıgµ`Ä°_YGÖ}c­e¨¬Yğ{zÈFq‡µ¡½aå¡Ú°
"İgÖŒ¬hû¹½iÖ—ø
şß÷xzVæyRÖ#<ã±X<%+^£¨fõˆÌæşil•;Øá±Yqâa"kl‘uI/?«u¢S>³	g½feD`~ÀÙc³2IÎ‡ÛY_SåÈVAÄw.é¿Ş‚5ÔõD×ßy4V¿•6Éz4a½`Á@Gœmµ7°ú 9 ª2ß}˜LxAwxƒ9¶Âš3’E·Æ£±¤ÉÊyM,6ÇšQÎù²æb=+—5î&/ğ,ÒøË’Xf-0GÌ'OÁZğ¡aÍˆ‡õ0°¾ÄŠê·Ü²Àjğ$¬³V1ÒeV/‚¶ª†è².FÆòŒÛl#s„˜‹VVñ&tğ_ÎêûI6íÈ‚ÆFX—çïX}„4¶‘™zû·}¯ó¸4˜áËYENà³Š•ËÛbÍÓ˜í¤	&ŞÖô+ü{ÌNÂ¯²xı®öx¬	•« îdrÖ:H¾†5#{uEÖb’¸D{[?Ös>É\•4HùYQÅ*iu¿õ¬DN\ù)|6Hãyd1+Ñ®JÆ¿è”4Âê²Í°&ô`ÖÌ )§ò¢ÄQd˜á8¢Oçïˆß¿èİ²fT)Kß .>˜u¼Ut_MäD·\osjD¿–J+şls¸C Œé#…ĞNâßFÿˆ*«şp+şº«¬Ì¡:sQÜ“µzñ²š "‚Cz„$¢„Ï³ü®V‹´Ò*şÃm¬‚:/(ùÂ‚Õ³\¼•¯_/’¸3îË¯Àíö¿eÿ¦Åññ›óSª¤”´ò‘•S9'‡›Yı›T>‹ ïv¶åÀVø‹XÃZ›{±z1¸UÃ"saX¸Œõ‘õÎMôéÓO´$Öyz|œ¦©¿r«ã«“t•Õ7Ù‰«¬`Í%—_±bg¬u#&IŞñ-ò-Š>p½qhå»4=ÎS—Ş‘u5œZÃÚ”¯6ùvÖe)ùvÍZ—}K¹©SØØˆz)¯º!>7m½µ¬HİÌMítc¬‹Q®(4A>„•øö2«ƒwQ¹gç‰pÁZ$§ÈèFÖ‰İÌš…-¦µ¬±ë›ìÄƒYeXˆ»óO±.<şF`ıDş3oWÑª„ú-«´êfVº†Õpº†5âtoV«è:VMmÛŸFQCéo¼¦V$W‹èFV+og­Úr³Xù¥¬¢~Ğ/“ë_ÜeMtX…Ò’è=uEÇœ-Ë£°:ù¥¬>ğ¬‹¯cMX“Œd×–XÎ–¥à·7§kY}jWS‡û²²|9k¨7VwTŒ¶ŠºòWt¥Müö…[T³Ê‚‹íWvØ«“t«¬Öe´Ê*;m¸Â·¬1ü¥¬á&?6«p)—Eg7±&æ¬×\şÖ6àxwVé~ËÅeùoÙM¬B»‰›mœ•Ÿé°jÜ)¦lTÅ*è
kG¯6¬Ê[)+òÛô÷tënêÿÂé]Y5§†5´‚jVÜ]TÅŠº7³f…¤ußÿÏœ­g!=v•=¬ºl‡ÊàæüËXÎCKqw‘Áæs¨Ûp-kıÓwÓ—ü®ZÁnN{¦6ŒÔ°6áû¥7wgÏzV“Õ¬\­óKwŞq¨ÛĞùÅ« ğÓ	Ñ/|¼eÅ_jA–«\¹Ì¡Ãš‘CÅšTM^şeĞİX³ædm„ßëf™µM\B5-ãäPmUˆŠµ~3_±¨kÜw•98_e5Š®gı@7‰oÃV•#´ÔhY%Õ¬Š–g'?·•¡ÌzÔ.7²şDwßr’–X—´`Á9$Õ&sFK¬¡%+¬‹òå¬‡L{-«St/Ö\Tm 'éN¬uõkX%m–õ røK¬ÈhõÅw”\p9IôpV$DN.XùÁ…ûVY¼Ä2kµŞ~)kx‘¤ëY—gÇ²NÃ5.6³6ô_ÎYX\‘—u›jïLÑî±ª{³Æ,Ö¨,~ÕB3*zÖ÷DëX9ïlU|‰íàå~8ºò=¾ıò­ppZ/ü‘7Âª‰®ˆÜë!L®¼ÂËÈ?e´2¼8u‡5§År¸û¬_AèÃ!ø´’XHç6áwft³e”Q‡5WT/—,wauŠ–5F¢NÄ|Z¿É /~µ±æwŞÏË¨Ãê$İµµ¬oe½*Ù5o¾‘4¶‰şáÓ;ÖW3ùg	ºƒyä›Ê?Û°uY=ßº…u1Ó›UG61Ÿ?Ò¯:°¾¬ó™$}|Gç¿çŸ¿‘54µ¸U>ëHdŞ[yññ5ù1§øJ\ü§£åcø¿ÒÿúM¬Šc¨ëûõfQ´Ö‹K7ùì%æ6Ñğşt">Pæcø¿ÒÏüë7±JÊrOXñ÷¿äGYÉ¾e*ÃßÄïèİ)™n2º¢-Ö [VCşÊ²*šşŞGÊ~<’I[q£ÿxJD6Qt­p‹ê1\™â-«Î¾”õ§Gf•¥$nŞ,ùQàJ¹Ñô¼I è&ÖRTº	]VÜñ/ì‘˜³*ñØ¬¢TD³øCvúã7Š2ªÚ0Qt­ Ú€7™ïWqÖIèŸ\°:õ¨¬/…`c}üó‡âPòiFÕØš*Z®[ID…(Ä‚U­ÎW»™¥\½	3Æ|¨c.ò1X¿Em	§üz"÷êgnşL’iX)Ï¨ú$ïAgóÉQ½'¬Q›lœ×MÅ½XjVÊ¬OîÕ]¸~AEXFƒL‘óë¹•‘q¿ó^›"Ã®@N­EªXáDÅÊÍÅªÕz_Vš•÷zAGj/<ã„Ø",£Af(2"Êç¥sEDÕ­ ºàt•µTNPÍÊp¬á9Îïõ‚µ¬±A«†8!v`9áäÕ!şBş¢\P5ªêVt¶‘K¨&„™‘_ŒhÃ¬âA¬§šÕ¢mŠO.–º•Yõ“8<ªÁì‡3gËZâ¯Ãˆµ5kzÙÏW<„Õ+7³FjV‡«¬QÍJÜ^b–ƒ“¸PTù”áR—5+‡O`TAıæ+“W®\¨÷4ğpÖ2²¨Ôm`c±<b5 ‘'„3ßğ·XŸÄ”QÅšp¶2Q=k™‘ÆÂcÆ³®}ÁYôeäô,„C¸â˜Õ€Ëğ<"m:)È3¢†[ĞõÙ
¯n=kkñh´¬Ûg)v*hú±bÍ, Ï:‰ÉØ(¬ÿ^~ùC}²Îgó¬:!‹–‡³]bM(	ˆ%œ,øÈô~ÓÄÂÛ¿	&	}Îcãgœ—Ïï˜çÊ¶)gV~¼VæÄÙ5óõ>á¼²×¬yÅzäYÉÁÁDKAìcßZ/~WŸÔö’"
ˆÜ|q#:¬%g+ç`}ˆpò A±|Šòê$Mòø5¹©gı`2"Ö‚Ö·6ˆ:¥•mSÖšá¯oÅ:Ö‡È!§É„S0¾‘käÂ’Opœñ³°BNTë1Ö¥g­Ã¬2¼ne?=kÄ©Q‘ÕÒ"p¨B;ŸEÁöñ¡eò‰ÊÙ‚•>8Z•™6øy”ù¬ª|¥ä³İôô¬!"V³jÀqkŒÊÈ7î€›Éòÿbâ;é‘¿Èy3/!‰Èù{VEZê¾¢FµS7(›ËOÍúí’½«4"WÌJä'>Cµ<¾å-ë×ŠˆVY[jN–ÃîªsùIYª(}Ö5kFK’—Vİ1ë"ÎWLÆH’¼Âº=1Ø
k
+ø‘eVƒ¸ğ­É(¸ŠÑù†µÖÕ*h…U‘®hbÙkãíOÎúUåÎ'5*»ˆì·¬nUòŠjNÍi‡•$yÖÅ£È»oµJ²XËjñä¬IåšÕ¬‰CDö()ã÷TÉ™Î¨’sNÍzò7œ5òGZ¶õ:ıvë5—™U×LæÊ °ÆTIJ>Q%gWö¼9­D?WX–¨.¯
‘ÃÃå¬B{V«ÊÌ ß%y’PYftNÍÀ4œVå/ä",£¡ïş€„´Ğ³ë5RmI=k¤Q‰4Ü“pŠ¡^`.òä-Ì¼ˆ³«](©¾U³–é­öŸ…(ÇİXŸ´_cšÕ"¦×.ãÆùpà’ß€êSdÔ¸.‚B¥ñb('Š ½Ú;<¦tY¿ÇµÓÔ¢eMèìW"oÒªt+gµ!!¨ÖÄ5«ËÊÈ.Y
¸µ_7Ïêpë,ÊB{—Š“¨ zGVnòÕS-¨ÖEeõ-Ü´À|™µ	+í«°Ï0å#2A‹ˆeuºÊ*©a­Ç°*¼9"·ÊêM½ëXÀµ²İƒÄœ–ÍÚàĞx$Ç­¯5³VD„Š‚¸Zæü¯
_n~ùÉY}áª|Ã‰×S¡Oøøš:¬W]³š5ÁÎšÕ(ªúÕ"Ø
TğYxiGª»OÉZpÆò®TP¹ÒÄßÿ,ø_·±ÖPD>kuz¾qf°9ä´Âšrjä+v¹<ÂßShh½H®Y|M×ô«A#LÿŞ`ë¬Ihe»ÅT]ƒòen.qçpCıl\TäÅd2]~Ì×¬NÂ$ï°
~ÅÖYEÉKÙˆ^ŒĞ5 pƒ=¤%ñ~vø’ò« ¢úuŞß³è²Î±]Ö¯Û NÄ¬±F‰F˜Œ}¸˜¼Ø¹g}G+ıÊm€º‰æÊV¼ÄöX#?-3Òğ¥2r‰F`µòŒ.J|¤0ûœ¤Z¬¤.«Ÿ–¨§©F=†9oYº¬S>nÕÖZCF»Ä f¥ÖŞ¡_¤ZŒ Î|]Ãº$9tYŸóqK¬óÈúĞgFô³¸½osa«°ÒÏä¥fmghmßVâwø[Öõä§r£ì/Î·ÆšÆÖ‡¹İ¡ÅÜ^Y¶Û(ÈNÉV~IDÎÕì^¬¸èœ?5ëa”'Î‡¹íÁ·—O:¬Ëâ*‹N‘ólY·×®auXh‡­±N£"ñÛiï¹íä ò''<Ëì?çU›ÔªÃº^2ÿmZEå°5ÖYT*¿VõY‚oùI)u	—ÑÖ¸ÙØWDù»‹rØk¿š5çm™Œ¼zUlÿæ|²ÊÊqÃ*Š ˆÈ}Á¡rØ«b²äU+ˆĞŠ*9§×æC½Æ(ªDÇäDRÉùıEYl•ˆ’SªäQÔÈ§Å4­¡;›İ_&™ÁvYß¾£&£5A›b%ƒmÉo á€b­CëD‹:Àğ`V?ß·%’Z±ÈèÑfmØØ/øôË%&‡`åì6VùPÖòˆó­³ºëYªø
}±ú­äDşœ[gõ†îÌŒ‚íàYó/_jš0‡Èø¸}Öˆ3"sÖQÁh6
‰ÜCYc­\ÂÇí³2”ïÃ
¹×‹è-‘{0«Q6æãÖY½kVá±™Û™¨K¬Ş¸K¬LWkænT>«’9il•µˆÈ‡R\gSTÒ‚u“¢¶Éª((¥0	¹›U²®Û"kasVG¾*[Ai"‡M‹¨hK¬ÌÖº¡‚È—ÁWˆ6ÎŞ¾µùÊc¶/"j¿<‘ÃÆYù×¶&NOÈ*·ÉzÈiÁZéGœ2»ÃúØê¡àl«¬O'Y;CzÏÑ)çCa}«1Ö„bƒ¡°–‘Å`Xñ=ÂoS?5kÁÙ X#íw?Âj†Ã
—8…u> Ö£Äb(¬‡‰ÁPXgaM&œ„5şgÎÂ9l+\jL‘'/’W­OâŒÿŸçFEÿ-Ê+õßáÿŠ0ÿÖü‡èŸûÂü-ŠØ¾úş÷Q~ğòÀü—ùÁ¿Ò'?øoŒÂyôßùAüşgõàÿî_tdÿÚ—Ÿóƒÿ/¶$™ƒï×<öl8
ßÄJ¦7Rg8öe¥g¡l$ÒØ
+õqä£yğ¤zP¡Œò˜Ëü`Ô>hıƒÇ|ß
.ÿó/nErÿË¤ÜvnĞyd=Á1Cß²”Ëá†óeÙ-[_‘äÍƒŒ*b¶T±}Pè)~ö¿¸q©Ø¢`Vî®Fİs\á™³Âø~ã²ĞÊ—}‡s™—ïó ¯}ü‘q+b§5*ã\8©	…š™ærbO\>‘–³¿n$<˜•)cn»4Y÷Á\ğı“¸¶zĞù)*üƒ*<h¥Éâü‹[d=ûüó$ı‡‹ó7Ó©»|ÿ)ù‘Ëö—7¸<ÿİûoœMíç÷¦÷ÃÅÇäG‘NİÏg§Õƒß„?¿ÿ”ğƒ©ıåÍ_şİûË·üàoíÏgÄádşöãÛ2á_Ü"ëùÛÓÉtúêòÍùéd’şpñóù©8<r¿^¿ıÃá<ı|yÆŒ³ô³½|{8™¦îç³“éœ?ÎÛS~p^?øæòü4™†ßüa2O?_3ó‘ğG9Kİç³ó"ÖØŠDõªÖŒ(¡ oJ™KòR
§,½£ †Ş’Âå„¤Söj%Ñkªïs·ñ‘å¬NıÂ'~—>3Í‹_óF¯ÁY'ÜßÒ¬,c>ú&™ä-O¿,#/ÔÙë\‘—"¦S«(ˆŸT¿Ağ ¹°òyùd•Í¹Èa{¬’z)#ëX+=,Î9=ù}A—>ÿã¤Ì~øËÏ?f2/?:ÿãi‘ÿrùÓ‡Rı—ß}ştIòO¿ıõãÏtúiRüîW:ÿåÃÉo‹¬~ğ×ğ ÊË_ıƒexğœøÁ_ÿõ’Şı¤Ò_>ÿtn#á9^BC?Ã¼Â÷q(¿ŒBùŒ/ƒï|ùëª*6šÕ«ò‹ª\?øŒ/¯e=£¤yvÁúWÊÑ{JXg–Şàröõ«Ì•¥÷\–+¾-E®İéÁBY®(Jé2Ëª.ºÂZ•¿«X¿]jò×\61¾
¬¸–Õß_fõ®ÚˆSÏZ™?JST$¹4™.c6 ”É*»‰oÄ…p²²›„vSâ¤­í¦úAQ=èïó~‘7Âƒ¯ë³Øn5}B{ØøíÖXS`Â^JğsNB“¹eÇŞÏñM>¬oòŒËVh‰´jò1»7|câô>Ü‰?	òG0‚ëóƒş³ÆÏñ^ šË[cUŞW/‚Ê_}á†úrVuòıè-wÊ¡b.BÅ{?ˆt{¬U\"Möî‹0**—šü7æ¤Ódy+­{PYÊóGeı¶}Ğß_ÃZÇ›æ˜Gæ Güg.z—û |…‡"âªén©‰ŒğÕ`côc–ô¾ú!ÿÖÜ?ø,øæÚ?8uõ MğgßÈú­or„o®cıºbåöÁû°‚o‡pû[|ÿü/±|Íé[à+şeÿK€öo¾¯šôÕƒ¨šèüAÂƒUCi©¬«Á¿ø®jò·Õ‹ü«¾ãğmú¾~‘Ô‹ö¿©Z€êA„6|Õù£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Ü$ÿËq¥Ñ‘ïxKK;täkic*w%OóIW¾ÍüÓ6.ø¼•¯„ã§‘ñùBş’Ÿ/Ñ‘o”Il”Gdpµ*ÿâÕªÉrÕ5›X;n!3håó	2-mÒyk‚åùÊ±Ñy	n‚Z9Ä~Ú%%—šŸÒ‰Ìù§J~3Z™ã’[Kƒ”Kµàyf·+&ƒ«U»­jªæ‚,ne\BüÎnÕÔ³’ÍrÙi«ÀA–Ë")#ÒhG…~"¾@¶Ë:Å¿#«œ,q©ùV:QütL¯É •ùi£Ÿµ"qHNæ¾²A+®ªšñ{¹´Z5é\Ï*Ş¾9»pÖW³è³Kg.-XóãÃi"â3ƒöyıI¼9×61è°şí…Kç‡S)4:¬Ç3!â³×ÖOoß_ØÔ-³şÆåÓ©±F—µ®:é´ª©zÀMÁÍ"L’8™„wp±î¬¯N"›çÓ™àb-
n:ˆäí™E`ã?%oß¼·N´Ràosét2I4ÚVé$LDòæÌ:t&û§øì=Wæm%Ãoìñt6Yb™µª:í°†ªÇ\‰ÁÍ"M"œŒÏ__tX¹elÓ|2\lß:±3ßü·¯-ÚoeãÿÁ.Œ“í·*ğ;íøÃÈÃD£ıV:™ğÓo.Cû­òè_£KÃ•»
‡ğ3å“¼ÑXTuø×èÒpÕô€‹«Uu¢q³(Ã¬“ø\6)›xVÃƒå¸óÂ¡™¤b’¼}mÑ~+ÿS|úúÒäÊ ıVşs7MÅ7±Fû­ôÁw“ä4ºĞÖÿ?º4n•uªÀ[ÅguÑÿ]šÏvš>ÃÕªZhÜÆ*¤›DçølS.¶¸,c}d'i¢Ñy+<küöµÅ‚5ÑñitiÒÌ Ãê0·ÌŠ%Ö	“ÓÈÂ¡È#]šÏvÚQ®ñJÀOO“·]Öºê«U'Sfåâò·æàß¸Cfı¡ËšFï¼Âúó[Sq¿…E#¿±	fÕéÿfĞ6àŸ¹†³\¹Ëú7úYùÃtYŸå¼}©XbÅOx‰é\Lã·%—šª®©ú:Uç\õ€Y'\ºE?G`ıìz82“+¬ÂÁyr¸ÄV\ê£Ø £‡-˜uÎ÷4zø“Ãø°±ÅBÇ:>Ó?˜C‘s©ı©—8¬Ä¥V7U³¥ªs®z0õŒK·³Nâs8²Xf5é5¬`ÑeXÃ}^Ë:õ¬Â`…õÌ¡\H+V%ÖóÀZp©[ÕqÕ»³¾v™Á*«c=¬ÑeM+V‡ë3ˆƒu¬ui}=Ätÿ¬4è²&o<ë$åR ÷ §oº¬É[_õxÂ¥NUX§\º…õ¼¾¿wä°`õ$²y>[fM‘_e=€¼ÊÙø"°J.µ¬G8¬ÂaÁšhX§K¬.ràml°`M´XÃZWÕÇ\ºU$gï?»œ‹Ë¬él&5:_0rëXgkXMò>°Î¸ÔaÍ+:¬ñÖØ€È¢Ã
™øª©àR§ªU;Ï_ÇzÄï ÷ôÙvê¦	& \•’4oµ‰½:_Q\e|X.µ¬iìÂ|EÎÅë,°¦)—:?eækXg‰Ÿ¯©àÒ¢ª0îî¬±g5«¬ŞòË¬Â\ÕÃ‡Q.p…U+ÖœK-ë<±‡WXŸá$ KºÉğOy€ÎOÁ ¨ª
.-U=˜Æºóü¬øÕÌşO–YåNşı¢Ña•:ØË¬±Ñ¥Icƒ.ë	ì4±C—U˜Ãø4²H¹Ø°D9Ø)— 
ÌšèÎO1k]•›·¨ùª~}Í¹tëK8Dw…Gœuß
«X#‹kb×±«E—UêÃä4²Ë¬±‹Íç5¬ŞnZaåªÚÛˆË¬'˜O¸ªÃ­¬s°n:}a¸Ø°
L"›:ÖÃ\Z°ãXL’·¯-:¬B‹×—&:¬¯ÜôH.«Â$9åÊ)[ÖÄÄÆ¹)r.- 
x#÷4²è°ÖUSÁ¥åª³D;Üõíë{ÄÅ†õ °æìr©}+³®ú9‘=’:y}a]l°`M"Ç~Ğè°¾:aÖ·oÎŒÃ‚uÒ°¦\Z äkX›ª]?§­
‹;²¾¿°]İtàY]>p©ûVï¿¾93X°¦<Ğß¼_eåÁëÒéDraÁÊßjÕEÎã"¾°.E—5~ïà}eñÆ`Áê«¾çªÓ	—Úª¯«ª°¸•Õ2«ˆÏŞ»œ‹ë„Y/lšÎ&\ê²òÄ8Ï–XãsıÙÆVÁ¬©›L%–X…ŒÏß\8,±F6uË¬¯‘¼5XbU'3.­T=€Å]XBZ²‡ıúj”9—o¥ÂGv–ãMsÅ$®,XrÊŠ\uª&¯•şi®ŒëÉ±.£ì2k\ıTÜy®©*
.uªæ¡Uw`µq™Å2k¦¥‹¶FÌ*\:®°–\96¸Âê®°ÆETb)8è2­ÌRÑ³úŸŠˆK]Vë«v{ ®Ê.·Å(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£Œ2Ê(£ŒÒ9ätEbN•Ì±ö¾FW,ì¾L8]‘D£‡›ï{‰l•vSsê²ÆDwc]šh°|¯9.ì.³pºk ¬Yšû¯êoöÙî2«â´†õ€ÓZÖÄ`k&{d>Û]fı_í½nÜ8ÇGPÁ&0Ûé5ÖÈz•¼AœÎ.G.T¨ÌâG¹Xl™7HFpnGpv2Ô~Ù†SÜá
%ŞÿŠ\~HZıDj8Ô~9ÿë
–SAOsf„ÇJp4DÀx˜6eˆ¬Í˜5†çXsÏ²Z†gì°Mt[JxÆ¬©CÑˆ2MXİ?CïÉUR–¿m(G†¨œ!â,H¨¶ÆC$®”xl‹†Üúoï4?3Y5×XƒÜ	K-õ˜÷"\ÃCVYK¤ã!¡[ vì…]KÒŠ‡Yi•b!Û¥ñ ı6³Ø¨*†‹;–A¬|Úæ­ˆæx_­j¨” A©=8Q K3(«ô­´‘f¥?:‘ÑbÂ÷üz‘ÅFXSº0x¸$kolôÃõ;æ}µŠø¾
¡
m0µ-Ğ½ ü¡vx(é¾¥º†`^¬–âQ*+•ÊjeÇjøÂx¸âKÎÌg“'Ä×š+Ö+N"kƒ¦ö‰ˆlÆ{şHe‡%uH0SV=ºŸ±şe²„è	ë5%¡ªbú„•Şb©¬Øy‚™õar2*kŠ—dÇ'}¸`^s#YdÕX9°–¤Wk°•«öá‰µÀËÎ—x'se-)Êê±FÛdåÈÚJ¸­v¿ë4œ2 Ä>œ­2MÆœãe5_Íd‘Us0ù¢1¼	]4à÷Mí!6ÁÎGü¸ëÃw3õ›"ëb‘iêè#ÏW¼L¿šÏ;VÍÁ‰5MØ¦ÊZ×N~ªmÚ³z˜©?œĞZ¬²Zã™•õ‹İ·«æ`WíAY«*ø4à÷ºö0¹—×{ÖÔwÔãÂ\ç9}OÙ3¬+óåæÓ£>|dİ<bİÍsêïû¾oÛïæ§\Cô'Ûô€õÖ;e>¢mÓ®A«×¤ÚÙ&8Í_Ç^Èµê#"O«Íò¾„kÈñp¬fb}+©T§1çÔ®kˆ¬•‡é¾Û+a$Aİ•[#ÍĞÿw™@ğRdÖgÖßuƒğR”Š‡—¢D4:ë¬³Î:ë¬_^? ¸Ú<<
endstream
endobj
109 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
110 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
111 0 obj
<</OP false/OPM 0/op false>>
endobj
133 0 obj
<</A 134 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
134 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
103 0 obj
[135 0 R]
endobj
104 0 obj
<</Length 12100>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(promotion of most types of hor)-25 (mone therapy by manufac-)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(turers also decreased.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 144.5524 721.1196 Tm
(18)Tj
ET
BT
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 10.5 0 0 10.5 70.5 704.8947 Tm
(Studies have documented substantial reductions in the)Tj
0 Tc 0.002 Tw -1 -1.23095 Td
[(use of HR)60 (T in the US and other countries subsequent to)]TJ
-0.00301 Tc 0.00301 Tw 0 -1.23095 TD
(the publication of the WHI findings.)Tj
ET
BT
/T1_1 1 Tf
-0.002 Tc 0 Tw 6 0 0 6 211.8567 682.3447 Tm
[(7,8,19)-24 (-)-1 (2)-1 (4)]TJ
ET
BT
/T1_0 1 Tf
-0.00301 Tc 0.00301 Tw 10.5 0 0 10.5 237.4737 679.0447 Tm
(These studies)Tj
0 Tc 0.024 Tw -16.90226 -1.23095 Td
[(took a range of approaches to estimate changes in HR)60 (T)]TJ
-0.00301 Tc 0.00301 Tw T*
[(use. Analyses of phar)-25 (maceutical marketing data and na-)]TJ
-0.017 Tc 0.017 Tw T*
(tional patient care surveys highlighted the marked drop in)Tj
-0.02299 Tc 0.02299 Tw T*
(prescribing of oral estrogen and estrogen/progestin combi-)Tj
0 Tc 0.005 Tw T*
(nations that occurred after July 2002, while noting little)Tj
-0.02499 Tc 0.02499 Tw T*
(change in the use of vaginal preparations. The data used in)Tj
-0.019 Tc 0.009 Tw T*
[(t)-10 (h)-10 (e)-10 (s)-10 (e)-10 ( )-10 (analyses were not person-level and did not allow for)]TJ
-0.02499 Tc 0.015 Tw T*
(direct estimates of population use rates.)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 216.2902 578.9447 Tm
(7,8,19)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 232.9182 575.6447 Tm
(Cross-sectional)Tj
-0.034 Tc 0.024 Tw -16.4684 -1.23094 Td
(surveys in the context of trials or routine medical care docu-)Tj
-0.019 Tc 0.009 Tw T*
(mented utilization at selected points in time but did not al-)Tj
-0.01199 Tc 0.002 Tw 0 -1.23094 TD
(low for longitudinal analysis.)Tj
ET
BT
/T1_1 1 Tf
-0.011 Tc 0 Tw 6 0 0 6 179.2658 540.1697 Tm
(21,22,25)Tj
ET
BT
/T1_0 1 Tf
-0.01199 Tc 0.002 Tw 10.5 0 0 10.5 202.1977 536.8697 Tm
(Person-level drug pur-)Tj
-0.033 Tc 0.02299 Tw -13.54264 -1.23095 Td
[(chasing data of)15.4 (fer the opportunity to quantify purchases and)]TJ
0 -1.23095 TD
(describe users at specific points in time as well as the ability)Tj
-0.035 Tc 0.013 Tw T*
(to track changes in therapeutic regimens over time.)Tj
ET
BT
/T1_1 1 Tf
-0.034 Tc 0 Tw 6 0 0 6 256.7463 501.3947 Tm
(20,23)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 70.5 485.1697 Tm
(W)Tj
-0.0018 Tc 0.86201 0 Td
(e)Tj
-0.002 Tc 0.002 Tw 0.69208 0 Td
(examined HR)Tj
-0.00191 Tc 5.44853 0 Td
(T)Tj
-0.002 Tc 0.85905 0 Td
(use among female members of an)Tj
0 Tc 0.26401 Tw -8.86167 -1.23097 Td
[(Israeli HMO from 1998 through 2007 to deter)-25 (mine)]TJ
0.005 Tw T*
[(whether changes in the extent and patter)-25 (ns of use of the)]TJ
-0.004 Tc 0.004 Tw T*
(treatment occurred subsequent to changes in prescribing)Tj
-0.02499 Tc 0.013 Tw T*
(guidelines for this class of medications. )Tj
ET
BT
/T1_2 1 Tf
0 Tw 10.5 0 0 10.5 60 405.5446 Tm
(Methods)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.009 Tw 10.5 0 0 10.5 70.5 384.6196 Tm
[(W)80 (e used the phar)-25 (macy purchasing records of Maccabi)]TJ
-0.00301 Tc 0.002 Tw -1 -1.23095 Td
(Healthcare Services to examine use of estrogen replace)Tj
0 Tc 21.95304 0 Td
(-)Tj
-0.011 Tc 0.011 Tw -21.95304 -1.23096 Td
[(ment therapy \(oral, transder)-24 (mal, and vaginal products\) in)]TJ
-0.02499 Tc 0.015 Tw T*
(female members aged 45 years and older)Tj
-0.0251 Tc 15.46544 0 Td
(.)Tj
-0.02499 Tc 0.46484 0 Td
(Maccabi Health)Tj
0 Tc 6.02267 0 Td
(-)Tj
-0.00101 Tc 0.00101 Tw -21.95294 -1.23096 Td
[(care Services is Israel\325)55 (s second-lar)20 (gest HMO, providing)]TJ
-0.02 Tc 0.02 Tw T*
(medical and preventive services to approximately 1.7 mil)Tj
0 Tc 21.95298 0 Td
(-)Tj
-0.00301 Tc 0.00301 Tw -21.95298 -1.23095 Td
(lion members, 25% of the Israeli population. During the)Tj
-0.01801 Tc 0.01801 Tw T*
(study period, the total population of HMO members grew)Tj
0 Tc 0.00999 Tw T*
[(from 1.3 million to 1.7 million, while the number of fe)8 (-)]TJ
-0.02499 Tc 0.007 Tw T*
(male members aged 45 years and older grew from 150,000)Tj
0.013 Tw T*
(to 251,000. )Tj
-0.022 Tc 0.022 Tw 1 -1.2381 Td
[(The patient infor)-25 (mation systems of Maccabi Healthcare)]TJ
-0.02499 Tc 0.006 Tw -1 -1.2381 Td
(Services are fully computerized and capture visits to hospi-)Tj
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(tals, physicians, and other health professionals; prescrip-)Tj
-0.017 Tc 0.017 Tw 0 -1.2381 TD
(tion drug purchases; laboratory testing; and imaging stud-)Tj
-0.009 Tc 0.009 Tw T*
[(ies. A)75 (vailable data regarding prescription drug purchases)]TJ
-0.02499 Tc 0.02499 Tw 0 -1.23809 TD
(include identification numbers for the patient and prescrib)Tj
0 Tc 21.95287 0.00001 Td
(-)Tj
-0.021 Tc 0.021 Tw -21.95287 -1.2381 Td
(ing physician, date and place of purchase, and drug classi)Tj
0 Tc 21.95292 0.00001 Td
(-)Tj
-0.013 Tc 0.01199 Tw -21.95292 -1.2381 Td
[(fication number)55 (. Drug classification numbers identify the)]TJ
-0.02499 Tc 0.02 Tw T*
(drug name, active ingredient\(s\), dosage, route, and number)Tj
-0.01601 Tc 0.01601 Tw 0 -1.2381 TD
[(of units per package. W)80 (e searched the phar)-25 (macy purchas-)]TJ
-0.011 Tc 0.011 Tw T*
(ing database for all purchases of products in the category)Tj
0 Tc 0.13499 Tw 0 -1.23809 TD
[(of hor)-25 (mone replacement therapy)65 (, comprising: \(1\) oral)]TJ
0.02 Tw 0 -1.2381 TD
[(medications, including estrogen-)-75 (only and estrogen/pro-)]TJ
-0.00101 Tc 0.00101 Tw T*
(gestin combinations, \(2\) vaginal preparations, including)Tj
-0.00999 Tc 0.00999 Tw 0 -1.23809 TD
[(estrogen creams and suppositories, \(3\) transder)-25 (mal prod-)]TJ
-0.02299 Tc 0.02299 Tw 0 -1.2381 TD
(ucts, including estrogen patches and gels, and \(4\) tibolone,)Tj
-0.00259 Tc 24.57143 65.09048 Td
(a)Tj
-0.00301 Tc 0.002 Tw 0.69134 0 Td
(synthetic steroid that has been available in Israel since)Tj
-0.02499 Tc 0.02499 Tw -0.69134 -1.23809 Td
[(2003, but is not included in the drug for)-25 (mulary that by law)]TJ
0.013 Tw T*
(must be supplied to HMO members. )Tj
-0.022 Tc 0.022 Tw 1 -1.21905 Td
[(W)80 (e used 3 separate approaches to assess the overall im-)]TJ
-0.005 Tc 0.005 Tw -1 -1.21905 Td
[(pact of changing knowledge regarding HR)60 (T on purchas-)]TJ
0 Tc 0.02299 Tw 0 -1.21905 TD
(ing. First, we calculated total annual purchases of these)Tj
-0.022 Tc 0.022 Tw T*
(types of medications by category and used these figures to)Tj
-0.02299 Tc 0.02299 Tw T*
(calculate purchase rates and to examine time trends. In ad-)Tj
0 Tc 0.026 Tw T*
(dition, we studied changes in the frequency with which)Tj
-0.02499 Tc 0.011 Tw T*
[(women commenced therapy)65 (, as well as changes in the type)]TJ
-0.01401 Tc 0.01401 Tw T*
[(of product \(ie, oral, transder)-25 (mal, vaginal\) they used when)]TJ
-0.022 Tc 0.022 Tw T*
[(starting therapy)65 (. A new user was defined as any woman in)]TJ
-0.007 Tc 0.007 Tw T*
[(the tar)20 (get age group who made an HR)60 (T purchase after at)]TJ
0 Tc 0.02699 Tw T*
(least 1 year with no such purchases. The first drug pur-)Tj
-0.024 Tc 0.024 Tw T*
[(chased in the year was used to deter)-25 (mine the type of estro-)]TJ
-0.02499 Tc 0.013 Tw T*
(gen therapy used to start treatment. )Tj
0.005 Tw 1 -1.21905 Td
(As a third indicator of changes in attitude toward the use)Tj
0.00101 Tw -1 -1.21905 Td
[(of estrogen therapy)65 (, we examined the rate at which users of)]TJ
-0.009 Tc 0.009 Tw T*
(oral HR)Tj
-0.00909 Tc 3.07919 0.00001 Td
(T)Tj
-0.009 Tc 0.85178 0 Td
(medication discontinued treatment or switched)Tj
-0.017 Tc 0.01601 Tw -3.93097 -1.21905 Td
(to another type of product. For the purposes of this analy-)Tj
-0.02499 Tc 0.015 Tw T*
(sis, we defined discontinuation as 120 days without an oral)Tj
-0.005 Tc 0.005 Tw 0 -1.21906 TD
(medication purchase, even if the patient later began pur-)Tj
0 Tc 0.03 Tw 0 -1.21905 TD
(chasing again. W)Tj
-0.00011 Tc 6.89314 0 Td
(e)Tj
0 Tc 0.72351 0 Td
(calculated duration of therapy as the)Tj
-0.021 Tc 0.021 Tw -7.61665 -1.21905 Td
(number of days elapsed from the date of the first purchase)Tj
-0.02499 Tc 0.022 Tw T*
(to the date of the last purchase, for any period with a break)Tj
-0.01401 Tc 0.01401 Tw T*
(of less than 120 days between purchases. Switching from)Tj
-0.01199 Tc 0.01199 Tw T*
(oral therapy was defined as a purchase of another type of)Tj
-0.015 Tc 0 Tw T*
(HR)Tj
-0.01511 Tc 1.2989 0 Td
(T)Tj
-0.015 Tc 0.015 Tw 0.84586 0 Td
(within 120 days of the last oral drug purchase. Each)Tj
-0.019 Tc 0.019 Tw -2.14477 -1.21905 Td
(patient entered the analysis of discontinuation and switch-)Tj
T*
(ing only once, regardless of how many times she resumed)Tj
-0.02499 Tc 0.013 Tw T*
[(and discontinued therapy)65 (. )]TJ
0 Tc 0.021 Tw 1 -1.2381 Td
(Analysis of switching and discontinuation of therapy)Tj
-0.00101 Tc 0.00101 Tw -1 -1.23809 Td
(was limited to women who made at least 2 purchases of)Tj
-0.00999 Tc 0.00999 Tw 0 -1.23809 TD
(oral medication during the study period. W)Tj
-0.01041 Tc 16.79185 0.00001 Td
(e)Tj
-0.00999 Tc 0.68346 0 Td
(used autore-)Tj
-0.015 Tc 0.015 Tw -17.47531 -1.2381 Td
(gressive integrated moving average \(ARIMA\) time series)Tj
-0.008 Tc 0.008 Tw T*
[(analysis to assess trends in monthly HR)60 (T purchases over)]TJ
-0.02499 Tc 0.019 Tw T*
[(the period of the study)65 (. ARIMA analysis included an inter-)]TJ
-0.01801 Tc 0.01801 Tw T*
(vention variable to indicate purchases occurring after July)Tj
0 Tc 0.117 Tw T*
(2002, when the WHI findings were widely published.)Tj
-0.005 Tc 0 Tw 0 -1.2381 TD
[(Pearson\325)55 (s )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 10.5 0 0 10.5 360.3714 229.4196 Tm
(c)Tj
ET
BT
/T1_1 1 Tf
6 0 0 6 366.0799 232.7196 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 10.5 0 0 10.5 371.674 229.4196 Tm
[(tests were used to evaluate changes in HR)60 (T)]TJ
-0.017 Tc 0.017 Tw -5.11181 -1.23809 Td
(population purchasing rates and in the proportion of users)Tj
-0.011 Tc 0.011 Tw T*
[(commencing therapy with dif)20 (ferent treatment modalities.)]TJ
-0.02499 Tc 0.002 Tw 0 -1.23809 TD
(Life-table analysis was used to assess the impact of the cal)Tj
0 Tc 21.95293 0.00001 Td
(-)Tj
-0.006 Tc 0.006 Tw -21.95293 -1.2381 Td
(endar year in which treatment was started on duration of)Tj
-0.019 Tc 0.019 Tw 0 -1.2381 TD
[(therapy)65 (. Follow-up for purposes of life-table analysis con-)]TJ
-0.007 Tc 0.007 Tw 0 -1.23809 TD
[(tinued through December 31, 2007. W)82.2 (omen who died or)]TJ
0 Tc 0.032 Tw T*
(left the HMO within 120 days of their last purchase, as)Tj
-0.009 Tc 0.009 Tw 0 -1.2381 TD
(well as women whose last purchase was within 120 days)Tj
0 Tc 0.033 Tw 0 -1.23809 TD
(of the last possible follow-up date, were censored from)Tj
0.00999 Tw 0 -1.2381 TD
(analysis as of the date of the last purchase. All analyses)Tj
0.15199 Tw T*
(were conducted using SPSS version 14.0 \(SPSS Inc.,)Tj
0.118 Tw 0 -1.23809 TD
(Chicago, IL\). This project received approval from the)Tj
-0.024 Tc 0.024 Tw 0 -1.2381 TD
(HMO Helsinki Committee for Research Involving Human)Tj
-0.02499 Tc 0 Tw T*
(Subjects.)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 60.5 23.9116 Tm
(252)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
105 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
106 0 obj
<</OP false/OPM 0/op false>>
endobj
135 0 obj
<</A 136 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
136 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
99 0 obj
[137 0 R]
endobj
100 0 obj
<</Length 11370>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 44.116 492 464.685 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
27.357 0 0 27.357 58.4855 488.6202 Tm
(P)Tj
ET
BT
/T1_1 1 Tf
-0.008 Tc 0.11099 Tw 10.5 0 0 10.5 76.625 501.6202 Tm
(rior to 2002, estrogen replacement)Tj
0.157 Tw 0 -1.23809 TD
(therapy was widely recommended)Tj
-0.033 Tc 0.004 Tw -1.58333 -1.23809 Td
(for the relief of menopausal symptoms, as)Tj
-0.02699 Tc 0.019 Tw T*
(well as for the prevention of osteoporotic)Tj
-0.01199 Tc 0.004 Tw T*
(fractures and heart disease.)Tj
ET
BT
/T1_2 1 Tf
-0.011 Tc 0 Tw 6 0 0 6 170.3076 452.9202 Tm
(1,2)Tj
ET
BT
/T1_1 1 Tf
-0.01199 Tc 10.5 0 0 10.5 180.1393 449.6202 Tm
(Numerous)Tj
-0.02699 Tc 0.019 Tw -11.44184 -1.23809 Td
(observational studies had indicated a car-)Tj
-0.008 Tc 0.082 Tw 0 -1.2381 TD
[(dioprotective ef)20 (fect of postmenopausal)]TJ
-0.02699 Tc 0 Tw 0 -1.23809 TD
(hor)Tj
0.02 Tw 1.27639 0 Td
(mone replacement therapy)Tj
-0.02 Tc 10.24444 0 Td
[(\(HR)60 (T\), al-)]TJ
0 Tc 0.033 Tw -11.52083 -1.2381 Td
(though an increased risk of stroke was)Tj
-0.017 Tc 0.01601 Tw 0 -1.2381 TD
(also observed.)Tj
ET
BT
/T1_2 1 Tf
0.009 Tc 0 Tw 6 0 0 6 117.8154 387.9202 Tm
[(3-)24 (5)]TJ
ET
BT
/T1_1 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 128.2904 384.6202 Tm
[(Prior to 2002, HR)60 (T)1 ( )1 (u)1 (s)1 (e)]TJ
-0.02499 Tc 0.024 Tw -6.50385 -1.23809 Td
(in the US was widespread, although esti-)Tj
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(mates of population rates of use varied.)Tj
-0.0051 Tc 0 -1.2381 TD
(A)Tj
-0.005 Tc 0.05701 Tw 1.01925 0 Td
(telephone survey conducted in 1995)Tj
-0.007 Tc 0.002 Tw -1.01925 -1.23809 Td
(estimated that 37.5% of US women be-)Tj
-0.005 Tc 0.013 Tw 0 -1.23809 TD
(tween the ages of 50 and 74 years used)Tj
0 Tw 0 -1.2381 TD
(HR)Tj
-0.08 Tc 1.31886 0 Td
(T.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 6 0 0 6 81.9924 309.9202 Tm
(6)Tj
ET
BT
/T1_1 1 Tf
10.5 0 0 10.5 89.809 306.6202 Tm
(T)Tj
-0.005 Tc 0.217 Tw 0.53577 0 Td
(wo studies extrapolated from)Tj
0.246 Tw -3.37472 -1.23809 Td
(drug purchasing data suggested rates)Tj
-0.03 Tc 0.01801 Tw 0 -1.23809 TD
[(among women aged 50)-107.8 (\32074 years of 33%)]TJ
-0.005 Tc 0.01199 Tw T*
(and 41% in 1995 and 2000, respective-)Tj
0 Tw T*
(ly)Tj
0 Tc 0.70265 0.00001 Td
(.)Tj
ET
BT
/T1_2 1 Tf
-0.004 Tc 6 0 0 6 69.9504 257.9202 Tm
(7,8)Tj
ET
BT
/T1_1 1 Tf
-0.005 Tc 0.005 Tw 10.5 0 0 10.5 79.9857 254.6201 Tm
(Use of HR)Tj
-0.0051 Tc 4.18137 0.00001 Td
(T)Tj
-0.005 Tc 0.85581 0 Td
(among Israeli women)Tj
-0.00101 Tc 0.00101 Tw -6.94058 -1.2381 Td
(during the same time period appears to)Tj
-0.034 Tc 0.024 Tw T*
(have been less prevalent than in the US; a)Tj
-0.01601 Tc 0.006 Tw 0 -1.2381 TD
(1998 telephone survey of Israeli women)Tj
-0.00999 Tc 0.186 Tw T*
[(aged 45)-25 (\32074 years estimated that 17%)]TJ
-0.035 Tc 0.00101 Tw 0 -1.23809 TD
[(were current HR)60 (T users.)]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 154.1407 192.9202 Tm
(9)Tj
ET
BT
/T1_1 1 Tf
-0.035 Tc 0.00101 Tw 10.5 0 0 10.5 159.1992 189.6202 Tm
[(HR)60 (T use among)]TJ
-0.017 Tc 0.017 Tw -9.44754 -1.2381 Td
[(Israeli women aged 50)-110 (\32074 years attend-)]TJ
-0.00999 Tc 0.00999 Tw 0 -1.2381 TD
(ing family-practice clinics was, not sur-)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(prisingly)65 (, somewhat higher)40 (, at 27%.)]TJ
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 202.149 153.9202 Tm
(10)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 70.5 137.6201 Tm
[(The W)80 (omen\325)55 (s Health Initiative \(WHI\))]TJ
-0.009 Tc 0.009 Tw -1 -1.2381 Td
[(findings questioning the safety and ef)20 (f)1 (i)1 (c)1 (a)1 (c)1 (y)1 ( )1 (o)1 (f)1 ( )1 (l)1 (o)1 (n)1 (g)1 (-)1 (t)1 (e)1 (r)-24 (m)]TJ
-0.02499 Tc 0.02499 Tw T*
(estrogen therapy for prevention of chronic conditions were)Tj
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(published in July 2002.)Tj
ET
BT
/T1_2 1 Tf
-0.058 Tc 0 Tw 6 0 0 6 157.1152 101.9202 Tm
(11)Tj
ET
BT
/T1_1 1 Tf
-0.004 Tc 0.004 Tw 10.5 0 0 10.5 165.3588 98.6201 Tm
(In response, the US Preventive)Tj
-0.007 Tc 0.007 Tw -10.03417 -1.23809 Td
[(Services T)71.1 (ask Force and several professional groups and)]TJ
-0.008 Tc 0.008 Tw 24.57143 3.87234 Td
[(health maintenance or)20 (ganizations \(HMOs\) changed their)]TJ
0 Tc 0.047 Tw 0 -1.23809 TD
[(guidelines for the use of HR)60.9 (T)75 (, reaf)20 (fir)-25 (ming its value for)]TJ
-0.02 Tc 0.02 Tw T*
(treatment of menopausal symptoms but deemphasizing its)Tj
-0.022 Tc 0.022 Tw 0 -1.2381 TD
(use for prevention of chronic conditions.)Tj
ET
BT
/T1_2 1 Tf
-0.021 Tc 0 Tw 6 0 0 6 480.5013 90.5797 Tm
[(1)-1 (2)-24 (-16)]TJ
ET
BT
/T1_1 1 Tf
-0.022 Tc 0.022 Tw 10.5 0 0 10.5 496.6095 87.2797 Tm
(It was recom-)Tj
0 Tc 0.062 Tw -17.01042 -1.23809 Td
(mended that symptomatic treatment be provided in the)Tj
-0.01801 Tc 0.01801 Tw T*
[(lowest ef)20 (fective dose and for the shortest time period pos-)]TJ
0 Tc 0 Tw T*
(sible.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 340.4535 51.5797 Tm
(17)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.039 Tw 10.5 0 0 10.5 349.4885 48.2797 Tm
[(In parallel with changing attitudes toward HR)60 (T)75 (,)]TJ
ET
0 0 0 0 k
157.5 17.75 394.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(251)Tj
ET
0 0 0 0 k
60 562 492 106.556 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 0.011 Tw 16.8 0 0 16 60 640.9177 Tm
[(Use of Hormone Replacement Thera)10 (p)35 (y)80 (, 1998\3202007: )]TJ
0 -1.5 TD
[(Sustained Impact of the W)90 (omen\325)79 (s Health Initiativ)20 (e Findings)]TJ
ET
BT
/T1_0 1 Tf
10.5 0 0 10 60 580.9177 Tm
(Barbara G Silverman and Ehud S Kokia)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tw 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60 715.5309 492 21 re
f
0 0 0 1 K
0.5 w 
60 720.417 m
552 720.417 l
S
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc 0.011 Tw 13 0 0 13 60 727.6668 Tm
[(W)88 (omen\325)78 (s Health)]TJ
ET
60 60.25 m
294 60.25 l
S
BT
/T1_0 1 Tf
-0.02499 Tc 8.5 0 0 8.5 60 48 Tm
(Author information provided at the end of the text.)Tj
ET
0 0 0 0.14999 k
239 149.46 313 359.3409 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.007 Tc 0 Tw 7 0 0 7 251 486.4172 Tm
(BACKGROUND)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 301.8243 486.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 8.5 0 0 8.5 307.4643 486.4172 Tm
[(T)37 (rials of hormone replacement therapy \(HR)18 (T\) for prevention of)]TJ
0 Tc 0.049 Tw -6.64286 -1.29412 Td
(chronic disease in postmenopausal women have suggested that the risks of\)Tj
-0.01801 Tc 0.01801 Tw 0 -1.29411 TD
(treatment outweigh the benefits. The publication in 2002 of the W)Tj
0 Tw 27.82727 0 Td
(omen\325)Tj
-0.0182 Tc 2.61402 0 Td
(s)Tj
-0.01801 Tc 0.75966 0 Td
(Health)Tj
-0.02499 Tc -31.20096 -1.29413 Td
(Initiative \(WHI\) study sparked a rapid decline in HR)Tj
-0.0251 Tc 21.29108 0.00001 Td
(T)Tj
-0.02499 Tc 0.83835 0 Td
(purchases among American)Tj
-22.12944 -1.29412 Td
(women. )Tj
ET
BT
/T1_6 1 Tf
-0.036 Tc 7 0 0 7 251 428.4172 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 288.4204 428.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
8.5 0 0 8.5 293.8027 428.4172 Tm
(T)Tj
-0.0251 Tc 0.47499 0 Td
(o)Tj
-0.02499 Tc 0.01801 Tw 0.80207 0 Td
[(examine the impact of the WHI findings on patterns of HR)18 (T use in)]TJ
0.011 Tw -6.31267 -1.29412 Td
(Israeli women.)Tj
ET
BT
/T1_6 1 Tf
-0.02 Tc 0 Tw 7 0 0 7 251 403.4172 Tm
(METHODS)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 285.0153 403.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.01401 Tw 8.5 0 0 8.5 290.5646 403.4172 Tm
[(W)18 (e linked purchases of estrogen preparations from 1998 to 2007 by)]TJ
0 Tc 0.036 Tw -4.65466 -1.29411 Td
(female Israeli health maintenance organization members aged 45 years and\)Tj
-0.015 Tc 0.015 Tw 0 -1.29412 TD
(older to membership data. For each year)Tj
-0.0148 Tc 17.51954 0 Td
(,)Tj
-0.015 Tc 0.54114 0 Td
(we calculated total annual purchases)Tj
-0.02499 Tc 0.009 Tw -18.06068 -1.29412 Td
(and rate of HR)Tj
-0.0251 Tc 6.15992 0 Td
(T)Tj
-0.02499 Tc 0.84763 0 Td
(utilization, characterized new users by age and mode of therapy)Tj
0 Tc 26.71464 0 Td
(,)Tj
-0.02499 Tc 0.011 Tw -33.72218 -1.29413 Td
(and examined rates of switching between modes of therapy)Tj
-0.0253 Tc 24.95467 0 Td
(.)Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 251 345.4172 Tm
[(RESUL)74.3 (TS)]TJ
ET
BT
/T1_6 1 Tf
10 0 0 10 283.1476 345.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
8.5 0 0 8.5 290.6659 345.4172 Tm
(T)Tj
0.215 Tw 0.55591 0 Td
(wenty percent of women aged 45 years and older purchased)Tj
0.166 Tw -5.22249 -1.29412 Td
(estrogen products in 2001, versus 10% in 2007 \(p < 0.001; )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 0 8.5 489.7402 334.4172 Tm
(c)Tj
ET
BT
/T1_6 1 Tf
5 0 0 5 494.4053 337.1672 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
0.166 Tw 8.5 0 0 8.5 497.1848 334.4172 Tm
(\). V)Tj
0 Tw 1.64768 0 Td
(aginally)Tj
-0.019 Tc 0.019 Tw -30.6106 -1.29412 Td
(administered products accounted for a rising percentage of purchases, fr\om 5%)Tj
-0.011 Tc 0.011 Tw T*
(in 1999 to 18% in 2007. An increasing percentage of new users aged 55 ye\ars)Tj
-0.02299 Tc 0.02299 Tw T*
(and older started with a vaginal product \(62% in 1999, 82% in 2007\). A\fter 2002,)Tj
-0.02 Tc 0.02 Tw T*
(new users of oral therapy discontinued use more quickly than those who s\tarted)Tj
-0.00301 Tc 0.00301 Tw T*
[(oral therapy before 2002. T)37 (ibolone accounted for an increasing percentage of)]TJ
-0.02499 Tc 0.011 Tw T*
(oral drugs purchased \(12% in 2003, 29% in 2007\). )Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 251 254.4171 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
10 0 0 10 302.7154 254.4171 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
0.07899 Tw 8.5 0 0 8.5 309.0773 254.4171 Tm
[(The WHI findings had a rapid and sustained impact on HR)18 (T)]TJ
-0.008 Tc 0.008 Tw -6.83262 -1.29412 Td
(utilization in a large population of Israeli women, including a sharp de\crease in)Tj
0.007 Tw 0 -1.29411 TD
(the rate of use, particularly of oral preparations, as well as reduced d\uration of)Tj
-0.01199 Tc 0.01199 Tw 0 -1.29412 TD
(therapy and increased use of vaginal preparations and tibolone as first \choices)Tj
-0.02499 Tc 0.011 Tw T*
(for treatment. )Tj
ET
BT
/T1_6 1 Tf
-0.036 Tc 0 Tw 7 0 0 7 251 196.4172 Tm
[(KEY)-377.8 (WORDS)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 292.8581 196.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 8.5 0 0 8.5 298.1792 196.4172 Tm
(hormone replacement therapy)Tj
-0.0251 Tc 12.6089 0.00001 Td
(,)Tj
-0.02499 Tc 0.51687 0 Td
[(Israel, pharmacoepidemiology)74 (.)]TJ
ET
BT
/T1_8 1 Tf
-0.0251 Tc 0 Tw 8.5 0 1.80673 8.5 251 181.4172 Tm
(Ann)Tj
-0.02499 Tc 1.96763 0 Td
(Pharmacother)Tj
ET
BT
/T1_0 1 Tf
8.5 0 0 8.5 322.581 181.4172 Tm
(2009;43:251-8.)Tj
0.011 Tw -8.42129 -1.76471 Td
(Published Online, 3 Feb 2009, )Tj
ET
BT
/T1_8 1 Tf
0 Tw 8.5 0 1.80673 8.5 361.7747 166.4172 Tm
[(www)55.2 (.theannals.com)]TJ
ET
BT
/T1_0 1 Tf
-0.0251 Tc 8.5 0 0 8.5 433.7303 166.4172 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51686 0 Td
(DOI 10.1345/aph.1L438)Tj
1 g
/T1_9 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1792 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_10 1 Tf
0 Tc 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
49 0 obj
<</BaseFont/EYSPAI+GillSans-Bold/Encoding 46 0 R/FirstChar 32/FontDescriptor 48 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 271 0 0 0 552 552 552 0 0 0 0 552 552 552 271 0 0 0 0 0 0 0 0 0 0 0 604 0 833 333 0 0 0 0 0 0 0 0 677 604 719 823 0 1167 0 0 0 0 0 0 0 0 0 531 0 500 583 552 302 542 583 271 0 0 271 958 583 594 583 0 448 427 406 583 510 0 0 510 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 271]>>
endobj
61 0 obj
<</BaseFont/JTWRAJ+Helvetica-Oblique/Encoding 58 0 R/FirstChar 32/FontDescriptor 60 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278 0 0 722]>>
endobj
65 0 obj
<</BaseFont/QDTYHD+Helvetica-Bold/Encoding 62 0 R/FirstChar 32/FontDescriptor 64 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
62 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
64 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262178/FontBBox[-170 -227 1001 963]/FontFile3 63 0 R/FontName/QDTYHD+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
63 0 obj
<</Length 313/Length1 313/Subtype/Type1C>>stream
  QDTYHD+Helvetica-Bold   @ø øøøøû>ûwú}úW
 ‹‹
 ‹‹      ²   €•002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki      üwŸø§š÷,—’Ÿ˜‹÷£—ü|‹õ
÷ Œ
_÷ªù
endstream
endobj
58 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t 119/w]/Type/Encoding>>
endobj
60 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 59 0 R/FontName/JTWRAJ+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
59 0 obj
<</Length 1421/Length1 1421/Subtype/Type1C>>stream
  JTWRAJ+Helvetica-Oblique   Eø øøøøû:ûtú|ú7
 ‹
 o
 ‹‹      ü  !¬  l €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F X  M T    < ~  Ã ı‰Â!sºëH†–«%œ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğ- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖüœ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûé-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³ŸûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙ÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=ûü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;Ó vøŸw›ùIùYøŸ4 ü.‰&ø.)&ü.‰'ø.,÷+üŸåñø)ôü)æü‹õâó÷Sõ#!ü@ vùawÎã÷/ùa3ıaû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹óu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
46 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 48/zero/one/two 55/seven/eight/nine/colon 70/F 72/H/I 82/R/S/T/U 87/W 97/a 99/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v 121/y 208/endash 213/quoteright]/Type/Encoding>>
endobj
48 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 47 0 R/FontName/EYSPAI+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
47 0 obj
<</Length 2969/Length1 2969/Subtype/Type1C>>stream
  EYSPAI+GillSans-Bold   Aø øøøøûEûzú5
 ‹‹
 ‹‹       Q±  s }‹”Copyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans  %  6 T F  P G ) S N O 3 Q M B D U 5 I Z     o     4 V J E * 8  W ' H '   A ” æ é0w¨èW™ìE^ÎQs³ß!rõY¦Ç]Ö0IŠ¹Ş		Ğü÷A‚÷"ø¹wÑ÷>÷ê÷>øÚù>üû8\1)DÆíøû>üûg÷#/÷Z÷O÷.Ù÷vøûs‚ì÷v¾á°÷ê÷øøH£[`•Qû>R6û+÷y—‹Hvp~`T\Ÿ\%€ŸÒtÕ÷ÏÁë÷.ûy‹¾«¬¨ÉdÊ)‚á÷×ğá°÷*÷_÷ø’÷#ZG^zQ0S»İ†÷ß÷<’ûêûû"&'û!û$ô-÷6¯â‹ÈŞûÔ÷{Ë‘°°ÄÃ±eL‘üS‚á÷Çá°÷/÷f÷/øÁ÷z÷Eû&Êûûû9û1û%÷,÷+ñ÷1Ã÷Kû/&gSGTX®÷ó¶¼ÊÔªO1ûğ v÷şî÷÷‚wÜ÷%è÷vøa¨È®Ÿ¸›–Š†±Ø÷	èue‘oû	6DûtI(Íûş÷%÷şÍî÷K v÷¨÷÷¦wØ÷>÷è÷>ù‰ù>û>û¦ûè÷¦û>ı>÷>÷¨÷èû¨÷>û^ v÷â÷‚wË÷%°÷eøaû%üa÷%÷[Ğà«­½À¢¤s±³÷aªr–n‹S[^+`‰÷È vø	ì‚wÊ÷%÷[÷%÷[÷%¼÷døaû%üa÷%Ü÷Éµ®±¡±¶¸r@û¥÷%÷»¾¬²¦µÀ«fIû¢÷%÷¼ô@Ğ"FVnFOÍkU«;np†€p¼qqzrtH vø	ã3ìÇ÷%÷A÷%Ø÷aøaû%üa÷%¸÷½Ä±¦¯´ªpJû­÷%÷¹÷+´CP^uV]¦ v÷©÷÷/÷×÷>÷K÷C×ù>ı>÷>÷©¼ç¦ûû&Ô÷O+÷\vßE®Ù¯²Ã‹Ö‹ñ8éû ‹ûûáË¬qXQ]w\1Hûev÷qì÷›v°é-òÄ÷%÷[÷'ö÷^øaû%ıG÷%÷‘w­·´÷åì÷(î÷-ñûYb|ib0§¯¢”ªĞ³X35_UDnq” nü vù>wÊ÷%÷dù>û%ı>÷%û‚á÷¼ì¬÷'÷÷%ø§÷si€‰|‚”¢÷fğ<²ûBHxfOû
º¹Í©ÅÊŸi`ˆûUO:uûQÂTÕ½¹™±Ãf•¢|»²Ä£³ûtÚusn~pqv¡¦¹´Ÿáªû*‚ò÷—vªö³÷/øc÷sKlƒh8TÁİÜÃ¿â¯·€w±÷ [O—\û,û'û!û$ô-÷6¼¼• Åûˆ‚ö÷œîÙ÷%øøaû<÷%yûUûloÍûZûŞ_ë¸±“ ¾ôwdo„m^q¨¸÷R÷<Ğ vøÁ÷÷§÷>ùHù>ı,û÷‹üÁ÷>øÁ÷‹H vø õ÷hwÉ÷%÷@÷%÷cù>û%ı>÷%÷º¼­¨ ­¸©kFû›÷%÷º÷6¾7R\sVa‰û û\vù>wŒøø‘øaû,#û*÷û/÷Hüûû¼÷.ü—vê÷½û=í•ÙãïÎbºP\hj]f›u®}‘[uTnq) vù>w÷Z÷+÷ñù>û+ı>÷+)—v÷÷÷b÷½÷&÷.÷,÷‚÷;÷÷WËó¥Ú‹ß÷+ğûû)%ûû÷!÷­Ï÷hPk`_\lµÈÇ¬¶¸º¨cK)‚ï÷jì÷Qï»÷,û÷&÷÷&û÷,ìøzøãIíû&û8AûI£bÇdòFkiT<ûç8÷÷ åÜ÷ÕiÃG®ìÂ¬§»Ëìû&†Ntfdcr°ÆÅ£®²´¢kPò˜ûÄKmb^\l¶ÍË©´º¹©aHû* v÷9÷…ø”ø÷½ü”ûø”)‹÷øA÷÷Ò÷,ø÷ûp÷÷/Ê÷	á÷9ÔûJWy\Aû#ÀÂÈ«»¾³^VVyYS6Z@F'C3xøW)‚÷øP÷·÷,÷3÷,ø÷ì÷]>÷&û-û+ûû{ûbØû$÷2÷4Ï÷-÷\û,–û"€-HMx×÷÷”êÒÉœBû)—vø¿÷ËøW÷¶÷W÷Šù?“üWû÷ü‚÷B÷÷B»÷B`÷øa[dd[[²d»»²²»»d²[ û¼[dd[[²d»»²²»»d²[]‚÷øV÷¶÷C÷@÷Cøªù°5F›?û2%=û
û‰÷ï´‹ûchtJ@O¢Ì)û'hÏÆl÷÷,÷×÷÷‚ûïn‹ò­²¡ÈÅÆz_îH‚ì3ãø	wÇ÷%÷A÷%xø÷%øaû&¸ûº^|ci_eh¢Ì÷±û%û»ûÙSæÅ¸¡À¹ü vøawå÷4Â÷4û,÷%è÷døaû%üa÷%0BùG_gg__¯g··¯¯··g¯_H‚ì3ã÷±ì÷hw®÷'÷Y÷%¼ø ù>û%û…dd•aû/)û!ûç%÷¼±˜¬´|f÷%¼û%÷pmr€lG`Ãßç¶ÀÔ¥­| ûÑ vù>wİ÷>÷ù>û>ı>÷>ø™—vùGwŠøÛøH÷hüQÔ÷¿ùGûHû4üûCøûûCüû5øûH÷ÀıGÔü vø$v÷Ìw·÷J½øí•ÙãïÎbºP\hj]f›u®}‘[uTnqû —vøjwø÷k‚Ü÷højû.(û’)÷’û/] v÷¬÷÷,÷×÷>ø¶ù>üjı>÷>÷¬÷À÷ûÀ÷,÷Àû ûzá÷ÿ aÀ ÿ GaHÿ IáHÿ ›ıpì5á§÷û÷1÷÷÷%÷ò€ø¦øaû¦û:cûRñ@6Ñ[Æ‚‰p…R~Zj¤yª‚‰ô@%qvYdN¿B÷V÷)ê»ö¢„¯m©ñ@?ØûD]ÀÁ÷[İİò€¤¤œ®´¦„¡{§Íê€ûíBº¯°»½¬fa[fc]]e±¸ô@÷\ülcpK>a®­µ ÏÓ´yj‚”ù>”ûz”÷Š—÷Ù’üÆ”î
Œ
yXO	÷ªù
endstream
endobj
101 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
102 0 obj
<</OP false/OPM 0/op false>>
endobj
137 0 obj
<</A 138 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
138 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
84 0 obj
<</CreationDate(D:20090130163019Z)/Creator(QuarkXPress\(tm\) 6.52)/ModDate(D:20140825201611-07'00')/Producer(QuarkXPress\(tm\) 6.52)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 139
0000000000 65535 f
0000042030 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000095906 00000 n
0000142924 00000 n
0000142411 00000 n
0000141766 00000 n
0000000000 00000 f
0000120263 00000 n
0000119750 00000 n
0000119106 00000 n
0000000000 00000 f
0000105618 00000 n
0000105109 00000 n
0000104480 00000 n
0000000000 00000 f
0000079976 00000 n
0000079463 00000 n
0000078821 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001838 00000 n
0000058184 00000 n
0000058762 00000 n
0000058559 00000 n
0000057538 00000 n
0000031819 00000 n
0000032500 00000 n
0000032295 00000 n
0000015119 00000 n
0000023731 00000 n
0000024164 00000 n
0000023957 00000 n
0000016187 00000 n
0000027763 00000 n
0000028197 00000 n
0000027989 00000 n
0000015801 00000 n
0000022344 00000 n
0000022633 00000 n
0000022430 00000 n
0000016878 00000 n
0000189400 00000 n
0000189860 00000 n
0000189648 00000 n
0000185744 00000 n
0000064109 00000 n
0000064599 00000 n
0000064386 00000 n
0000057104 00000 n
0000022888 00000 n
0000023182 00000 n
0000022982 00000 n
0000016599 00000 n
0000187532 00000 n
0000187900 00000 n
0000187689 00000 n
0000186332 00000 n
0000186842 00000 n
0000187142 00000 n
0000186929 00000 n
0000186691 00000 n
0000017701 00000 n
0000018113 00000 n
0000017898 00000 n
0000017032 00000 n
0000096451 00000 n
0000095963 00000 n
0000001942 00000 n
0000069317 00000 n
0000069638 00000 n
0000069923 00000 n
0000070254 00000 n
0000070574 00000 n
0000070894 00000 n
0000001882 00000 n
0000002044 00000 n
0000002118 00000 n
0000002399 00000 n
0000000016 00000 n
0000193171 00000 n
0000000097 00000 n
0000042329 00000 n
0000042354 00000 n
0000069059 00000 n
0000069117 00000 n
0000017612 00000 n
0000002668 00000 n
0000002693 00000 n
0000042071 00000 n
0000042129 00000 n
0000042174 00000 n
0000042273 00000 n
0000069162 00000 n
0000069261 00000 n
0000174295 00000 n
0000174321 00000 n
0000192908 00000 n
0000192967 00000 n
0000161852 00000 n
0000161879 00000 n
0000174032 00000 n
0000174091 00000 n
0000134450 00000 n
0000134477 00000 n
0000161528 00000 n
0000161587 00000 n
0000161648 00000 n
0000112293 00000 n
0000112320 00000 n
0000134126 00000 n
0000134185 00000 n
0000134246 00000 n
0000096889 00000 n
0000096916 00000 n
0000111969 00000 n
0000112028 00000 n
0000112089 00000 n
0000071226 00000 n
0000071253 00000 n
0000096565 00000 n
0000096624 00000 n
0000096685 00000 n
0000096731 00000 n
0000096832 00000 n
0000112135 00000 n
0000112236 00000 n
0000134292 00000 n
0000134393 00000 n
0000161694 00000 n
0000161795 00000 n
0000174137 00000 n
0000174238 00000 n
0000193013 00000 n
0000193114 00000 n
trailer
<</Size 139/Root 83 0 R/Info 84 0 R/ID[<41826E465C66F8DA921D21131FEE9C78><6ECBDF72D21DB2110A00E90910000000>]>>
startxref
193399
%%EOF
